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Abstract
Remyelination is a spontaneous regenerative process whereby myelin sheaths are restored
to demyelinated axons. Key players in this process are oligodendrocyte progenitor cells
(OPCs), a widespread population of CNS progenitor cells which persist into adulthood. Re-
myelination is impaired in patients with chronic demyelinating conditions such as Multiple
Sclerosis, and as with other regenerative processes, its efficiency declines with increasing
age. Hence, there is a need for the development of therapeutic interventions that will aid in
promoting endogenous remyelination when the endogenous regenerative potential is com-
promised. The nuclear receptor RXR𝛾 is an important positive regulator of OPC differen-
tiation and an accelerator of endogenous remyelination in aged rats. RXR𝛾 functions as a
ligand-induced transcription factor and is able to regulate gene transcription. It does so by
heterodimerising with other nuclear receptors and recruiting co-regulators involved in chro-
matin remodelling. However, we lack understanding on the specific mechanism by which
RXRγ promotes OPC differentiation.
With the work presented in this thesis I demonstrate that RXR𝛾 function is regulated
at multiple signalling levels. Proximity ligation assays revealed that RXR𝛾 remains con-
sistently bound to its partners throughout the oligodendrocyte lineage, and the biological
relevance of each heterodimer is determined by the dynamic association of co-regulators.
This is in turn influenced by ligand presence and subcellular receptor localisation. To iden-
tify the genes controlled by RXR𝛾 in OPCs I carried out ChIP sequencing, which revealed
genes involved in proliferation and cell cycle control. Further functional assessments aided
me in the development of a hypothesis whereby RXR𝛾 activation does not directly influence
oligodendrocyte formation, but rather promotes cell cycle exit thereby accelerating and fa-
cilitating OPC differentiation. Altered nuclear receptor expression and ligand presence in
ageing OPCs may consequently impair this process.
My thesis provides an alternative hypothesis to how RXR𝛾 regulates lineage cell pro-
gression, highlighting a new avenue in the development of therapeutic interventions tar-
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1.1 The inadequacy of mammalian brain regeneration
Regeneration is the ability of an organism to replace damaged tissues and organs. Regen-
erative processes can be divided into two types: physiological and reparative. The former
consists of the spontaneous replacement of worn out tissue to meet physiological needs in or-
der to preserve homeostasis. Examples are the continuous replacement of the skin as well as
the great production of red blood cells at changing altitudes to meet oxygen demands (Sawka
et al., 2000; Chuong et al., 2012). Instead, reparative regeneration occurs post-traumatically
and is able to replace whole damaged tissue parts.
All organisms have the capability to regenerate. However, the extent to which they can
do so varies greatly across phyla and does not necessarily present a phylogenic relationship
(Brockes and Kumar, 2008). Invertebrates are amongst the most fascinating examples of
organisms with great regenerative capabilities. The freshwater Hydra polyp was the first
organism to be studied in the context of biological regeneration. It has been observed that
both small fragments as well as single cells of Hydra can completely regenerate a whole
new animal (Gierer et al., 1972; Glass, 1988). Some vertebrates are also capable of dramatic
regeneration. The urodele amphibians (newts and axolotls) are an exceptional example as
they are the only adult vertebrates capable of regenerating whole limbs, tail, jaw and much
more.
Conversely, mammals do not present such outstanding regenerative capacity. Due to
the discrepancies in regenerative capability across the animal kingdom, the importance of
studying regeneration was recognised from the very first studies in the field (Morgan, 1901),
and today regenerative medicine presents an important clinical challenge for the scientific
community. In adult mammals we observe differences in the regenerative capacity of var-
ious organs and tissues within the same organism. Regenerative ability is directly related
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to the presence of progenitor cells in the organs of interest (Iismaa et al., 2018). Tissues
with successful regeneration tend to have a niche of highly proliferative stem cells includ-
ing, for example, the skin or the intestine. In contrast, systems such as the central nervous
system (CNS) tend to present poor regenerative capacity. Once mature neurons are formed
throughout embryonic development, neural stem cell (NSC) numbers deplete and neurogen-
esis no longer occurs, with the exception of two brain areas: the granular layer in the dentate
gyrus of the hippocampus and the sub-ventricular zone of the lateral ventricles (Kaplan and
Hinds, 1977; Lois and Alvarez-Buylla, 1993; Eriksson et al., 1998; Merkle et al., 2004; van
Wijngaarden and Franklin, 2013). In contrast to the deficient regenerative quality of adult
neurogenesis after the loss of neurons, loss of oligodendrocytes leads to a highly successful
CNS regenerative process termed remyelination (Franklin and ffrench Constant, 2017).
1.2 Remyelination is a highly efficient regenerative process
in the adult CNS
Oligodendrocytes are the glial cells responsible for the myelination of neuronal axons in
the CNS. Myelin is essential to neuronal function and survival as it acts as an insulating
layer allowing for fast and efficient propagation of action potentials, as well as providing
trophic support to the axon. In young mammals, primary demyelination is followed by
the robust process of remyelination, whereby whole myelin sheaths can be restored along
the denuded axon (Franklin and ffrench Constant, 2017). This has been elegantly shown
with numerous toxin-induced models of primary demyelination. These experimental mod-
els commonly use toxins such as injection of ethidium bromide (EB) or lysolecithin in white
matter tracts, or oral administration of cuprizone to specifically kill oligodendrocytes (Blake-
more and Franklin, 2008). The common goal is to induce primary demyelination, however,
their mechanism of action differs. EB is injected in either the rat caudal cerebellar pedun-
cle or the mouse spinal cord. Being an intercalating agent, EB kills all nucleated cells in
the area, thereby sparing neurons but not glial cells when injected into the white matter
(Blakemore, 1982, 2005). Lysolecithin is a membrane solubilising agent to which oligo-
dendrocytes are specifically susceptible (Hall, 1972; Jeffery and Blakemore, 1995). This
makes lysolecithin a more delicate toxin compared to EB, as usually astrocytes, microglia
and other glial cells tend to be relatively spared. Lysolecithin is typically injected into the
corpus callosum (CC) or into the spinal cord. Copper chelator cuprizone is less invasive
as it is administered orally alongside the standard animal diet (Blakemore, 1972, 1973). It
leads to global demyelination, but the prominent area affected is the CC (Matsushima and
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Morell, 2001). Demyelination is caused by the dysfunction of the mitochondrial complex IV
to which oligodendrocytes are vulnerable (Venturini, 1973; Faizi et al., 2016). In these mod-
els (although to a lesser extent for cuprizone) the lesion is focal, thereby making it defined
and easy to find and follow over time. Additionally, these models do not have an adaptive
immune mediated demyelination component, therefore demyelination is spatiotemporally
separated from the remyelination phase, allowing the study of the regenerative process per
se.
Remyelination is also observed in Multiple Sclerosis (MS). MS is an autoimmune pri-
mary demyelinating disease and is the prominent cause of neurological disabilities among
the young population. Despite the myelin restoration, ultimately remyelination fails causing
an accumulation of disability (Patrikios et al., 2006; Goldschmidt et al., 2009). MS, along-
side leukodystrophies, which are demyelinating diseases due to genetic defects in myelin
related genes, are clinical examples of how crucial myelin is to our basic function and sur-
vival (Franklin and ffrench Constant, 2017).
1.2.1 The importance of myelin and its regeneration
Myelin is produced and maintained by oligodendrocytes in the CNS and Schwann cells in
the peripheral nervous system (PNS). It is formed by an outgrowth of the membrane of these
cells, which wraps around the axon multiple times and finally is compacted. In contrast
to conventional cell membranes, myelin presents a substantially higher dry mass of lipids
(70-85%), the prevalent one being cholesterol, and is composed to a lesser extent of pro-
teins (15-30%) involved in its compaction, substance transport and exchange (Baumann and
Pham-Dinh, 2001; Nave and Trapp, 2008). Myelin allows for faster action potential con-
duction (Waxman and Bennett, 1972). This is achieved by myelin acting as an insulator,
decreasing the capacitance and increasing the membrane resistance of axons. This confers
an evolutionary advantage, as the only other way to achieve the same effect in their unmyeli-
nated counterparts is by dramatically enlarging the axon diameter (Gillespie and Stein, 1983;
Zalc et al., 2008). This is because the action potential propagation speed and axon diameter
are directly proportional in unmyelinated axons. Only cephalopods such as the squid have
been able to develop ‘giant axons’, which are mainly involved in their escape response. Ver-
tebrates were unable to do the same as it implied an impractical substantial increase in the
size of the nervous system (Zalc et al., 2008). Instead, vertebrate myelin evolved in the jaw-
less fishes for the development of the aforementioned fast escape reflexes, and approximately
600 million years later we find naturally selected myelinated preys and predators (Nave and
Trapp, 2008). Myelin, therefore, allowed for higher computational power, complexity and
faster information transmission within a reasonably sized nervous system. The myelinated
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areas along axons are termed internodes, in which the insulating property of myelin resides.
Due to its compaction, myelin acts as a barrier preventing ion diffusion. Consequently, the
only area where ion diffusion and exchange can occur is in the non-myelinated paranodal
areas called ‘nodes of Ranvier’. Here we find clustering of ion channels and transporters
such as voltage-gated Na+ channels, K+ channels and Na+-K+ pumps (Mata et al., 1991).
Voltage-gated Na+ channels allow for Na+ entry and propagation of the action potential
after axonal membrane depolarisation, and their intervallic clustering at the nodes of Ranvier
forms the basis for ‘saltatory conduction’, which is able to speed action potential conduction
10 times more than in their unmyelinated counterparts (Salami et al., 2003). The Na+-K+
pumps are involved in maintaining the resting potential by pumping Na+ out of the axon and
K+ into it, and are ATP driven as they need to pump both these ions against their concen-
tration gradients. In myelinated axons the Na+-K+ pumps are also restricted to the nodes of
Ranvier.
As the area over which they are distributed is reduced, less energy is required to restore
and maintain the membrane potential following a depolarisation event (Harris and Attwell,
2012). Therefore, not only does myelin promote fast action potential propagation, but it also
allows the neuron to restore membrane potential in a less metabolically demanding condi-
tion. However, calculations by Harris and Attwell (2012) suggest that, when considering
the energy required to produce and maintain oligodendrocytes and myelin, myelination does
not result in a reduction in energy consumption. The importance of myelin compaction
for correct action potential transmission is apparent when observing the homozygous auto-
somal recessive mutant shiverer, a transgenic mouse lacking myelin basic protein (MBP).
MBP is a structural protein essential to the compaction of myelin and its absence in the
shiverer mouse leads to severe myelin decompaction, resulting in a distinct phenotype in-
volving tremors around the onset of developmental myelination, followed by progressively
worse tonic seizures as the mouse develops and resulting in premature death 90-150 days
after birth (Readhead, 1987). Due to impaired myelin compaction, shiverer mice may lack
defined internodes. This is supported by the dispersed distribution of K+ channel subunits
along the dysmyelinated axons of these mice (Sinha et al., 2006; Eftekharpour et al., 2007).
The same dispersion may also occur for Na+ channels, thereby compromising the highly
structured organisation of the nodes, essential for action potential propagation and recov-
ery. However, this mutant does not present neurodegeneration, suggesting an inability to
correctly control action potential propagation and signal integration at the neural network
level.
A more recently described function of myelin is that of metabolically supporting the
axon, thereby promoting both its function and survival. Neurons are metabolically expen-
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sive cells due to their highly specialised design and function. With axons projecting as far
as the length of the whole spinal cord, neurons require an efficient transport system from
the soma to the axon in order to transport organelles, newly synthesised proteins and energy
metabolites necessary to avoid neurodegeneration. Energy to support this transport system
is likely produced throughout the length of the axon where glucose transporters are located.
However, whilst unmyelinated neurons are accessible to energy metabolites present in the
extracellular space throughout their entire axon, in myelinated neurons the area directly ex-
posed to the extracellular space is limited to the unmyelinated Nodes of Ranvier (Morrison
et al., 2013). The presence of myelin makes axons inaccessible for most of their surface area,
thereby preventing the direct transport and diffusion of energy metabolites such as glucose
(Mierzwa et al., 2010). It has therefore been hypothesised that metabolic substrates must
be provided by the oligodendrocyte and transported into the axon via the myelin (Morrison
et al., 2013). Evidence of this comes from both transgenic animals lacking myelin specific
proteins as well as clinical cases. Pelizaeus-Merzbacher disease (PMD) is a leukodystrophy
presented by patients with a mutation in the gene encoding for proteolipid protein (PLP) 1,
and the first observations of oligodendrocyte metabolic support derived from the study of
PLP1 null mice. These mice develop and myelinate normally, however, after 12 months
they present axonal swelling, axon loss and neurodegeneration (Griffiths et al., 1998). Al-
though the exact mechanism leading to axon degeneration in these mice is still unknown,
it has been hypothesised that it could be due to impaired axonal transport (Edgar et al.,
2010). Another oligodendrocyte specific gene that has been linked to metabolic support of
axons is CNP1, which encodes for the enzyme 2’,3’-cyclic nucleotide 3’-phosphodiesterase
(CNPase). CNP1 null mice also show severe neurodegeneration, however by electron mi-
croscopy (EM) they do not present defects in myelin compaction, nor demyelination (Lappe-
Siefke et al., 2003; Rasband et al., 2005). Using high-pressure freezing EM, Snaidero et al.
(2014) visualised a system of cytoplasmic channels between the compacted layers of de-
veloping myelin. The channels run from the oligodendrocyte cell body to the inner most
myelin tongue which is directly in contact with the axon. Within these channels, it is possi-
ble to observe microtubules and vesicles, components essential for motor-driven transport.
The group further observed that the cytoplasmic channels are kept throughout adulthood and
identified CNPase to be essential in the maintenance of such channels (Snaidero et al., 2017).
Mechanistically, CNPase antagonises the membrane compaction exerted by MBP at specific
locations, thereby creating pockets of cytoplasm between the oligodendrocyte cell body and
the axon. It is thought that these spaces allow for efficient diffusion of metabolites and other
cargo (Snaidero et al., 2017). Therefore, it can be speculated that CNPase-deficient mice
lack cytoplasmic channels due to complete compaction of myelin, consequently impairing
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metabolite diffusion and transport to the axon and compromising its function and survival.
Further evidence of the crucial role of oligodendrocytes in metabolically supporting ax-
ons comes from their involvement in lactate transport to the neurons via the extracellular
membrane transport channel MCT1. Monocarboxylate transporters (MCT) are transporters
involved in the transport of pyruvate, lactate, ketone bodies and so on. In the CNS, MCT1
is found predominantly on oligodendrocytes and MCT2 is localised on neurons. Based on
their distribution, a model for intercellular shuttling of lactate for energy transfer had already
been hypothesised in the nineties by Pellerin et al. (1998). However, the group attributed the
supply of lactate largely to astrocytes. It was not until MCT1 was experimentally downreg-
ulated or pharmacologically blocked specifically in oligodendrocytes that its importance to
neuronal survival became apparent. MCT1 inhibition via antisense oligonucleotides or drugs
in organotypic spinal cord cultures leads to axon injury and neuronal loss of motor neurons
(Lee et al., 2012). This is especially true when they are cultured in glucose-free media, as
under these conditions neurons become dependent on lactate: preventing oligodendrocyte-
dependent lactate release results in neuronal death without affecting the oligodendrocyte.
Neuronal death can be rescued by adding lactate directly into the cultures. In vivo, down-
regulation of MCT1 via lentiviral delivery of shRNA and oligodendrocyte-specific MCT1
knock out mice both present axon degeneration and in some cases neuronal loss (Lee et al.,
2012; Fünfschilling et al., 2012). Despite the lactate flux from the oligodendrocyte to the
neuron is never measured directly in these studies, they still make a strong case for the impor-
tance of oligodendrocyte lactate transporters for neurons. It has therefore been hypothesised
that MCT transporters in the myelin may provide axonal mitochondria with lactate, glucose
and other metabolites to produce enough energy for axonal maintenance, and their disruption
can lead to neurodegeneration (Lee et al., 2012; Fünfschilling et al., 2012).
1.2.2 The consequences of myelin loss
Primary demyelination is a pathological process characterised by the loss of myelin sheaths
wrapping axons. Unlike in Wallerian degeneration, where myelin degenerates as a conse-
quence of axonal loss, primary demyelination results from an insult directly targeting the
oligodendrocyte, subsequently leading to its death (Franklin and ffrench Constant, 2008).
Demyelination can occur as a result of numerous insults of different origin such as genetic,
in the case of leukodystrophies, inflammatory, viral, hypoxic-ischaemic or due to acquired
metabolic defects (Love, 2006). Regardless of its causes, however, demyelination results in
a conduction block leading to impaired function (Smith et al., 1979).
The default response to all demyelinating insults is remyelination, which is able to re-
store myelin sheaths around denuded axons and resolve the conduction block (Figure 1.1).
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Evidence for this comes not only from toxin-demyelinated animal models, but also from
pathological studies of post mortem tissues of MS patients, where the incidence and dis-
tribution of remyelinated lesions has been analysed. Studying heterogeneous patients with
varying clinical courses and durations of the disease, as well as the ample sampling of le-
sions from only two patients with a long clinical course, revealed extensive remyelination
occurring in MS lesions (Patrikios et al., 2006; Patani et al., 2007; Boyd et al., 2013). Across
the global population of MS patients, 20% present highly remyelinated shadow-plaques, a
percentage which appears to be independent of relapsing-remitting or progressive MS (Pa-
trikios et al., 2006). One of the limitations of these studies is the use of myelin-specific dyes
such as Luxol fast blue to identify shadow-plaques when bona fide remyelination can only
be identified using EM.
Remyelinated fibres are identified by the correlation between the axon diameter and the
myelin sheath thickness. This relationship is called the 𝑔 ratio and is calculated by divid-
ing the axon diameter by the diameter of the axon and myelin. Developmental myelination
presents a relationship between axon diameter and myelin thickness, where the larger the
axon diameter, the thicker the myelin wrapping it (Hildebrand and Hahn, 1978). However,
using the toxin-induced demyelination animal models, it has been clearly shown that the 𝑔
ratio is never restored to the original value obtained in development. This appears to be in-
dependent of the time the animals are left to remyelinate for, and even after six months of
recovery, original 𝑔 ratio values are not reached in large diameter axons (Blakemore, 1974;
Ludwin and Maitland, 1984). The above relationship is less clear in smaller diameter axons
as it is hard to distinguish the 𝑔 ratio of remyelinated axons from that of normally myelinated
axons (Stidworthy et al., 2003). Therefore, the only way to assert that remyelination has truly
occurred is by carrying out EM and calculating the 𝑔 ratio of the lesion of interest.
Electrophysiological studies have demonstrated that despite the abnormally thin myelin,
remyelination restores conduction in the previously demyelinated axons. Electrodes im-
planted in the spinal cord of cats were used to record neuronal action potentials in the de-
myelinated lesion itself, two months prior to lysolecithin injection, and up to four months
after lesion induction (Smith et al., 1979). Recordings showed that in demyelinated lesions
activity is almost nil, with small, very weak peaks of activity being recorded. This could
be due to the reported observation that upon demyelination axons redistribute Na+ chan-
nels along the denuded axons to try and preserve some form of conduction (Felts et al.,
1997). Weak conduction is regained at approximately the onset of remyelination and sheath
thickening over time correlates with the activity returning to the levels recorded prior to de-
myelination (Smith et al., 1979). This suggests that remyelination safely restores saltatory









Myelin sheath restoration Neurodegeneration
Fig. 1.1 The consequences of primary demyelination. (A) Oligodendrocytes wrap myelin
around axons; when oligodendrocytes die as a consequence of an insult, the neurons are
demyelinated leading to conduction block. The default response to demyelination in a young
CNS is the generation of new myelin sheaths and remyelination. If remyelination is impaired,
as in the case of MS, neurons are left vulnerable to degeneration resulting in functional
deficits. (B) A schematic of a white matter transverse section: the top panel shows axons
myelinated by developmental myelin and the criteria used to calculate the 𝑔 ratio. The middle
panel represents demyelinated axons, a process which can be induced experimentally by
focal injection of toxins such as EB and lysolecithin. Following demyelination induction,
we can observed remyelinated axons presenting thinner myelin sheaths than the original
developmental myelin.
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Duncan et al., 2009). Due to this, remyelination is thought to be the cause of the remission
phases in relapsing-remitting MS (Compston and Coles, 2008).
A lower incidence of neurodegeneration has been observed in remyelinated lesions com-
pared to chronically demyelinated ones, in both human MS lesions and in experimental au-
toimmune encephalomyelitis (EAE), the most widely used animal model for MS (Kornek
et al., 2000). Following from the axonal trophic support provided by myelin, it is logical
that remyelination could aid in preventing neurodegeneration in the setting of chronic de-
myelinating diseases. However, the conclusions made by Kornek et al. (2000), as well as
in other similar studies, are simply observational and therefore describe correlation without
demonstrating causality. More functional approaches have involved the prevention of re-
myelination by X-irradiating cuprizone treated mice (Irvine and Blakemore, 2008). These
animals show increased neurodegeneration compared to the non-irradiated controls. This
phenotype could be rescued by transplanting neural progenitors which differentiated into
oligodendrocyte lineage cells in vivo. Despite these studies present strong evidence for the
neuroprotective role of remyelination, we still cannot determine whether remyelination is the
cause of increased neuronal survival in a disease setting or whether remyelination occurs in
areas where axons are alive and have the potential to survive a priori (Franklin and ffrench
Constant, 2017).
Nonetheless, there are clear benefits that come with remyelination, making it an impor-
tant biological process to basic neuronal function and survival.
1.2.3 The stages of remyelination
By virtue of the toxin-demyelination models developed, the various stages leading to re-
myelination have been characterised in detail. As with any regenerative process, remyeli-
nation comprises four distinct yet overlapping stages (Figure 1.2). Firstly, there is an initial
inflammatory response to the injury, immediately followed by the recruitment of resident
progenitor cells. Consequently, the progenitors differentiate into post-mitotic residents of
the tissue of interest and finally they execute the endogenous repair required (Levine and
Reynolds, 1999; Fancy et al., 2004). The correct outcome of each of these phases is funda-
mental if remyelination is to be carried out to completion and for its functional benefits to
be achieved.
Inflammation
Primary demyelination leads to a quick inflammatory response driven by resident microglia
and macrophages, and depletion of inflammatory cells within the lysolecithin lesion at the
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early stages of remyelination resulted in remyelination of fewer axons three weeks after lesion
induction (Kotter et al., 2001). There was no effect on the repair outcome if the depletion
was delayed to the second phase of remyelination, suggesting that the innate immune re-
sponse is essential at the initial stages of the process (Kotter et al., 2001). The importance of
inflammation in achieving successful remyelination was further shown by gain-of-function
experiments where oligodendrocyte progenitor cells (OPC) were transplanted in the retina
of adult rats. Inflammation induction in retinal areas via the administration of zymosan, a
TLR-2 ligand, resulted in increased differentiation of transplanted OPCs and myelination
of retinal ganglion cell axons compared to OPCs transplanted in non-inflamed areas (Setzu
et al., 2006). This model provides further evidence in support of the view that an inflamma-
tory response associated with demyelination is a salient trigger in activating OPCs and cre-
ating conditions favourable to remyelination. Efficient remyelination by the innate immune
system involves two fundamental functions: myelin debris clearance and the secretion of
factors important for the lesion environment and for OPC recruitment (Messersmith et al.,
2000; Murtie et al., 2005; Kotter et al., 2006; Zhou et al., 2006). It has been shown that
myelin debris prevents OPC differentiation in vitro (Robinson and Miller, 1999), observa-
tions which have also been confirmed in vivo. Administration of myelin debris to EB lesions
in rats negatively impacted remyelination efficiency without affecting neither macrophage
nor OPC recruitment (Kotter et al., 2006). Therefore, clearance of myelin debris via phago-
cytosis is a crucial step for oligodendrocyte formation and consequently remyelination. In
vitro observations that treatment of primary OPCs with microglia-conditioned media could
modulate their behaviour also suggest a phagocytic-independent role for the innate immune
system in remyelination (Miron et al., 2013). Miron et al. (2013) found the growth factor
activin-A to be an important modulator of OPC differentiation in the conditioned media
experiments. Similarly, other factors produced by the innate immune system during this in-
flammatory stage have been discovered to affect remyelination. These include transforming
growth factor (TGF) 𝛽, insulin-like growth factor and endothelin 2 (McMorris and Dubois-
Dalcq, 1988; McKinnon et al., 1993; Yuen et al., 2013), which are further summarised by
McMurran et al. (2016). Contrary to the belief that CNS inflammation always has a neg-
ative impact, the above evidence indicates that, in the context of remyelination, a robust
inflammatory response is necessary in order for regeneration to occur successfully.
OPC activation and recruitment
Following the onset of inflammation OPCs are recruited into the lesion. In order for OPCs
to be mobilised, they first need to become activated; this term is used to describe the state of
OPCs upon disruption of their homeostatic environment (Levine and Reynolds, 1999; Fancy
1.2 Remyelination is a highly efficient regenerative process in the adult CNS 11
et al., 2004; Nakatani et al., 2013; Moyon et al., 2015). What exactly determines OPC ac-
tivation is still unknown; however, it has been hypothesised that tissue damage is initially
sensed by microglia and astrocytes, which in response release an array of factors into the
tissue microenvironment. These are in turn sensed by resident OPCs and lead to a shift in
the signalling pathways activated within the progenitors, changing their transcriptional pro-
file (Nakatani et al., 2013; Moyon et al., 2015). Microarray analysis of neonatal, adult OPCs
and oligodendrocytes from homeostatic white matter, as well as OPCs in demyelinated le-
sions, revealed that homeostatic OPCs resemble oligodendrocytes in their transcriptional
profile more closely than neonatal OPCs. Instead, activated OPCs in demyelinated lesions
transcriptionally resemble their neonatal antecedents (Moyon et al., 2015). Therefore, in an
injury setting, OPCs shift from a homeostatic to an activated state which closely resembles
neonatal OPCs (Fancy et al., 2004; Moyon et al., 2015). The purpose of this activation is
to make OPCs more responsive to migratory and proliferative signals involved in recruiting
them to the lesion. Numerous factors have been shown to contribute to OPC recruitment,
many of which have been shown to be released by the innate immune system, reactive astro-
cytes as well as cells of the vasculature (Messersmith et al., 2000; Spassky et al., 2002; Arai
and Lo, 2009; Lindner et al., 2015; Moyon et al., 2015; Tsai et al., 2016). Recruitment is
successful only if there is a fine interplay between migratory/proliferative signals and cues
preventing OPC differentiation. The proliferative response is controlled by numerous mi-
togens including Platelet-derived growth factor (PDGF) and FGF2. Increasing levels of
PDGF-A result in higher numbers of OPCs in the lesion whilst knockouts of their recep-
tors lead to a decrease in the density of progenitors (Woodruff et al., 2004; Murtie et al.,
2005). Semaphorins, which are important guiding cues for axons to find to their synaptic
target in neurodevelopment, have also been shown to influence OPC migration (Piaton et al.,
2011; Boyd et al., 2013). Gain and loss of function experiments both in vitro and in vivo
have shown that semaphorins 3A and 3F, for which OPCs express the receptors, influence
the recruitment of adult OPCs to demyelinated lesions (Williams et al., 2007; Piaton et al.,
2011; Boyd et al., 2013). Among these cues we also find signals inhibiting OPC differentia-
tion such as Notch, canonical Wnt signalling and the regulation of cyclin dependent kinases
(CDK): these prevent premature cell cycle exit, ensuring that the correct number of OPCs
in the lesion is reached in order for remyelination to occur (Fancy et al., 2009; Zhang et al.,
2009; Caillava et al., 2011).
OPC differentiation and remyelination
Once OPCs are recruited into the demyelinated lesion, a transition to the differentiation stage
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Fig. 1.2 Schematic showing the stages of remyelination. (A) Upon primary demyelination
macrophages and microglia mount an inflammatory response, clearing myelin debris via
phagocytosis. Reactive microglia and astrocytes activate neighbouring OPCs which migrate
and proliferate in the lesion. Upon reaching a certain density, OPCs start to differentiate
creating newly formed oligodendrocytes that will restore the lost myelin. (B) A timeline of
the events following toxin injection in a toxin-induced demyelination model. Adapted from
(Franklin and ffrench Constant, 2008).
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differentiation both at the molecular and cellular levels. At the molecular level, terminal dif-
ferentiation of progenitors usually involves a two-step mechanism, where they firstly exit the
cell cycle (usually via antagonism of CDKs) and subsequently increase the expression of cell-
specific genes involved in differentiation (Ruijtenberg and van den Heuvel, 2016). As with
any other progenitor cell, it has been shown that OPCs lacking the CDK inhibitor p27 con-
tinue to proliferate at the expense of differentiation in vitro (Casaccia-Bonnefil et al., 1997).
Other common stem cell-specific factors are involved in controlling OPC proliferation, in-
cluding important transcriptional regulators such as E2F1 and c-Myc (Magri et al., 2014b,a).
E2F1 targets the expression of cell cycle genes and its inhibition is essential to promote cell
cycle exit. In accordance with this, mouse gliomas, tumours resulting from OPCs, present
an increased expression of E2F1 (Magri et al., 2014b) The expression of the proto-oncogene
c-Myc has been used to control reprogramming of cells (Thier et al., 2012), suggesting its key
role in determining cell fate. c-Myc also controls important cell cycle genes, and its silencing
results in their promoter regions to be silenced via chromatin methylation and compaction,
whilst promoting genes involved in differentiation (Magri et al., 2014a). More recent inter-
est has developed in the involvement of specific transcription factors determining chromatin
modification and transcription of oligodendrocyte differentiation-specific genes, as shown
by Moyon et al. (2016).
At the cellular level, an example of a determining factor shown to promote OPC differ-
entiation is the cell density within a given space. In vitro assessment of the impact of cell
density on differentiation in development revealed that OPC differentiation is induced once
a specific density is reached (500-600 cells/mm2). This is the case regardless of the initial
seeding density of the cells (Rosenberg et al., 2008). Density could impact cell fate in a
number possible ways: a high number of OPCs could prevent proliferative mitogens from
reaching a portion of the cells, which will then become oligodendrocytes, they may inhibit
further proliferation via contact-dependent inhibition as in other cell types, or the spatial con-
straints may mechanically induce OPC differentiation (Rosenberg et al., 2008; Hughes et al.,
2013; Watt and Huck, 2013). This model could apply in an adult in vivo setting, whereby
a lesion requires a certain density of OPCs to ensure complete remyelination, making OPC
density crucial for differentiation.
The picture we are presented with is a complex array of signals apparently disconnected
from each other, and future research has the aim of piecing this information together for
a complete picture of what is happening in vivo. The result of OPC differentiation is the
production of new oligodendrocytes which will extend their processes, make contact with
demyelinated axons and subsequently wrap them with newly formed myelin sheaths (Za-
wadzka et al., 2010).
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1.3 Oligodendrocyte lineage cells throughout life
1.3.1 The role of OPCs in development and adulthood
OPCs arise during embryonic development from three spatiotemporal distinct waves origi-
nating from the neuroepithelium (Kessaris et al., 2006). In the murine brain, the first wave of
OPCs is derived from the ventral telencephalon, specifically the medial ganglionic eminence
and the anterior entopeduncular, at embryonic day (E) 11.5. The second wave is also derived
ventrally, from the lateral and caudal ganglionic eminence at E16.5. The first two waves
spread to populate the whole telencephalon until the final dorsally derived OPC wave arises
postnatally. Subsequently, dorsal OPCs populate the dorsal areas of the telencephalon, elim-
inating OPCs derived from the first ventral wave (Kessaris et al., 2006). In the adult brain,
dorsally derived OPCs mainly populate the cortex and corpus callosum, whilst other brain
areas are mainly populated by ventrally derived OPCs from the second wave (Kessaris et al.,
2006). OPCs clearly present developmental heterogeneity. However, whether this translates
to a functional heterogeneity is still to be determined.
Myelination occurs mainly postnatally in the first 10 weeks in rodents, and the first 10
years in humans (Yeung et al., 2014). OPC numbers drop in the first years of life and sta-
bilise around five years of age, whilst production of new oligodendrocytes follows the in-
verse pattern, plateauing closer to 10 years of age (Yeung et al., 2014). This is a critical
age for human development, as exponential learning of both motor and cognitive skills oc-
curs during this period. In fact, the onset of myelination correlates with the development
of numerous abilities, including motor coordination, fine motor tuning and cognitive skills.
The impact that myelination can have on development is reinforced by the observation that
myelin deficits arise in many common developmental disorders such as autism and attention
deficit hyperactivity disorder (Bercury and Macklin, 2015), as well as in psychiatric con-
ditions like Schizophrenia (Uranova et al., 2004; Windrem et al., 2017). Even though the
bulk of myelination occurs in the first years of life, increase in white matter volume persists
throughout adulthood (Lebel et al., 2012; Hill et al., 2018; Hughes et al., 2018). This raises
an important question: do OPCs have a function in CNS homeostasis and what could this
entail? A reasonable assumption would be the replacement of old oligodendrocytes with
new ones as for post-mitotic cells in other tissues. However, there is no current evidence of
oligodendrocytes undergoing apoptosis during homeostasis, and post mortem experiments
looking at the integration of radioactive carbon in individuals of different ages show that
there is some but little oligodendrocyte turnover throughout life (Yeung et al., 2014). This
has also been observed in the mouse, where in vivo two-photon imaging used to monitor
oligodendrocyte formation in MOBP-EGFP transgenic mice revealed minimal turnover of
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oligodendrocytes in the adult mouse cortex (Hughes et al., 2018). Nevertheless, new myelin
is continually produced in both the adult human and rodent, suggesting that already exist-
ing oligodendrocytes may be responsible for the increase in myelin volume with age (Yeung
et al., 2014; Hill et al., 2018). Interestingly, learning new skills, such as juggling or play-
ing a musical instrument for humans, as well as sensory enrichment for mice, have been
shown to alter white matter volume (Bengtsson et al., 2005; Scholz et al., 2009; Hughes
et al., 2018). Despite the white matter being full of oligodendrocytes, an increase in its vol-
ume may not necessarily be due to an increase in newly formed oligodendrocytes, but rather
be due to production of more myelin by pre-existing oligodendrocytes or to an increase in
neurogenesis which consequently requires myelin for new neurons. McKenzie et al. (2014)
have shown the implication of adult de novo myelination in mice that learnt motor skills
such as running on a complex wheel. Upon learning this skill, an increase in the number of
new oligodendrocytes produced was observed. Inhibition of oligodendrocyte formation and
adult myelination by deleting myelin regulatory factor (Myrf ), mice found greater difficulty
in learning new motor skills (McKenzie et al., 2014). Subsequently, a rapid production of
newly formed oligodendrocytes was observed in the early hours following the introduction
of the mice to the wheel, coinciding with synaptic changes required for learning (Xiao et al.,
2016). This suggests that OPCs and adult oligodendrogenesis contribute to the process of
learning and, even though this research is in its early days, it appears that they play a much
more active role than previously thought.
Further research is required to fully understand the possible roles carried out by OPCs
in homeostasis, and as of today the most well-defined role for adult OPCs remains their
involvement in remyelination. Due to this, ever since their first discovery by Raff et al.
(1983), OPCs have been at the centre of CNS regenerative research. This is because they
are the largest CNS progenitor population, making up 5%-8% of the total adult CNS, and are
spread evenly throughout the grey and white matter (Pringle et al., 1992), but whether they
are to be considered legitimate adult stem cells is still subject of debate in the field.
1.3.2 Are OPCs bona fide stem cells?
For any adult stem cell to be considered as such, it needs to present certain properties and
capabilities. These include self-renewal, mitotic quiescence, multipotency, enabling tissue
regeneration as well as having a niche (Crawford et al., 2014).
OPCs are able to proliferate throughout the entire lifespan of an organism (Young et al.,
2013). Numbers of OPCs in vivo are similar between animals of different age, suggesting
that a stable OPC density is maintained throughout lifetime (Rivers et al., 2008). Ablation
of single OPCs under homeostatic conditions causes neighbouring progenitors to proliferate
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and replace the missing cell, ensuring maintenance of the correct cell density (Hughes et al.,
2013). Furthermore, multiple episodes of demyelination do not result in a depletion of pro-
genitors, meaning that the progenitor pool continually self-renews and is never exacerbated
(Penderis et al., 2003).
OPCs have been reported to exhibit asymmetrical division, whereby a stem cell divides
to generate a daughter cell that will retain stem cell identity, thereby achieving self-renewal,
and a daughter cell destined to differentiate. This is obtained by the asymmetrical division
of cell fate determinants at cytokinesis, where the daughter cells receive unequal fate de-
terminants thereby conditioning their distinct cell fates (Morrison and Kimble, 2006). True
asymmetrical division occurs at the basal lamina of tissues, in an apical-basal orientation,
as in the case of skeletal muscle satellite cells. Upon satellite cell division, the daughter
cell closer to the basal surface retains stem cell identity, whilst the more apical daughter
cell presents transcription factors involved in myogenic differentiation (Kuang et al., 2007).
Although OPCs present different cell fates as discussed further below, this does not indi-
cate true asymmetrical division. Indeed, OPCs have been reported to asymmetrically divide
cell fate determinants such as the proteoglycan NG2. Monitoring of the segregation of NG2
upon OPC division showed that out of the two daughter cells, the one retaining NG2 would
continue to self-renew, whilst the daughter lacking NG2 would differentiate (Sugiarto et al.,
2011). However, further evidence is required for OPCs undergoing true asymmetrical divi-
sion, as in vivo time-lapse studies demonstrate that the vast majority of OPCs differentiate
without any prior cell division event (Hughes et al., 2013). Additionally, the absence of
a true basal lamina in their microenvironment suggests that OPCs may divide in a planar
orientation raising an important question on how OPCs achieve polarity upon cell division
(Crawford et al., 2014).
OPCs are able to regenerate whole myelin sheaths after demyelination, and there is sub-
stantial evidence that new oligodendrocytes come from OPCs rather than from already exist-
ing oligodendrocytes (Zawadzka et al., 2010; Crawford et al., 2016). However, OPCs are not
only restricted to the oligodendrocyte lineage. The first in vitro studies immediately pointed
towards the bipotent nature of OPCs. By isolating these cells from the rat optic nerve, Raff
et al. (1984) observed that neonatal OPCs had the potential to differentiate either into oligo-
dendrocytes or type II astrocytes, depending on the media they were exposed to. Even though
OPCs may present the potential to differentiate into astrocytes, there is very little evidence
of this phenomenon in vivo, where reactive astrocytes in lesions derive from pre-existing as-
trocytes (Zawadzka et al., 2010). On the other hand, fate-mapping analysis in the context of
demyelination found OPCs to give rise to Schwann cells capable of remyelinating CNS ax-
ons (Zawadzka et al., 2010). CNS Schwann cells arise only in lesion areas which lack astro-
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cytes; the inhibitory effect of astrocytes on Schwann cells had already been observed in vitro,
and the use of a signal transducer and activator of transcription 3 knockout mouse model, in
which astrocytic activation was abrogated, resulted in a decreased oligodendrocyte-mediated
remyelination and an increase in Schwann cell remyelination upon toxin-induced demyeli-
nation (Guenard et al., 1994; Black et al., 2006; Zawadzka et al., 2010; Monteiro de Castro
et al., 2015).
OPCs have been described to be evenly spread throughout the entire CNS of organisms
(Dawson, 2003). These observations come from immunohistochemistry studies of various
brain regions, where OPCs were immunolabeled with antibodies targeting the OPC marker
NG2 (Dawson, 2003). The even distribution of OPCs throughout the CNS suggests that they
may lack a stem cell niche unlike other stem cell types.
Adult NSCs, for example, reside in two niches: the subventricular zone and the sub-
granular layer. Signals from the neurogenic niche influence the proliferation of NSCs, or
their differentiation into mature neurons when required (Song et al., 2002; Shen et al., 2004;
Alvarez-Buylla et al., 2008).
NSCs in these niches are involved in tissue homeostasis for the olfactory bulb and mem-
ory formation, and their role could be the reason as to why they are only restricted in these
specific areas (Winocur et al., 2006; Curtis et al., 2007). OPCs, on the other hand, are needed
for remyelination, a process which may be required in any area of the CNS. However, all pre-
vious studies have assessed staining in a restricted plane limited to brain slices, potentially
compromising the observations and conclusions that can be made. Recent unpublished ef-
forts by Neumann and Segel in the Franklin laboratory aim to disentangle whether there is
indeed one or multiple OPC niches throughout the murine CNS.
OPCs, therefore, do have stem cell capabilities such as multipotency, self renewal and
the ability to generate a progeny of oligodendrocytes which carry out remyelination, even
after multiple rounds of demyelination (Penderis et al., 2003).
1.3.3 Oligodendrogenesis involves transcriptional and morphological
changes in OPCs
Despite their multipotency, oligodendrocytes remain the main progeny of OPCs (Zawadzka
et al., 2010). The linear transition from OPC to oligodendrocyte involves a series of changes
at the morphological, chromatin remodelling and transcriptional levels, all of which are es-
sential for the creation of a completely new cell with a different physiological role. OPC dif-
ferentiation in vitro involves dramatic morphological changes, starting with a bipolar OPC
which, over time, will become a multi-processed cell. Eventually, the cell will grow and
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spread sheaths on the surface it is cultured on. If the oligodendrocytes in vitro are pre-
sented with something to myelinate, such as axons (Gardner et al., 2012), nanofibres (Lee
et al., 2013; Bechler et al., 2015) or micropillars (Mei et al., 2014), they will wrap their
sheaths around them, thereby becoming a myelinating oligodendrocyte. These morpholog-
ical changes are accompanied by the expression of stage-specific markers (Pringle et al.,
1992; Schumacher et al., 2012; Xiao et al., 2016), allowing for a more precise distinction
between the various stages.
Markers for the entire oligodendrocyte lineage, such as Olig2 and Sox10, are essential to
the differentiation program (Yu et al., 2013; Hornig et al., 2013). Both are transcription fac-
tors shown to control the transcription of genes essential to OPC differentiation. Olig2 has
been shown to be fundamental in both specification of the oligodendrocyte lineage as well
as its differentiation (Takebayashi et al., 2002; Yue et al., 2006). ChIP-sequencing analysis
has revealed that Olig2 recruits a SWI/SNF chromatin remodeller to enhancer regions con-
trolling the expression of OPC differentiation regulators such as Myrf, Olig1 and 2, Sox10
and Zfp191. The recruitment of SWI/SNF makes the chromatin in these areas accessible,
thereby allowing their transcription and promoting differentiation (Yu et al., 2013). Sox10
is also necessary for terminal differentiation of OPCs, as its loss prevents differentiation and
CNS myelination. Like Olig2, Sox10 also binds to enhancer regions of OPC differentiation
genes such as Myrf, thereby controlling their expression (Hornig et al., 2013). Olig2 and
Sox10 are therefore essential to driving the expression of transcription factors that in turn
will allow for the production of myelin proteins and OPC differentiation.
As well as transcription factors, chromatin modification itself is crucial for OPC differen-
tiation to occur, as it controls whether a gene is accessible for transcription or not. Numerous
histone deacetylases (HDAC) have been reported to influence OPC differentiation or specifi-
cation, including HDAC 1, 2, 3 and 11 (Ye et al., 2009; Zhang et al., 2016a; Liu et al., 2009).
Furthermore, components of chromatin remodelling complexes such as BRG1-dependent
SWI/SNF, SIRT1, and p300 have all been reported to influence OPC differentiation, either
by inhibiting or promoting it (Yu et al., 2013; Jablonska et al., 2016; Zhang et al., 2016a)
The inhibition of negative regulators of differentiation is also a crucial aspect of oligo-
dendrogenesis. OPCs have high levels of transcription factors involved in maintaining stem
cell identity, such as Hes5, Id2, Sox5 and 6, which prevent differentiation and myelina-
tion (Samanta and Kessler, 2004; Liu et al., 2006; Stolt et al., 2006). Id2 is downstream of
the oligodendrogenesis inhibitor bone morphogenic protein (BMP) 4, and it has been sug-
gested that Id2 prevents Olig1/2 from exerting their function by directly interacting with
them (Samanta and Kessler, 2004). Hes5, on the other hand, is downstream of the Notch
signalling pathway. Although the role of Notch in OPCs remains controversial, Notch lig-
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Fig. 1.3 The oligodendrocyte lineage differentiation timeline. The top panel shows im-
munocytochemistry staining of an OPC, immature and mature oligodendrocyte in vitro.
The cells have been stained with the lineage markers Olig2 and O4 to show their morphol-
ogy. OPCs have a simple bipolar morphology, and as they differentiate they become multi-
processed and grow in size, until they become mature and lay down sheaths in culture. Dif-
ferentiation entails changes in the gene expression profile of the cell as it progresses through
the lineage. The most commonly used stage-specific markers are shown, as well as markers
used to identify the entire lineage. The process of differentiation consists in the same cell
transitioning between one phase to the next, thereby the expression of stage-specific mark-
ers is not a binary event, but rather a smooth transition. Usually a combination of the above
markers is used to assess different stages of the lineage. The immunocytochemistry pictures
above are not the same magnification.
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ands have been shown to inhibit OPC differentiation (Wang et al., 1998), and this may be
due to their induction in Hes5 expression which in turn will prevent Sox10 from exerting
its function (Liu et al., 2006). As well as Notch signalling, canonical Wnt signalling is in-
volved in preventing OPCs from differentiating, where the transcriptional complex formed
by 𝛽-catenin and Tcf7l2 prevents OPC differentiation (Fancy et al., 2009).
Therefore, despite being a seemingly linear process, oligodendrogenesis is highly de-
manding, both at the transcriptional and metabolic level. Negative regulators of differenti-
ation need to be inhibited while positive regulators need to be promoted, and these include,
but are not limited to, the ones highlighted above. The pathways governing these events
are tightly controlled and intertwined, giving rise to a highly complex molecular network
governing oligodendrogenesis.
1.4 Ageing leads to remyelination failure
1.4.1 The hallmarks of ageing
Ageing is the time-dependent loss of homeostatic mechanisms resulting in the functional de-
cline of an organism. Impaired homeostasis implies tissue dysfunction, which consequently
makes us more susceptible to a whole array of diseases with increasing age. This is an inter-
esting observation as it implies that ageing is the primary risk factor for numerous diseases,
including neurodegeneration, heart conditions, diabetes, cancer and many more (Jaul and
Barron, 2017). Consequently, the research in this field aims at finding ways to slow the rate
of ageing, maintaining cells and tissues in a juvenile-like state, in order to achieve increased
health and an extended lifespan.
Why and how we age are amongst the biggest mysteries in modern biology, and even
though the conceptualisation of an ageing organism can be difficult, the identification of
several molecular and cellular hallmarks have helped in understanding its essence (López-
Otín et al., 2013). These hallmarks can be broadly divided into two categories: intracellular
and extracellular hallmarks. Intracellularly, ageing cells present an accumulation of damage
in both nuclear and mitochondrial DNA, telomere attrition, numerous epigenetic alterations,
mitochondrial dysfunction, cellular senescence and deregulation of proteostasis and nutrient
sensing (Koga et al., 2011; Faggioli et al., 2012; Forsberg et al., 2012; Tsurumi and Li,
2012; Park and Larsson, 2011; Johnson et al., 2013). Extracellular hallmarks present altered
intercellular communication as well as changes in the ageing microenvironment that can
negatively impact resident progenitors (López-Otín et al., 2013). OPCs are no exception
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to this, and their functional deterioration is caused by intrinsic and extrinsic factors in the
ageing microenvironment, both of which culminate in the OPC ageing phenotype.
1.4.2 Remyelination efficiency declines with age
Despite remyelination going to completion, its efficiency declines with increasing age (Gilson
and Blakemore, 1993; Shields et al., 1999; Sim et al., 2002). Ageing, in fact, gives rise to
changes affecting the intrinsic properties of OPCs as well as factors in their extrinsic mi-
croenvironment, culminating in an inability of the progenitors to carry out their regenerative
role. I have previously described the events involved in remyelination, and a delay in the
process could be the result of either impaired OPC recruitment and/or an inability of the
recruited OPCs to differentiate within a lesion. So where in these processes is the bottle-
neck causing unsuccessful remyelination in ageing? There is evidence for defects in both
the recruitment and differentiation of OPCs in ageing animals (Sim et al., 2002).
OPC repopulation in toxin-induced lesions is delayed in old animals compared to their
young counterparts (Sim et al., 2002). Demyelinated lesions in aged rats accumulate pro-
genitors mainly at their border rather than being evenly spread throughout, and are unable
to match the OPC density displayed by younger animals at early recruitment time points
(Sim et al., 2002). An explanation could be that OPC numbers decline with increasing age,
making the available number of progenitors to recruit lower than in young organisms. De-
spite the ability to self-renew, an age-related decline in stem cell numbers has been observed
also in the case of NSCs, for example, (Maslov et al., 2004), making this a fair assumption.
However, evidence so far points towards OPC density remaining constant throughout life,
at least in the brain areas assessed to date, and overall, a high number of OPCs reside in the
aged rodent brain (Sim et al., 2002; Doucette et al., 2010; Rivers et al., 2008). Nevertheless,
if the number of OPCs does not change with ageing, other factors must be impairing their
recruitment. Studies on OPC cell cycle dynamics revealed that their cell cycle slows down
with age progression, presumably due to a lengthened G1 phase (Psachoulia et al., 2009;
Ruckh et al., 2012; Young et al., 2013). Besides the change in OPC cell cycle dynamics,
the specific implications of which have not yet been directly assessed in remyelination, it
cannot be excluded that signals shown to influence OPC proliferation and recruitment may
also be altered with age. The latter is a feasible possibility, as the expression of growth fac-
tors such as PDGF-A, IGF-I, and TGF-𝛽1 decreases with age, indicating a change in how
the ageing innate immune system responds to demyelination (Hinks and Franklin, 2000). It
is therefore possible to hypothesise that the slow recruitment and proliferation of OPCs in
old animals may be a consequence of altered cell cycle dynamics of aged progenitors and
impaired intercellular communication in the aged microenvironment.
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If lack of OPC numbers in the lesion was the main cause of impaired remyelination in
ageing, then increasing OPC recruitment should restore successful remyelination. Overex-
pressing PDGF-A in experimentally demyelinated lesions enhanced the OPC numbers re-
cruited. However, this did not have any effect on neither the timing or the extent of remyeli-
nation (Woodruff et al., 2004). Sim et al. (2002) further observed that, as well as delayed
migration, aged lesions presented a delay in OPC differentiation. As impaired epigenetic
regulation of gene expression is a key hallmark of ageing cells, and HDACs exert a salient
role in OPC differentiation, their ability to regulate this process in old animals was assessed.
Overall, cuprizone-induced demyelination in young animals is followed by a rapid increase
in HDAC1 and HDAC8 expression in OPCs, a process essential to the control of Sox2 ex-
pression, which in turn inhibits differentiation. Instead, aged OPCs present decreased ex-
pression of HDAC1 and 8 and increased expression of Sox2 following demyelination (Shen
et al., 2008). This study serves as an example of the impaired and inefficient epigenetic
regulation exhibited by aged progenitors, resulting in the persistent expression of genes pre-
venting OPC differentiation. The study of intrinsic factors governing OPC differentiation
can be complicated due to the difficulty of isolating and culturing aged progenitors in vitro,
and only recently are we beginning to explore the multitude of intrinsic factors governing
the transcriptional program of OPC differentiation. On the other hand, the extrinsic factors
impairing progenitor differentiation in aged animals have been better characterised, the ma-
jority of which seem to be mediated by an aged immune system. Aged animals present a
delayed immune response following demyelination. The importance of an immediate im-
mune response to demyelination has been previously outlined, and its delay implies a shift
in the timeframe of the entire remyelination process. It may therefore be that, with ageing,
remyelination is not impaired per se, but may rather be extensively delayed. However, aged
macrophages also present impaired phagocytosis capability, resulting in inefficient myelin
debris clearance (Natrajan et al., 2015; Lampron et al., 2015). Myelin debris has been shown
to be a key inhibitor of OPC differentiation both in vitro and in vivo (Kotter et al., 2006),
and its persistence in aged lesions due to lack of clearance could be the reason for impaired
OPC differentiation. Further evidence of the importance of a young and efficient immune
system in promoting remyelination came from experiments involving heterochronic parabio-
sis (Ruckh et al., 2012). In these experiments, young mice were joined with aged mice so
that they would share their circulation. Toxin demyelination was then induced in the aged
animal and remyelination was assessed. The experiment showed that upon exposure to a
youthful systemic environment, remyelination was indeed enhanced, with aged OPCs be-
ing both more proliferative and presenting higher levels of differentiation compared to the
isochronic-old controls. Remyelination was indeed carried out by aged OPCs as there was
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no engraftment of young OPCs in the lesions, but a high number of young macrophages were
found in the lesion, which correlated with increased myelin debris clearance (Ruckh et al.,
2012).
Based on the above, it is clear that a combination of both intrinsic and extrinsic factors
contribute to the ageing phenotype of OPCs which, however, remain responsive to exoge-
nous signals promoting their proliferation and differentiation. The parabiosis experiments
by Ruckh et al. (2012), as well as the currently unpublished work by Neumann et al. in the
Franklin laboratory on the effect of calorie restriction on aged OPCs provide evidence that
in vivo rejuvenation of OPCs is possible, as extrinsic signals can override the intrinsic pro-
genitor ageing phenotype. This area of research will be fundamental in the development of
regenerative therapies as ageing progenitors are clearly different to their younger counter-
parts.
1.4.3 Multiple Sclerosis is also a disease of age
The majority of neurodegenerative diseases arise in the aged population, establishing a strong
causal relationship between ageing and neurodegeneration (Wyss-Coray, 2016). Instead, in
the majority of cases MS has an onset in young adulthood, which has set it apart from other
neurodegenerative diseases with regards to its age onset. Despite the earlier appearance of
the disease, age is a salient factor in influencing both the form of MS affecting the patient
and its clinical course (Confavreux and Vukusic, 2006; Sanai et al., 2016).
In 80% of patients, MS presents as relapsing remitting MS (RRMS), which is charac-
terised by episodes of acute inflammation causing neurological impairment, followed by
recovery, probably due to remyelination (Compston and Coles, 2008; Franklin and ffrench
Constant, 2008). Over time, approximately 65% of the RRMS patients will enter the sec-
ondary progressive phase of MS (SPMS) where recovery no longer occurs and disability
progressively accumulates. The remaining 20% of cases present as primary progressive MS
(PPMS), where the disorder is progressive immediately from the onset (Compston and Coles,
2008). It has been reported that patients over 65 years of age tend to have a progressive course
compared to younger patients (Minden et al., 2004). Older patients, therefore, tend to present
with PPMS, and older age onset of RRMS results in an earlier conversion to SPMS (Scalfari
et al., 2011). Indeed, patients that developed RRMS at the age of 20 halved the risk of an
early conversion to SPMS compared to patients that developed RRMS at the age of 40 (Scal-
fari et al., 2011). Confavreux and Vukusic (2006) showed that MS patients reached specific
levels of disability at approximately the same age regardless of disease onset and whether it
started as RRMS or PPMS, further suggesting an age-dependent increase in disability accu-
mulation. After reaching the critical switch when disability starts to accumulate, there is no
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difference between the PPMS and SPMS patients in reaching the next disability score despite
the difference in inflammatory episodes (Confavreux and Vukusic, 2006). This suggests that
at this critical point of the disease the accumulation in disability does not tightly depend on
the inflammatory state of MS, but likely results from other mechanisms such as the age-
dependent inability to remyelinate and to restore function (Franklin and ffrench Constant,
2017).
Although it is hard to assess the course of remyelination in MS patients, pathological
data points towards a strong effect of age on the successful outcome of remyelination. As
in aged animals, a fraction of MS lesions present little to no OPCs within them (Boyd et al.,
2013). It has been shown that MS lesions can aberrantly express chemorepellent cues such
as Sema3A and netrin which negatively influence OPC migration, resulting in impaired OPC
recruitment (Boyd et al., 2013; Tepavcevic et al., 2014). Furthermore, analysis of chronic
MS lesions shows that the majority (60%-70%) contain sufficient OPCs, suggesting that the
remyelination rate-limiting factor may indeed be their differentiation rather than recruitment
(Wolswijk, 1998; Lucchinetti et al., 1999; Chang et al., 2000). OPCs recruited into these
lesions present an immature morphology compared to their young counterparts at equiva-
lent time points, raising the question of what is impairing their differentiation (Wolswijk,
1998; Chang et al., 2000). As with old animals, the aged immune system has a fundamental
role and it has been observed that macrophages of MS patients showed impaired phagocytic
activity, which is fundamental to myelin debris clearance and allowing OPC differentiation
(Natrajan et al., 2015). Overall, the lack of OPC differentiation appears to be the driving
cause of remyelination failure in the majority of MS lesions with ageing, and this reflects
in MS patients where remyelination impairment may be a deterministic factor in disease
progression.
1.4.4 Developing remyelination therapies
It is clear that remyelination carries out beneficial effects involving neuroprotection and pro-
moting neuronal function, and as a consequence its failure leads to irreversible neurological
damage. Despite the above, there are no current remyelination enhancing therapies avail-
able in the clinic. However, efforts are being invested in the development of such therapies
(Franklin and ffrench Constant, 2017). Two major approaches are being taken in trying to
enhance remyelination: those involving exogenous or endogenous therapies. Both strategies
are being tested in animal models and the choice of therapy should depend on the pathology
that the patient presents with (Franklin and ffrench Constant, 2017).
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Cell transplantation therapies
Cell transplantation therapies for remyelination involve the transplantation of exogenous
cells with the potential to give rise to myelinating cells. This method is particularly valuable
in the cases where demyelination occurs as a result of genetic defects, such as in leukodys-
trophies, as the transplanted cells should take over the role of the original defective OPCs.
In fact, glial cell transplantation has been a success in different animal models including in
shiverer mice (Windrem et al., 2004, 2008) and in dogs with PLP mutations (Archer et al.,
1997). Both showed the potential of extensive myelination, and Windrem et al. (2008) further
reported increased rodent life span and resolution of the typical shiverer symptoms. Further-
more, numerous cell types have been successfully transplanted in toxin-induced models of
primary demyelination, including OPCs, Schwann cells and olfactory ensheathing cells, all
resulting in successful engagement and myelination of demyelinated axons (Groves et al.,
1993; Franklin et al., 1996; Bachelin et al., 2005). However, human CNS stem cell trans-
plantation therapies in the context of MS raise major concerns, the biggest being the logic
behind the approach. If the majority of MS lesions contain OPCs that retain the ability to
remyelinate but fail, mainly due to the hostile aged environment, then transplanted progen-
itors will likely face the same issue. As mentioned above and further reviewed by Pluchino
et al. (2004), numerous candidates have been successfully transplanted in animal models;
however, the source of primary cells remains a matter of ethical discussion. The advent of
induced pluripotent stem cells (iPSC) has certainly aided in these discussions, as the pa-
tient’s somatic cells can be used to generate the desired cell type, also minimising the risk
of graft rejection (Xie et al., 2016). Indeed, the engraftment of OPCs derived from hu-
man iPSCs into neonatal shiverer mice resulted in successful myelination and increased life
span (Wang et al., 2013). However, the protocols to obtain these cells are still inefficient
and protracted, and the genomic instability of iPSCs leads to the risk of tumour formation
(Steinbeck and Studer, 2015; Xie et al., 2016). Transplants are highly invasive and compli-
cated procedures with a further risk of haemorrhage and cell aggregate formation (Steinbeck
and Studer, 2015). This operation would probably need to be carried out every time a new
lesion arises in the patient, leading to multiple rounds of transplants, further increasing the
risk of complications in these patients.
Enhancing endogenous remyelination
An appealing alternative is the development of endogenous remyelination therapies, which
aim at enhancing remyelination by the already resident OPCs. It is clear that myelination

























Fig. 1.4 OPC differentiation is a process affected by numerous factors. The factors can
be split into two categories: those preventing OPC differentiation and those promoting OPC
differentiation. Some of these have been shown to also be involved in remyelination and
for this reason they are currently being studied as potential targets for future remyelination
therapies.
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the aim of such therapies is to understand how these factors can be targeted to manipulate
the remyelination outcome. With this aim, remyelination therapies take one of the following
two approaches: the direct promotion of OPC differentiation, or the inhibition of negative
regulators in the lesion environment (Franklin and ffrench Constant, 2017).
Compound screenings and micropillar assays successfully identified various antagonists
of the M1 muscarinic acetylcholine receptors (mAchR) to increase OPC differentiation and
micropillar wrapping (Deshmukh et al., 2013; Mei et al., 2014). OPCs express mAchRs, and
M1 mAchR knockout specific to the oligodendrocyte lineage showed accelerated kinetics of
co-culture myelination. Treatment with the antimuscarinic clemastine also accelerated re-
myelination in toxin models and attenuated EAE symptoms (Mei et al., 2016a). Clemastine
has been used for the clinical study ReBUILD (NCT02040298), which was successful in re-
ducing visual evoked potentials and improving low-contrast visual acuity in RRMS patients
with episodes of optic neuritis. ReCOVER (NCT02521311) is aimed at patients with acute
optic neuritis and is currently recruiting (Plemel et al., 2017). Compound screenings also
revealed other medications promoting myelination and remyelination, such as clobetasol and
miconazole, involved in activation of Glucocorticoid receptor (GCR) and the ERK1/2 path-
way respectively (Najm et al., 2015). Κ-opioid receptors, Oestrogen receptor (ER), Thyroid
Hormone receptor (THR), and glycogen synthase kinase 3 (GSK3) are some of the other
targets that have been shown to modulate OPC differentiation in vitro and in vivo (Mei et al.,
2016b; Gonzalez et al., 2016; Zhang et al., 2016b; Medina-Rodríguez et al., 2017; Plemel
et al., 2017). Despite the initial success, a potential flaw of these studies is the use of cell
lines, iPSCs or young primary cells for their in vitro work and young animals for their in
vivo assessment. Young tissues and cells may respond well to such treatments; however,
aged OPCs are impaired in their usual functions and it may be that they are unable to re-
spond to such therapies. Given that the inability to remyelinate in MS patients is a function
of age, and that these medications will probably be aimed at groups presenting progressive
phases, it makes sense for such therapies to be tested on aged cells as well as animals before
being taken to clinical trials.
There are numerous negative regulators of remyelination in the lesion environment.
One of the most studied so far is the leucine-rich repeat and immunoglobulin-like domain-
containing nogo receptor-interacting protein 1 (LINGO1), which is specifically expressed in
the CNS. LINGO1 is well known as a regulator of axon outgrowth via the Nogo receptor, but
has also been identified as a negative regulator of OPC differentiation (Mi et al., 2005). Inhi-
bition of LINGO1 with antagonists resulted in OPC maturation in vitro and anti-LINGO1 an-
tibodies promoted remyelination in both EAE and toxin-models of demyelination (Mi et al.,
2009). Antagonising LINGO1 has been the main aim of RENEW (NCT01721161), a clini-
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cal trial involving the human monoclonal anti-LINGO1 antibody opicinumab, however there
was no difference in remyelination between the opicinumab and control group (Cadavid et al.,
2017). A follow-up extension study (RENEWed (NCT02657915)) aims to assess the patients
from the first trial for long-term effects on remyelination, however, very little is known about
the relevance of LINGO1 in MS lesions and how the effects of LINGO1 are exerted in the
animal models.
Wnt proteins are a family of secreted signalling molecules which canonically stimulate
the transcriptional activity of 𝛽-catenin. Canonical Wnt signalling occurs in both develop-
mental myelination and remyelination, however if the signalling pathway is dysregulated by
expressing a constitutively active form of 𝛽-catenin in oligodendrocyte lineage cells, then
both myelination and remyelination are impaired (Fancy et al., 2009). Wnt has been shown
to act through the transcription factor Tcf4, which is highly expressed in active MS lesions,
further suggesting its relevance in the disorder (Fancy et al., 2009). One of the strategies
suggested to reduce and control Wnt signalling is the manipulation of one of its transcrip-
tional targets, Axin2, shown to be required in OPC differentiation (Fancy et al., 2011). When
expressed, Axin2 regulates Wnt signalling via a negative feedback loop, and its manipula-
tion via the small molecule XAV939 stabilised Axin2 levels and accelerated remyelination
(Fancy et al., 2011).
Notch is a transmembranous protein which acts as a receptor for Jagged1. Upon this
interaction the Notch intracellular domain (NICD) is cleaved and translocated to the nu-
cleus where it acts as a transcription factor (Schweisguth, 2004). Notch signalling inhibits
OPC differentiation during development (Wang et al., 1998), however its involvement in re-
myelination remains uncertain (Stidworthy et al., 2004). Ablation of Notch1 in early OPCs
using Cre-lox via the Olig1 promoter resulted in earlier OPC differentiation but had no im-
pact on the overall rate of remyelination (Zhang et al., 2009). Notch1 ablation in immature
oligodendrocytes using the Plp promoter did not result in neither premature oligodendrocyte
maturation, nor in accelerated remyelination (Stidworthy et al., 2004). The Jagged1-Notch
pathway seems to be expressed in MS lesions, a downstream target of which is Hes5, an
inhibitor of OPC differentiation (John et al., 2002), making this pathway a relevant, but not
a dominant, candidate for negatively impacting OPC differentiation.
More recently, components of the extracellular matrix (ECM) have been implicated in
remyelination failure. Of the many components making up the ECM, hyaluronan and chon-
droitin sulfate proteoglycans (CSPGs) have been implicated in OPC differentiation. CSPGs
have been shown to prevent in vitro OPC maturation as well as their migration, and the use of
fluorosamine, an inhibitor of CSPG synthesis, resulted in accelerated OPC recruitment and
improved remyelination in the lysolecithin model (Lau et al., 2012; Keough et al., 2016). I
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have previously discussed the involvement of regulatory molecules such as semaphorins in
remyelination models and MS lesions; these are also valid candidates for future studies on
potential targets in remyelination therapies.
Age is a critical factor in determining disease progression in patients affected by MS.
This is partly due to aged microglia and macrophages being unable to phagocytose myelin
debris, ultimately preventing OPC differentiation. In vitro studies and microarray analysis
carried out by Natrajan et al. (2015) revealed that the aged phenotype of both rodent and hu-
man monocytes is in part due to an altered expression of Retinoid X receptor 𝛼 (RXR𝛼). The
aged phenotype can be successfully obtained in young monocytes via a monocyte specific
knockout of RXR𝛼, whilst rejuvenation of old monocytes is possible via the use of RXR ag-
onists. Furthermore, the ability of monocytes derived from aged rodents, aged humans and
MS patients to phagocytose myelin debris increased upon their in vitro treatment with the
RXR synthetic ligands 9-cis-retinoic acid (9cRA) and bexarotene. Modulation of phagocy-
tosis via bexarotene treatment has also shown to increase the clearance of amyloid-𝛽 deposits
in a mouse model of Alzheimer’s Disease (Cramer et al., 2012). These findings are of the
utmost relevance to MS patients, as bexarotene is an already FDA-approved rexinoid cur-
rently used for the treatment of cutaneous T cell lymphoma (Querfeld et al., 2006). Despite
its relevance in monocytes, the effects of RXR are not limited to the immune system alone.
RXRs are also expressed in oligodendrocyte lineage cells, and their role in remyelination was
first described during a microarray analysis of the CNS toxin lesion (Huang et al., 2010a).
It was revealed that the expression of RXR𝛾 is highly increased at time points coinciding
with the remyelination phase, and subsequent analysis of MS post mortem tissue suggested
a correlation between RXR𝛾 expression and remyelination capacity. Chronic inactive le-
sions contained significantly less RXR𝛾+ oligodendrocyte lineage cells compared to active
and remyelinated lesions. Huang et al. (2010a) went on to show that 9cRA treatment of
in vitro OPC cultures and cerebellar slices induces OPC differentiation and ex vivo myeli-
nation, whilst the opposite is observed when RXR𝛾 function is impaired via genetic and
transcriptional silencing or its antagonists. Furthermore, 9cRA treatment of toxin-induced
demyelination in aged rats resulted in accelerated remyelination (Huang et al., 2010a), and
this work is the basis of an ongoing clinical trial that uses bexarotene, an RXR agonist, in
MS patients.
In conclusion, in recent years numerous promising targets have been identified as candi-
dates for the development of remyelination therapies, however, often the ageing component
of MS is overlooked when testing their relevance in remyelination. All in all, RXRs are
emerging as particularly interesting candidates for the above, as their activation can drive
30 Introduction
OPC differentiation and remyelination in spite of ageing. However, the exact molecular
mechanisms involved in RXR driven OPC differentiation remain elusive.
1.5 RXR belongs to the nuclear receptor superfamily
Nuclear receptors (NR) are ligand-induced transcription factors able to translate small chem-
ical changes into large physiological effects by regulating gene transcription. They are ubiq-
uitously expressed and are able to influence a vast range of tissue physiologies including
development, growth, apoptosis and various aspects of homeostasis and metabolism (Evans
and Mangelsdorf, 2014). Up until the 1960s, it had been extensively observed that small
lipophilic molecules such as hormones and vitamins could influence tissue physiologies and
induce de novo synthesis of mRNA (Edelman, 1975). How exactly these molecules exerted
their function remained unknown until the development of radio-labelled oestrogen, which
revealed the existence of a putative receptor that could translocate from the cytoplasm to
the nucleus. The translocation was linked to the control of gene transcription (Jensen et al.,
1966). This concept was further supported by the observation that metamorphic hormones
in drosophila induced chromosomal puffing at specific locations, further implying a direct
effect of these receptors on DNA (Ashburner et al., 1974). The nature of the putative re-
ceptor remained elusive until the mid-1980s, when the complementary DNA (cDNA) of the
GCR and ER was isolated and cloned (Hollenberg et al., 1985; Miesfeld et al., 1986; Green
et al., 1986). The characterisation of the first NRs and the observation of highly conserved
homology at other genetic locations revealed the existence of a whole class of such receptors.
For example, Green et al. (1986) reported that the ER shared extensive homology with the
erb-A gene which was later discovered to encode a THR isoform (Weinberger et al., 1986).
During these years the continuous discovery of highly homologous receptors activated by
a whole range of specific lipophilic ligands revealed an array of new molecular pathways
governing gene transcription.
1.5.1 Characterisation of the NR superfamily
NRs make up one of largest families of transcription factors, with over 270 NRs found in the
nematode worm to much lower numbers in mammals including 47, 48 and 49 in rat, human
and mouse respectively (Zhang et al., 2004; Evans and Mangelsdorf, 2014). With the use
of gene sequence analysis it has been possible to track the emergence of the first NRs in
early metazoans and the highly conserved evolutionary template that emerged from sequence
comparison of NRs suggests they evolved from a common ancestor. Although Zn-fingers
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with NR similarities are found in yeast and plants, we still lack the evidence for these to be
considered their ancestors (Owen and Zelent, 2000). NRs emerged via two waves of gene
duplication: the first occurred in the early metazoans and it divided NRs into subfamilies,
whilst the second wave in vertebrates allowed the emergence of different isoforms of the same
receptor (Szanto et al., 2004). The study of the evolutionary conservation and relationship
of NRs characterised both structural and functional features that would allow the subsequent
classification of the superfamily. Laudet (1997) divided the superfamily into six subfamilies
as shown in Table 1.1.
The division in these subclasses remains arbitrary, and occasionally it is preferred to
divide them into three subclasses depending on the types of ligands involved in their activa-
tion.
In this case, the first class is the ‘steroid receptor family’, and is broadly made of the NRs
in class III of Table 1.1; the second class is the ‘thyroid/retinoid family’ made of mainly class
I; and the final class is the ‘orphan receptor family’, for which the cognate ligands are still
unknown (Bain et al., 2007). Ligands for some orphan NRs have been already described,
including bile acids, fatty acids, cholesterol derivatives and so on, making them a particularly
interesting avenue for the discovery of new signalling molecules (Chawla et al., 2001; Burris
et al., 2013).
The NR structure resembles the one of other transcription factors in that it is divided
into modules that correspond to autonomous functional domains as represented in Figure
1.5. Each domain is designed exquisitely for the specific signalling carried out by NRs.
NRs are made of six modular domains labeled A to F. The A/B domain is located at the N-
terminal of the receptor and is the least conserved region. In fact, alternative splicing of this
module accounts for the creation of different isoforms of the same receptor. This domain is
subject to post-translational modifications such as phosphorylation, which can influence their
transcriptional activity, as in the case of RAR, PPAR and ER, which can be phosphorylated
by cyclins and MAPK (Kato et al., 1995; Rochette-Egly et al., 1997, 2000; Juge-Aubry et al.,
1999). This is because the A/B module contains an autonomous transcriptional activation
function termed AF-1, responsible for the constitutive ligand-independent activation of the
receptor (Tora et al., 1989; Tzukerman et al., 1994; Burris et al., 2013). The C module is
the most conserved and contains the DNA binding domain (DBD), which includes two Zn-
finger core motifs that allow NRs to associate to the genome (Lee et al., 1993; Schwabe et al.,
1993; Mader et al., 1993). The DBD is followed by a hinge region (D module), conveying
flexibility to the DBD and allowing rotation of the module. The hinge region is between the
DBD and the ligand binding domain (LBD), termed E module (Aranda and Pascual, 2001).
The main function of the LBD is to allow binding of the ligand and contains AF-2, the ligand-
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Farnesoid X receptor FXR Bile acids
Liver X receptor LXR 𝛼,𝛽 Oxysterols
Peroxisome proliferator
activated receptor
PPAR 𝛼,𝛽,𝛾 Eicosanoids, Thiazolidines
Pregnane X receptor PXR Pregnanes
Retinoic acid receptor RAR 𝛼,𝛽,𝛾 Retinoic acid
Reverse ErbA RevErb 𝛼,𝛽 Unknown
Retinoid Z receptor RZR 𝛼,𝛽,𝛾 Unknown
Thyroid hormone
receptor
THR 𝛼,𝛽 Thyroid hormone











Retinoid X receptor RXR 𝛼,𝛽,𝛾 9cRA
Tailles-related receptor TLX Unknown
Ubiquitous receptor UR Unknown
III Androgen receptor AR Androgens




Glucocorticoid receptor GCR Glucocorticoids
Progesterone receptor PR Progestins
Testis receptor TR2 𝛼,𝛽 Unknown
IV NGF-induced clone B NGFI-B 𝛼,𝛽,𝛾 Unknown
V Steroidogenic factor 1 SF-1 𝛼,𝛽 Oxysterols
VI Germ cell nuclear
factor
GCNF Unknown
Table 1.1 The nuclear receptor superfamily is divided into six subfamilies based on
their amino acid sequence conservation. The full name and abbreviation of the receptors,
known subtypes and ligands are shown. Table adapted from Aranda and Pascual (2001).
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Fig. 1.5 Schematic of NR structure. (A) is a diagram representing the modular structure
of a generic NR. It is divided into autonomous domains. The A/B domain is located at the
N-terminal. This region also contains the ligand-independent transactivation domain AF-1.
The C domain binds to genomic elements. The D domain is a hinge region that allows for
flexibility. The E domain is involved in ligand binding and contains the ligand-dependent
transactivation domain AF-2. The role of the F region remains unknown. (B) illustrates
the 3D quaternary structure of the RXR𝛼-PPAR𝛾 heterodimer, where RXR𝛼 is illustrated in
pink and PPAR𝛾 is shown in yellow. The complex is shown bound to DNA, represented in
orange. Co-regulator peptides associated to the heterodimer are shown in green. This figure




























Fig. 1.6 Schematic representation of the signalling mechanism of RXR heterodimers.
It is generally accepted that in the absence of their cognate ligand the RXR-NR dimer is
bound to relevant HREs and associated to co-repressors inhibiting gene transcription. In the
presence of the ligand co-repressors are released and co-activators bind instead. The co-
activators allow for chromatin modifications and remodelling, and with recruitment of the
basal machinery gene transcription can now occur.
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dependent transactivation domain (Wurtz et al., 1996; Nagy and Schwabe, 2004). However,
the LBD exerts multiple functions that go beyond containing the ligand binding pocket of
NRs. It also mediates binding of heat-shock proteins and dimerisation of the receptors (Pratt
et al., 1988; Scherrer et al., 1993; Valentine et al., 2000).
1.5.2 RXR heterodimers are central to NR signalling
The ability of NRs to regulate gene transcription is determined by genomic variants of the
core motif AGGTCA, which allow sequence-specific binding to the genome (Beato et al.,
1995; Evans and Mangelsdorf, 2014) . These core consensus sequences are termed hor-
mone response elements (HRE) and are usually located in upstream regulatory promoter or
enhancer regions of genes (Kittler et al., 2013; Gadaleta and Magnani, 2014). Differences
in the orientation and spacing of the HREs determine how NRs associate to the DNA, re-
vealing that NRs can associate to the genome as homodimers or heterodimers as well as
monomers. Class III NRs tend to associate to certain palindromic repeats as homodimers,
whilst the non-steroidal class I NRs heterodimerise with RXR when associated to the DNA
(Beato, 1991; Yu et al., 1991; Bugge et al., 1992). RXR is capable of heterodimerisation,
and this finding gave rise to a wave of discovery that shifted the vision of NR signalling from
individual linear signalling pathways to the astonishing realisation of the existence of novel
interlaced signalling networks, developing new and fundamental concepts in the NR field.
It is conventionally accepted that unlike steroid NRs, which shuttle to the nucleus in
presence of the ligand, RXR heterodimers are already found in the nucleus associated to
their relevant HRE. However recent studies have shown that shuttling does occur for RXR
heterodimers as well. In the absence of their ligand, they are also associated to co-repressors
which prevent transcription of the downstream gene. Being small lipophilic molecules, NR
ligands can cross plasma membranes, and in the presence of their cognate ligand the RXR-
NR will release the repressors, co-activators will bind in their place, leading to chromatin
modifications that will make the chromatin more accessible to the basal machinery. Once
this is recruited, transcription of the downstream genes can occur.
However, the opportunity of discovering new signalling avenues via heterodimeric sig-
nalling comes at the cost of an increasingly complex system to disentangle where, the more
is learnt, the bigger the realisation of how little is known. The above remains an extremely
simplistic description as we still lack knowledge on the complexity of regulation of RXR-NR
signalling, but what does regulation of this system actually entail? As summarised in Figure
1.7, for RXR-NR to signal, four main things need to happen, suggesting that the system can


























Fig. 1.7 Schematic of the levels of control for NR signalling. In order for RXR het-
erodimers to signal four main things need to happen: (A) firstly the cognate ligand needs
to be present. The ligands are small lipophilic molecules that can cross cellular membranes
without the need of transporters. (B) Upon ligand binding, RXR heterodimerises with the
correct NR partner. This is essential for both shuttling and association to the desired HREs.
(C) Although it is conventionally accepted that RXR heterodimers are always found in the
nucleus, it has been shown that whole heterodimers are able to shuttle between the cyto-
plasm and nucleus upon ligand binding. Subcellular location is essential to the signalling
of these transcription factors and segregation in specific cellular compartments is thought to
be one of the ways in which this system is regulated. (D) Upon HRE binding co-regulators
are recruited in order to modify the chromatin and control transcription of the desired genes.
Depending on the HRE element bound, either co-activators or co-repressors are recruited
which may promote or inhibit gene transcription.
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Cognate ligand binding
NRs are one of the most commonly used drug targets for both human disease and lifestyle
(Overington et al., 2006). Despite being mainly studied and used in the cancer field, NRs
have also been targeted in metabolic and inflammatory disorders such as diabetes and rheuma-
toid arthritis as well as for the contraceptive pill and performance enhancing steroids (Over-
ington et al., 2006; Wang et al., 2010; Shirinsky and Shirinsky, 2011; Sladek, 2011; Dhiman
et al., 2018). This is due to their hydrophobic binding pocket, which permits easy manip-
ulation of their biological function with the use of both natural and synthetic ligands. As
illustrated in Table 1.1, NR ligands are small hydrophobic molecules including lipophilic
hormones, vitamins, xenobiotics, derivatives of retinoids, fatty acids, cholesterol and many
more. In the absence of the cognate agonist, the RXR-NR is in a conformation that allows as-
sociation of co-repressors which will silence transcriptional activity (Casanova et al., 1994;
Tong et al., 1996). When the agonist is present, it binds to hydrophobic signatures of the
pocket via van der Waal interactions (Huang et al., 2010b). X-ray crystal structure of NRs
revealed that this causes a structural conformational change of the receptor that releases the
repressors and exposes a hydrophobic surface which will bind co-activators possessing the
corresponding binding motif (Heery et al., 1997; Nolte et al., 1998; Gronemeyer et al., 2004).
The above is an extremely simple outline of the general consensus of how ligands af-
fect NR signalling and is based on the studies of the first NRs. The idea of a single ligand
for a single receptor which will elicit a very specific biological outcome remains an over-
simplification that is not typical of all NRs, especially RXR heterodimers. Firstly, we find
dual ligand regulation, where two different ligands are able to induce different outcomes by
activating the same receptor complex; this will be further discussed in the next section. It
has also been shown that many of these receptors can be activated by a variety of molecules
rather than by single ligands. This depends on the binding pocket of the individual receptors,
which could accommodate varieties of similarly structured molecules, and in some instances
ligands can be interchangeable as in the case of COUP-TF, whose crystal structure was found
to contain retinoic acid in its pocket and is also able to respond to it in transactivation assays
(Kruse et al., 2008). Adding to this complexity, crystal structure of the RXR partner PPAR
revealed two molecules bound simultaneously in the pocket of the receptor, with different
residues mediating the recognition and binding of different ligands (Tsukahara et al., 2006;
Bernardes et al., 2013). This final observation shows that unlike class III NRs, which are
typically viewed as endocrine receptors, RXR-heterodimers act as environmental sensors
and the overall biological outcome of their stimulation may be a result of the environmental
cocktail of ligands at that specific point in time. Finally, an important ability of NRs is that of
regulating their own activation by controlling the transcription of cytochrome P450 (CYP)
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enzymes involved in the production or degradation of their ligands. This has been described
for RXR, VDR, RAR, PPAR, PXR, LXR and FXR, and is important as these dynamics
are the drivers of physiological circuits (Kliewer et al., 1998; Wang et al., 1999; Evans and
Mangelsdorf, 2014).
Heterodimerisation of the correct NR partner
The dual ligand regulation of RXR heterodimers is one of the most fascinating aspects of
their biology, as the same receptor complex can be activated by two different ligands, one
acting on RXR and one acting on the partner. This ability divides RXR heterodimers into
two categories: non-permissive and permissive. Non-permissive heterodimers are formed
by RXR dimerising with RAR, THR and VDR. The ligand-dependent activity of RXR in
these complexes is suppressed by the associated partner, so the heterodimer can only be ac-
tivated in the presence of the partner’s ligand (Leblanc and Stunnenberg, 1995). The study
of the non-permissive heterodimer RXR-THR via nuclear magnetic resonance spectroscopy
(NMR) revealed that liganded THR induces a conformational structure where the LBD of
RXR is physically blocked, preventing the entrance of the RXR ligand (Kojetin et al., 2015).
Statistical coupling analysis predicts this mechanism to be conserved across non-permissive
partners (Shulman et al., 2004). In this scenario, RXR has often been termed the ‘silent
partner’, believed to play an auxiliary role in stabilising the complex for the signalling of its
non-permissive partners. However, recent data revealed that the presence of rexinoids mod-
ulates the interaction of RXR-VDR and RXR-THR with co-regulators, suggesting a more
dynamic allosteric signalling pathway than anticipated (Sánchez-Martínez et al., 2006; Fat-
tori et al., 2015). Permissive RXR partners include FXR, LXR, PXR, and PPAR, and when
bound to these the RXR-NR can be activated by the ligand of either receptors (Evans and
Mangelsdorf, 2014). If both ligands bind simultaneously, they act synergistically as shown
in the case of RXR-PPAR, where the net effect of the combined ligands is stronger than with
individual ligands (Kliewer et al., 1992). It therefore appears that the overall biological effect
of the RXR-NR activation may not be dictated exclusively by the presence of the ligand, as
the ability of ligands to activate the heterodimers reciprocally depends on structural changes
on RXR induced by the partner itself.
All tissues express multiple RXR partners simultaneously, begging the question of how
do certain RXR heterodimers prevail over others, if at all. If we therefore consider a limited
pool of available RXR at any one time, we can imagine the rise of a competitive system
where the availability/sequestration of RXR is dependent on the expression level of all of
its partners. This hypothesis is supported by the observation of extensive cross-talk between
RXR and its partners as well as between the partners themselves (Chan and Wells, 2009). An
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example is PPAR, which has been found to compete with VDR for its binding with RXR𝛼.
In this study, overexpression of PPAR𝛾 abrogated the effects of calcitriol activated VDR,
which could in turn be rescued by overexpressing RXR𝛼, suggesting the competitive nature
of these receptors (Alimirah et al., 2012). The above has also been reported between PPAR,
THR and LXR (Hunter et al., 1996; Ide et al., 2003). Further regulation of the system is
therefore achieved with RXR availability as a limiting factor for NR signalling.
Shuttling to the nucleus
Although ligand availability and partner association both play important roles in regulating
RXR-NR activity, other mechanisms have been hypothesised to contribute to the responses
modulated by RXR heterodimers. An example is the subcellular compartmentalisation of the
dimers. As NRs have been shown to continually shuttle between the nucleus and cytoplasm
of cells (DeFranco, 2002) this is a coherent hypothesis as to elicit transcriptional regulation,
transcription factors need to be located in the nucleus. Active nuclear import and export of
proteins is mediated by nuclear localisation sequences (NLS) in the protein to be transported.
These are recognised by importins, which in turn mediate the nuclear import of the cargo
by interacting with machinery at nuclear pores (Kumar et al., 2006). NRs harbour one or
more types of NLS, therefore suggesting that the nuclear translocation of such receptors is
a regulated event (Hsieh et al., 1998; Black et al., 2001; Prüfer and Barsony, 2002; Zhang
et al., 2018). The use of fluorescent protein-labelled chimeras and fluorescence resonance
energy transfer microscopy (FRET) has aided many of the discoveries made regarding the
translocation of RXR-NR between the nucleus and the cytoplasm. If we take RXR-VDR as
an example, both receptors can be transported into the nucleus as monomers via two distinct
mechanisms. However, RXR dimerises with VDR in the cytoplasm and can be translocated
to the nucleus as an already formed heterodimer (Prüfer et al., 2000; Yasmin et al., 2005).
FRET and photobleaching experiments suggest that the subcellular distribution of liganded
and unliganded VDR is highly dependent on RXR, and heterodimers containing mutant RXR
failed to distribute unliganded VDR. This correlated with reduced basal transcriptional ac-
tivity (Prüfer et al., 2000). However, in response to the VDR ligand calcitriol, RXR-VDR
shuttles to the nucleus. This effect is not obtained in the presence of 9cRA, nor by mutation
of the RXR NLS, suggesting that, for this heterodimer, the partner dominates the localisation
and consequently the activity of the receptor complex (Prüfer and Barsony, 2002; Yasmin
et al., 2005). Therefore, the distribution of both the heterodimers and monomers is another
important level of controlling their signalling pathway.
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Association of co-regulators
The ultimate function of RXR heterodimers is to regulate gene transcription, and this is de-
pendent on the recruitment of factor complexes that are involved in determining chromatin
state and therefore its accessibility. A generally accepted view is that in absence of the ligand,
RXR-NR binds to co-repressors via a specific motif, able to interact with the LBD, conse-
quently silencing transcriptional activity (Casanova et al., 1994; Tong et al., 1996; Perissi
et al., 1999; Webb et al., 2000). However, the conformational change imposed by ligand
binding releases co-repressors and exposes a hydrophobic surface to which co-activators can
now associate and induce chromatin modifications that will allow transcription (Egea et al.,
2000; Evans and Mangelsdorf, 2014). Examples of co-repressor molecules include silenc-
ing mediator for retinoic and thyroid hormone receptor (SMRT) and nuclear co-repressor
(NCoR), both of which have been shown to bind RAR and THR in vitro, however are re-
leased upon treatment with the respective agonists (Hörlein et al., 1995; Chen and Evans,
1995). These two complexes are known to directly interact with HDACs (Kao et al., 2000;
Huang et al., 2000), suggesting that one of the mechanisms by which SMRT and NCoR
prevent gene transcription is by inducing histone de-acetylation via HDACs. Common co-
activator complexes include ATP-dependent chromatin remodeller factor SWI/SNF, HATs
such as CBP/p300 and the TRAP/DRIP complex, which is involved in the recruitment of
RNA polymerase II (Dilworth et al., 2000; Rachez et al., 2000; Ito et al., 2002).
Although the above view is still generally accepted in the field, recent research has clearly
shown that the above remains a overly simplified model of how these receptors control gene
transcription. Co-regulator recruitment is highly dependent on the NR structure imposed
by the presence and sequence of its HRE (Fernandez, 2018). This has been shown, for ex-
ample, in biophysical studies involving RXR-THR and RXR-VDR (Putcha and Fernandez,
2009; Zhang et al., 2011). In the former study it was observed that the binding affinity of
the co-activator SRC1 is altered in the presence or absence of relevant HREs (Putcha and
Fernandez, 2009), whilst the latter study revealed that the binding affinity alterations be-
tween co-regulators and RXR-VDR are due to the structural dynamicity caused upon DNA
binding (Zhang et al., 2011). Furthermore, the composition of the HRE is also able to in-
duce the inverse effect of what is expected from a NR agonist, therefore, upon binding of
liganded RXR-NR, co-repressors are recruited and transcription is inhibited. (Fernandez,
2018). These are termed negative HREs and have been described for numerous RXR part-
ners as well as class III NRs (Schoorlemmer et al., 1994; Radoja et al., 1997; Koszewski
et al., 2000; Dostert and Heinzel, 2004; Sharma et al., 2013).
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Thus, RXR is an integral part of NR signalling as it can form heterodimers with other NRs.
Signalling of RXR heterodimers is controlled at different molecular levels, whereby each
level influences the other. Heterodimerisation as well as nuclear import/export both depend
on ligand presence and are partner dependent processes. The co-regulator association is
further dependent on ligand binding and DNA interactions, both of which have long-range
effects on the heterodimer structure, and it is this allosteric communication between ligand,
DNA and co-regulator, that provides a link between the target genomic area, the distinct co-
regulator recruited and the consequent chromatin remodelling that will occur (Fernandez,
2018).
1.6 RXR and its partners influence aspects of OPC biology
important to remyelination
1.6.1 The involvement of RXR and its partners in remyelination
Despite being highly conserved and ubiquitously expressed, it is clear that RXR heterodimers
carry out process-specific functions. One of these is their involvement in regulating stem
cells, as they are key players in their self-renewal as well as in their differentiation and re-
programming (Sun and Shi, 2010). These aspects also hint at their potential as an important
avenue for regenerative medicine. Indeed, NRs have been found to regulate regenerative
processes in a variety of organs, including skin, bone and liver, and have been found to in-
fluence both the early inflammatory stage of regeneration as well as the later reparative phase
(Vacca et al., 2014; Jin et al., 2015; Rieger et al., 2015; Merlen et al., 2017). In this regard,
remyelination is no exception.
Although the impact of NRs on the immune system will not be discussed further, it is
worth mentioning that EAE mice treated with agonists for THR, VDR, PPAR etc. result in
lower clinical score and amelioration of the symptoms, a result which is compromised when
carrying out the same experiments in the respective NR knockdown or knockout animals.
Further in vivo and in vitro assessments suggest that these ligands modulate the immune sys-
tem of EAE animals in a variety of ways, including regulating phagocytic activity, reducing
pro-inflammatory aspects such as CNS monocyte infiltration, activation and gliosis, whilst
increasing the number of cells in an anti-inflammatory state (Calza et al., 2002; Lovett-Racke
et al., 2004; Hindinger et al., 2006; D’Intino et al., 2011; Joshi et al., 2011; Kanakasabai et al.,
2011; Mayne et al., 2011; Dell’Acqua et al., 2012; Paintlia et al., 2013; Montarolo et al., 2015;
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Secor McVoy et al., 2015; Zhen et al., 2015). Whilst the immunomodulatory aspect of NR
signalling in the above studies is of obvious relevance to the early clinical stages of MS,
their influence on remyelination remains unclear. Instead, to address the above, a series of
NR agonists and antagonists have been tested in toxin-induced demyelination models. In the
cuprizone model, treatment with thyroid hormone has shown the most successful results.
Thyroid hormone treated mice present an increase in differentiation markers such as MBP
in both the CC and the cortex (Franco et al., 2008; Silvestroff et al., 2012). However, they
also observed an increase in numbers of Olig2+, suggesting increased proliferation (Franco
et al., 2008). Enhanced OPC differentiation may therefore be the result of increased OPC
numbers and density rather than a direct effect on differentiation. Despite this, remyelination
assessment via EM showed that, unlike what has been observed in remyelinated tissue, upon
thyroid hormone treatment a lower 𝑔 ratio is observed compared to controls, suggesting that
new myelin is similar to that of developmental myelin (Zhang et al., 2015a). Supplementa-
tion of vitamin D via dietary intake or intraperitoneal injections also yielded positive effects
in the cuprizone model, whereby it showed a protective effect by reducing the extent of de-
myelination as well as increasing myelin content during the defined remyelination phases
(Wergeland et al., 2011; Nystad et al., 2014). On the other hand, activation of LXR, RXR
and RAR did not yield any differences in CC1+ staining in the cuprizone model, suggesting
they had no effect on OPC differentiation and consequently on remyelination (Kruczek et al.,
2015).
The choice of the cuprizone model makes demyelination induction a less invasive proce-
dure. However, it does come at a cost as a drawback of this model is the ambiguous separa-
tion between demyelination and remyelination, as both occur simultaneously. It may there-
fore be that these studies were undermined by the caveats of the cuprizone model which im-
peded correct analysis and interpretation of the data since, for example, Huang et al. (2010a)
clearly showed the positive effects of RXR activation on remyelination in the EB model.
These effects have been previously discussed in Section 1.4.4.
There is currently little data on the effects of RXR partners on in vivo remyelination, and
the majority of the data has been collected from cuprizone animals, however NRs have been
shown to have profound effects on OPC proliferation and differentiation both in vitro and ex
vivo. Based on this data, I hypothesise that RXR and its partners can influence differentiation
in three ways: by cell cycle control, by directly promoting differentiation and by aiding in
fatty acid and cholesterol metabolism.
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1.6.2 RXR and its partners regulate cell cycle and differentiation
The main field of research involving the study of NRs is the cancer field, as NRs play critical
functions in both the development and progression of cancers (Dhiman et al., 2018). Ad-
ditionally, they have been particularly useful for the development of cancer differentiation
therapies. As discussed by Altucci et al. (2007), unlike conventional chemotherapy which
aims at killing cancerous cells, cancer differentiation therapy tries to induce terminal dif-
ferentiation/apoptosis of tumorous cells by reactivating pathways that are suppressed during
tumorogenesis. RAR has been the most successful target for this treatment and is currently
used for the treatment of acute promyelocytic leukaemia (APL), showing high remission
rates (Cicconi and Lo-Coco, 2016). It has been currently shown that the induction of differ-
entiation can also be obtained with the use of rexinoids, which are more favourable as are
generally less toxic than retinoids (Miller et al., 1997).
The ability to induce differentiation and influence proliferative cells is not restricted
solely to RAR and RXR, but is observed across the NR superfamily. Indeed, there is in-
creasing evidence that NRs can regulate numerous aspects of stem cell biology, including
maintenance of stemness, induction of differentiation and trans-differentiation, as well as
being use in stem cell reprogramming (Jeong and Mangelsdorf, 2009). They do so for em-
bryonic stem cells (ESC) as well as for adult stem cells. However, the way in which NRs
influence stem cell regulation is tissue-specific, a surprising finding considering their highly
conserved evolution.
RAR is a potent master regulator of embryonic development, which became clear via the
studies of its teratogenic effects (Durston et al., 1989; Avantaggiato et al., 1996). In the bone
marrow of RAR𝛾−/− mice, there is a reduction in the hematopoietic stem cell (HSC) pool and
an increased number of differentiated cells, suggesting an inability in maintaining the HSC
population (Purton et al., 2006). This is also observed in mesenchymal stem cells (MSC)
where the use of RAR𝛼 and 𝛽 antagonists in vitro resulted in chondrogenesis (Kafienah
et al., 2007). In the context of OPC biology, in the embryonic spinal cord retinoic acid (RA)
prevents their maturation (Noll and Miller, 1994) independently of the stimulation of cell
division (Laeng et al., 1994). RAR may elicit these effects by influencing the expression
level of the negative regulators of differentiation Hes5 and Id4 as has been shown by recent
RNA sequencing experiments, where OPCs derived from human ESCs were exposed to all-
trans retinoic acid (ATRA) (Kim et al., 2017).
The role of thyroid hormone as a potent driver of OPC differentiation has been exten-
sively described both in vitro and in the developmental in vivo setting. During develop-
ment, animals with hypothyroidism due to lack of triiodothyronine (T3) present delayed OPC
differentiation and myelination, whilst the opposite is observed in hyperthyroidic animals,
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suggesting a link between thyroid hormone and myelination (Ibarrola and Rodríguez-Peña,
1997; Marta et al., 1998). Both THR𝛼 and 𝛽 are expressed in OPCs, and the pattern of ex-
pression coincides with the peak of myelination in P7 rats. This time point coincides with a
switch in the expression of the THR isoforms in OPCs, where THR𝛽 is the prevalent isoform
(Carré et al., 1998; Sarlieve et al., 2004). T3 potentiates oligodendrocyte lineage terminal
differentiation in vitro (Almazan et al., 1985; Koper et al., 1986; Dugas et al., 2012) and
its use has been extensively adopted in tissue culture upon wanting to differentiate OPCs
into oligodendrocytes, as well as for the generation of oligodendrocytes from human iPSCs
(Ehrlich et al., 2017). OPC differentiation in T3 presence occurs at the expense of prolif-
eration as shown by the decrease of BrDU incorporation, a phenomenon observed both in
the presence as well as the absence of PDGF and FGF-2, suggesting that THR activation
overrides the effect of mitogens involved in maintaining OPC proliferation (Barres et al.,
1994).
VDR signalling is involved in osteoclast formation of chondrocytes, suggesting an in-
volvement in their terminal differentiation (Masuyama et al., 2006). Moreover, VDR is
also shown to be involved in cell lineage specification in the CNS, where multipotent NSCs
treated with vitamin D show both a more proliferative phenotype and acquire an oligoden-
drocyte fate rather than a neuronal one (Shirazi et al., 2015). However, OPCs treated in vitro
with calcitriol differentiate into oligodendrocyte at the expense of proliferation, suggest-
ing VDR as a potent regulator of cell cycle exit and differentiation induction (de la Fuente
et al., 2015). In this study, de la Fuente et al. (2015) further showed that antagonising VDR
signalling both in vitro and in ex vivo organotypic cerebellar slices blocked baseline differ-
entiation and remyelination. These effects are linked to the RXR-VDR heterodimer based
on co-immunoprecipitation (CoIP) experiments carried out on oligodendrocyte lineage cells
(de la Fuente et al., 2015).
As well as in the toxin-induced lesion, Huang et al. (2010a) demonstrated the specific
effects of RXR𝛾 on OPCs both in vitro and in cerebellar slices. The transcriptional and
pharmacological inhibition of RXR𝛾 resulted in reduced differentiation and remyelination,
whilst agonist activation increased both criteria. RXR𝛾 knockout animals are apparently
normal (Krezel et al., 1996), however, they do present depressive-like behaviours due to
reduced expression levels in dopamine D2 receptor, altered serotonin levels (Krzyzosiak
et al., 2010) and deficits in working memory, for which the molecular underpinning is still
unknown but could be due to impaired long term potentiation and depression (Wietrzych
et al., 2005; Chiang et al., 1998), and consequently synaptic plasticity. It is interesting to
note that in CNS cells, RXR𝛾 is predominantly expressed in OPCs as observed in the RNA-
seq database generated by Zhang et al. (2014). Furthermore, it falls within the top 500 genes
1.6 RXR and its partners influence aspects of OPC biology important to remyelination 45
differentially expressed in OPCs compared to newly formed and mature oligodendrocytes,
further suggesting a salient role in these cells. It is clear that, based on in vitro data, all the
above NRs influence different aspects of cell cycle and differentiation, and RXR𝛾 may be
involved in both areas, depending on which partners it predominantly associates to. This
has led to an unproven model whereby RXRγ switches its principal binding partner as OPCs
progress through the lineage, with each heterodimer being responsible for the maintenance
of a stage or progression to the next (Franklin and ffrench Constant, 2017).
1.6.3 RXR partners aid in cholesterol and fatty acid metabolism
Differentiation is an energy demanding task due to the dramatic changes that progenitor
cells need to undergo transcriptionally and metabolically (Folmes and Terzic, 2014). PPAR
is critical in energy and lipid homeostasis, regulating metabolic function based on the con-
trol of genes involved in both lipid uptake and storage. Due to their clear metabolic function,
PPARs have been used extensively in the treatment of metabolically derived disorders, such
as obesity and type II diabetes (Choi et al., 2014). PPAR𝛽 and 𝛾 both play a role in OPC
differentiation in vitro, as their activation results in increased MBP and PLP expression,
and pushes glial progenitors into acquiring an oligodendrocyte fate (Granneman et al., 1998;
Saluja et al., 2001; Sim et al., 2008). The differentiation observed could be due to increased
metabolic support by PPAR activation, as the use of both natural and synthetic PPAR ligands
on primary OPCs resulted in increased mitochondrial activity as well as promoting antiox-
idant protective effects via enzymes involved in protection against reactive oxygen species
(Bernardo et al., 2009; De Nuccio et al., 2011, 2015; Bernardo et al., 2017).
Another RXR partner involved in fatty acid metabolism is LXR. LXR𝛽 is expressed in
the oligodendrocyte lineage, and general LXR𝛾−/− mice present a higher 𝑔 ratio and re-
duced expression of oligodendrocyte markers compared to wild type animals (Makoukji
et al., 2011; Meffre et al., 2015). Although it cannot be excluded that the above could be
a consequence of compromised neurons rather than a defect in myelin per se (Wang et al.,
2002), force-feeding wild type controls with the LXR agonist T0901317 (T090) increases
MBP and PLP expression both at the transcriptional and protein levels, as well as promot-
ing in vitro OPC differentiation and remyelination in cerebellar slices (Meffre et al., 2015).
LXRs are key players in the regulation of cholesterol homeostasis (Courtney and Landreth,
2016a). The brain contains a quarter of total body cholesterol, which is produced locally in
the CNS. Within the CNS, myelin has the highest cholesterol content (Vitali et al., 2014;
Courtney and Landreth, 2016a). Saher et al. (2005) have shown the importance of choles-
terol in oligodendrocyte myelination with the use of mice in which the cholesterol biosyn-
thesis pathway was selectively inhibited in CNP+ by the impairment of squalene synthase.
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These mice present with severe phenotypes such as ataxia, tremors and premature death,
and although oligodendrocytes appeared healthy, there was severe CNS hypomyelination
(Saher et al., 2005). Oligodendrocyte cholesterol availability is fundamental, and regula-
tors of cholesterol metabolism such as LXR have critical roles in supporting OPCs in their
maturation towards becoming mature oligodendrocytes.
Thus, RXR𝛾 is a positive regulator of OPC differentiation and remyelination. Its partners
have been involved in important aspects of OPC biology, such as cell cycle progression,
promoting differentiation or providing metabolic support to differentiating OPCs. These
effects elicited by the partners may involve RXR𝛾 heterodimers, leading to the development
of the unproven ‘partner switching’ model.








Fig. 1.8 Schematic of the partner switching model. In this model it is hypothesised that
RXR𝛾 acts as an anchor protein and switches its principal binding partner as OPCs progress
through the lineage. This is because each heterodimer is responsible for the maintenance of
a lineage stage or progression to the next. This is based on in vitro and in vivo data whereby
RAR activation maintains OPCs in their proliferative state. On the other hand, activation
of VDR or THR promotes OPC differentiation at the expense of proliferation, suggesting
their involvement in inducing the first stages of differentiation. PPAR and LXR activation
have also been involved in OPC differentiation. Due to their involvement in fatty acid and
cholesterol metabolism as well as on in vivo data, they may be involved in the terminal stages
of differentiation where oligodendrocyte maturation and myelin sheath formation occur.
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1.7 Aims and objectives
RXR𝛾 , as well as its partners, influence various aspects of OPC biology relevant to its regen-
erative potential. However, how the effects observed by the partners are elicited via RXR
heterodimerisation remains unknown.
Due to the pleiotropic signalling of RXR, this information will aid in the development of
specific remyelination therapies targeting appropriate heterodimers and reducing treatment
side effects.
I hypothesise that RXR𝛾 acts as an anchor protein for the association of different NRs,
and that different RXR𝛾 heterodimers regulate different steps of oligodendrocyte lineage
progression.
Furthermore, RXR𝛾 acts by controlling transcription of target genes, and I hypothesise
these to be involved in oligodendrocyte-specific differentiation.
To answer these hypotheses I have set out to:
• Identify RXR𝛾 binding partners important in the oligodendrocyte lineage;
• Understand which heterodimers are important at different stages of lineage progres-
sion;
• Understand whether the system is regulated by other NR signalling levels such as
ligand, subcellular localisation and co-regulator binding;
• Identify the genes controlled by RXR𝛾 in oligodendrocyte lineage cells;




A table of all materials and kits used can be found in Appendix A, Table A.1.
2.2 Methods
2.2.1 Animal husbandry
All animal studies were ethically reviewed and carried out in accordance with the Animals
Scientific Procedures Act of 1986 and the GSK Policy on the Care, Welfare and Treatment
of Animals. The rat strain used for this project was Sprague Dawley (SD). SD rats were bred
in the Innes and MIRA Animal Facilities at the University of Cambridge. All animals were
kept under a light/dark cycle of 12 hours and fed a standard choke diet.
2.2.2 OPC isolation via mixed glia culture
Postnatal day 0-3 SD rats were euthanised via an overdose of intraperitoneal Pentoject injec-
tion following the Schedule 1 procedures of the Animal Scientific Procedures Act of 1986.
The brains were removed from the skulls and transferred to a petri dish of ice-cold Hibernate
A for low fluorescence (HALF), for which the formulation is shown in Table 2.1. The brains
were dissected by removing the meninges, olfactory bulbs, hindbrain and midbrain. The cor-
tices were cut into small pieces using scalpels and were digested for one hour at 37°C on a
55rpm shaker using a pre-warmed papain solution made of 34U/ml of papain and 3.7mg/ml
DNase in HALF. The reaction was stopped with 1ml of DMEM plus 10% fetal bovine serum
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(FBS). The solution was centrifuged at 200g for five minutes and re-suspended in 1ml of
mixed glia culture medium made of 10% FBS and 1/500 Mycozap in DMEM.
The mixed glia was cultured in T75 flasks pre-coated with Poly-D-Lysine-hydrobromide
(PDL) in mixed glia culture medium for 11 days. PDL coating of all culture material was
carried out by adding 5ug/ml of PDL dissolved in autoclaved double distilled water (dd𝐻2O)
for one hour at 37°C, followed by two washes using dd𝐻2O in order to remove excess PDL.
During the 11 days the media was changed every three days for six days and consequently
every two days. After this time the OPCs were separated from the rest of the cells. Loosely
attached microglia were removed by shaking the flasks at 37°C on an orbital shaker at 195rpm
for an hour, after which the medium was replaced with new mixed glia medium previously
warmed and C𝑂2 equilibrated. The flasks were left to shake on the same settings for 16h-
18h. The media was then transferred to a 10cm non-treated plastic petri dish and placed in
the incubator for 15 minutes; this allows excess microglia to attach to the plastic whilst the
OPCs remain floating. The supernatant was centrifuged at 300g for five minutes to obtain
the OPCs. The supernatant was removed and replaced with serum-free OPC medium, for
which the formulation is shown in Table 2.2. The OPCs were then plated according to the
experiment that would be carried out. A summary of OPC isolation via mixed glia culture
is represented in Figure 2.1.
Fig. 2.1 Mixed glia isolation. Rat pup brains are dissected and cultured as mixed glia for






L-Arginine hydrochloride 483 174.2
L-Asparagine-H2O 5.5 150.13
L-Cysteine hydrochloride-H2O 7.7 313.2
L-Histidine hydrochloride-H2O 200 209.6
L-Isoleucine 802 131.2
L-Leucine 802 131.2







L-Tyrosine disodium salt dihydrate 398 181.2
L-Valine 803 117.2
Vitamins
Choline chloride 28 139.62
D-Calcium pantothenate 8 238.27
Niacinamide 30 122
Pyridoxine hydrochloride 20 206
Thiamine hydrochloride 10 337
i-Inositol 40 180.2
Inorganic salts
Ferric Nitrate (Fe(NO3)3”9H2O) 0.25 404
Potassium Chloride (KCl) 5360 74.55
Sodium Bicarbonate (NaHCO3) 880 84
Sodium Chloride (NaCl) 89000 58
Sodium Phosphate dibasic (Na2HPO4) anhydrous 906 120
Zinc sulfate (ZnSO4-7H2O) 0.67 287.56
Other components
D-Glucose (Dextrose) 25000 180.2
Sodium Pyruvate 227 110.04
MOPS s10000 269.3
Table 2.1 Formulation for HALF comprising the list of components, their molecular
weight and the required 𝜇M in solution. HALF was made up in MilliQ water placed on
a stirrer. Each component was weighed and added to the solution, making sure that the
previous component was dissolved before adding the following one. The pH was adjusted
to 7.3 and the solution was filtered through a 0.22𝜇m to make it sterile. HALF was stored at
4°C.
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Component Stock concentration Final concentration
DMEM/F12 - 1X
N-Acetyl-L-Cystein (NAC) 6mg/ml 60𝜇g/ml
D-glucose 0.56M 25mM
Insulin 4mg/ml 10𝜇h/ml






Table 2.2 Formulation for OPC media. Once all the components were added the solution
was filtered through at 0.22𝜇m to make it sterile. Insulin was added after filtering. The
media was stored at 4°C.
2.2.3 OPC isolation via magnetic cell sorting
Postnatal day 2-7 SD rats were euthanised via an overdose of intraperitoneal Pentoject injec-
tion following the Schedule 1 procedures of the Animal Scientific Procedures Act of 1986.
The brains were removed from the skulls and transferred to a petri dish of ice-cod HALF.
The cortices were cut into small pieces using scalpels and digested for 30 minutes at 37°C on
a 55rpm shaker using a pre-warmed papain solution as for the mixed glia isolation in Section
2.1. The solution was then topped with Hank’s balanced salt solution (HBSS)-/- (without
calcium and magnesium) and centrifuged at 200g for five minutes.
The supernatant was removed and replaced with a trituration solution made of 2% B27 in
HALF. The solution was mixed by inversion and left to settle. This reduced the shear stress
on the cells. The first trituration was carried out with a 5ml serological pipette. The triturated
solution was left to sit in order for whole tissue pieces to settle. Only the supernatant was
transferred to a clean tube via a 70𝜇m strainer. This prevented the transfer of whole tissue
parts resulting in a single cell suspension. Another trituration solution made of 0.1% pluronic
acid in HALF was used to top up the solution and the procedure was repeated twice more
using progressively smaller fire polished Pasteur pipettes.
To remove any myelin debris that would prevent OPC differentiation in the later culture
a percoll gradient was used. A 90% percoll solution made using percoll and 10X PBS was
added to the single cell solution for a final percoll concentration of 22%. The solution was
mixed thoroughly by inversion and centrifuged at 800g for 20 minutes, after which the su-
pernatant was aspirated and the resulting pellet was washed with HBSS-/-. The total number
of cells was counted.
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Sodium pyruvate 100mM 2mM
Table 2.3 Formulation for MWB used in the MACS isolation. MWB was prepared in
autoclaved dd𝐻2O and the pH adjusted to 7.3. The solution was made sterile by filtering it
through a 0.22𝜇m filter. MWB was stored at 4°C.
For every 107 cells obtained, the pellet was resuspended in 500𝜇l of Miltenyi Wash
Buffer (MBW), 10𝜇g/ml of insulin and 2𝜇g of mouse anti-A2B5 antibody, an established
OPC marker. The formulation of MWB is shown in Table 2.3. The solution was incubated
for 20 minutes at 4°C and the tube was flicked every five minutes to maintain the cells in
suspension. The cells were then washed with HBSS-/-, the supernatant aspirated and the
pellet resuspended in 80𝜇l MWB, 10ug/ml of insulin and 20𝜇l of anti-mouse-IgM magAB
magnetic beads. This time the solution was incubated for 15 minutes at 4°C and the tube
was flicked every five minutes. The cells were then washed with HBSS-/- and resuspended
in 1.5ml of MWB and 10𝜇g/ml of insulin regardless of the total cell number after the percoll
gradient.
MWB was used to wet the magnetic cell sorting (MACS) column previously placed in a
magnetic field. The cell solution was transferred into the column and allowed to drip through.
The magnet retains the A2B5+ cells, whilst all the other cells dripped through. When the
elution stopped, the column was washed with clean MWB plus 10𝜇g/ml of insulin to get
rid of any excess non-specific cells still trapped in the column. Once the elution completely
stopped, the column was removed from the magnet and placed in a clean tube, pre-warmed
OPC medium was added to the column and the OPCs were eluted using a plunger. The OPCs
were plated on PDL-coated material according to the experiment that was being carried out.
A summary of OPC isolation via MACS is represented in Figure 2.2.
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Fig. 2.2 MACS isolation. Rat pup brains are dissected and a single cell suspension is ob-
tained. The OPCs are isolated using antibodies against A2B5, an OPC marker, followed by
an incubation with secondary antibodies conjugated to magnetic beads. By running the cell
suspension through a column in a magnetic field the non-specific cells are eluted and the
OPCs are retained. These can be eluted separately to obtain a pure fraction of OPCs.
2.2.4 FBS charcoal treatment
To prepare the charcoal, activate charcoal was diluted 2.5% w/v in sterile 1X PBS and kept
in agitation at 4°C for at least 12 hours. The solution was centrifuged five minutes at 500g,
the supernatant removed and the wet charcoal was washed twice with sterile 𝐻2𝑂. The wet
charcoal was incubated with FBS for a final concentration of 2.5% w/v and kept in agitation
at 4°C for 18 hours. The solution was then passed through a 0.4𝜇m strainer until all the
charcoal was removed and FBS depleted in retinoid and steroid molecules was obtained.
This FBS was used to prepare charcoal-treated mixed glia media.
2.2.5 Small molecule treatment
After isolation, OPCs were cultured in serum-free OPC medium in a 37°C incubator at 5%
𝐶𝑂2. They were left to recover overnight from the stress of the MACS with 10ng/ml PDGF-
AA and 10ng/ml bFGF. The following day the OPC medium was changes and nuclear re-
ceptor agonists or antagonists were added to the culture. The final concentration and the
duration of the treatment are specified for individual experiments reported in Chapter 3. All
treatment stocks were prepared in DMSO at a concentration such that the final DMSO con-
centration in culture would be 0.1%. To assess proliferation OPCs were treated for four days
and to assess differentiation they were treated for six days in vitro.
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2.2.6 EdU incubation
Ethynyl-2’deoxyuridine (EdU) was diluted in media to a 20𝜇M concentration and left to
warm and equilibrate at 37°C in the incubator. Once equilibrated, half of the medium in the
well was replaced with an equivalent volume of fresh medium plus EdU, for a final EdU
concentration of 10𝜇M. A complete change of media can cause cells to alter their cell cycle;
by changing only half of it this chance is reduced. The live cells were incubated with EdU
for four hours before fixation as reported in Section 2.2.8.
2.2.7 Isolation purity assessment using flow cytometry
OPCs were isolated using MACS. After elution the cells were divided equally between the
samples to stain and the controls. Approximately 300,000 cells per tube were obtained. The
cells were stained for cell death, OPCs, oligodendrocytes, microglia and red blood cells. For
each antibody used there was the equivalent fluorescence minus one (FMO) control. The live
cells were firstly stained in the dark for 15 minutes at room temperature (RT) with zombie
violet (ZV) diluted 1/100 in 1X PBS. The cells were topped up with 1X PBS and spun at 350g
for five minutes. The cells were then incubated in 100𝜇l of 1/100 relevant primary antibodies
for 20 minutes at 4°C. The tubes were topped up with 0.5% BSA in 1X PBS and spun down
at 300g for five minutes. The cells were incubated in the appropriate secondary antibodies
for 15 minutes at RT. The cells were spun down at 300g for five minutes, resuspended in
500𝜇l of 0.5% BSA in 1X PBS and sorted on a BD Influx cell sorter, equipped with 488nm,
640nm, 561nm and 405nm lasers. Results were analysed using FlowJo, LLC, a software for
single-cell flow cytometry analysis.
The staining protocol was set up by Natalia Murphy, the staining was carried out by
Alerie Guzmán de la Fuente (both members of the Franklin laboratory) and the cells were
flowed by the CIMR flow facility.
Antibody Dilution Supplier Cat. number
Primary antibodies
PE conjugated mouse anti-A2B5 (IgM) 1:11 Miltenyi Biotec 130-093-581
PECy5.5 conjugated mouse anti-CD11b 1:100 BioLegend 201820
Goat anti-MOG 1:40 R&D systems BAF2439
Mouse anti-OX83 1:50 BioLegend 250402
Secondary antibodies
PE/Cy7 rat anti-mouse 1:500 BioLegend 406614
A647 donkey anti-goat 1:800 Invitrogen A21447
Table 2.4 Antibodies used to assess purity of the MACS isolation using flow cytometry.
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2.2.8 Immunocytochemistry
Cells were fixed with 4% paraformaldehyde (PFA) at room temperature (RT) for 10 min-
utes and washed twice with 1X PBS. They were then blocked in blocking solution made
up of 5% normal donkey serum and 0.1% Triton-X 100 in 1X PBS for one hour at RT. If
the cells had been previously exposed to EdU, EdU detection was carried out by incubating
the coverslips for 30 minutes with the Click-iT reaction cocktail (Reaction Buffer, CuS𝑂2,
Alexa Fluor azide 488 and Reaction Buffer Additive) at RT as described in the Click-iT
EdU Alexa Fluor Imaging Kit. The coverslips were washed once with 1X PBS. The cells
were then incubated with the relevant primary antibodies diluted in blocking solution for 16
hours at 4°C. Excess primary antibody was washed away with 1X PBS and the cells were
incubated with secondary antibodies diluted in 1X PBS for one hour at room temperature.
Excess secondary antibody was washed away with 1X PBS. The cells were then incubated
for 10 minutes at RT with 2𝜇g/ml of Höechst in 1X PBS. The cells were washed twice with
1X PBS and once with dd𝐻2O. If the cells were on coverslips they were then mounted on
polysine slides with Fluoromount G. The slides were left to dry overnight at 37°C. Immuno-
cytochemistry pictures were taken using the Leica SP5 Confocal microscope at 10X, 20X
or 40X magnification, or using the GE Healthcare IN Cell Analyzer 2200 at either 10X and
20X magnification. Quantification of the images generated was carried out using CellPro-
filer, cell imaging analysis software. A list of the antibodies used for immunocytochemistry
is shown in Table 2.5.
2.2.9 Co-immuno precipitation
Co-immunoprecipitation (CoIP) was carried out using the Pierce Crosslink Immunoprecip-
itation Kit using 500𝜇g of total protein per sample. As a pre-clearing step, 20𝜇l of cross
linked 4% beaded agarose were added to the 500𝜇g protein sample. The sample was left
to shake at maximum speed at 4°C for an hour. This step aids in clearing any non-specific
binding of the sample that could bind to the resin beads. To bind the primary antibody to
the resin beads 20𝜇l of A/G plus agarose beads were added to the column and centrifuged
at 2000g for 1 minute at 4°C. The column was washed twice with 1X Coupling Buffer af-
ter which the bottom of the column was plugged and 10𝜇g of desired primary antibody
were added to the column. The antibody was topped up using 1X Coupling Buffer to a fi-
nal volume of 100𝜇l. The column was plugged at the top and incubated on a rotator for 1
hour at room temperature. After five washes with 1X Coupling Buffer the bound antibody
was crosslinked by incubating the column with 9𝜇l of 4,4-dimethyl-4-silapentane-1-sulfonic
acid (DSS) diluted in DMSO. DSS was further diluted to a final concentration of 2.5mM by
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Antibody Dilution Supplier Cat. number
Primary antibodies
Rabbit-anti Olig2 1:1000 Millipore AB9610
Goat-anti Olig2 1:200 R&D Systems AF2418
Rat-anti MBP 1:500 Serotec MCA4095
Rabbit-anti NG2 1:200 Millipore MAB5320
Rabbit-anti ENPP6 1:100 Abcam ab87587
Mouse-anti O4 (IgM) 1:500 R&D Systems MAB1326
Mouse-anti CNPase 1:500 Sigma Aldrich c5922
Rat-anti GFAP 1:1000 DAKO Z0334
Mouse-anti CD11b 1:300 Serotec MCA275R
Rabbit-anti p27 1:800 Cell Signalling 3686
Secondary antibodies
Alexa 488 donkey anti-rat 1:500 Invitrogen A21208
Alexa 647 donkey anti-rabbit 1:500 Invitrogen A31573
Alexa 488 donkey anti-rabbit 1:500 Invitrogen A21206
Alexa 568 donkey anti-rabbit 1:500 Invitrogen A10042
Alexa 568 donkey anti-goat 1:500 Invitrogen A11057
Alexa 488 donkey anti-mouse 1:500 Invitrogen A21202
Alexa 568 donkey anti-mouse 1:500 Invitrogen A10037
Alexa 647 donkey anti-mouse 1:500 Invitrogen A31571
Alexa 488 goat anti-mouse IgM 1:500 Invitrogen A21042
Table 2.5 Antibodies used for in vitro experiments. All antibodies are IgG subclass unless
specified otherwise.
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adding 41𝜇l of 1X Coupling Buffer directly to the column, which was once again plugged
and incubated on a rotator for 1 hour at room temperature. The column was washed four
times with Elution Buffer followed by another four washes with Lysis/Wash Buffer and the
bottom was plugged once again. The protein sample was spun at 2000g for 1 minute at 4°C,
and the supernatant was added to the column. The top was plugged and the column was
incubated on a rotating platform at 4°C for 16 hours, after which the column was washed
three times with Wash/Lysis Buffer and once with 1X Condition Buffer. The column was
placed in clean eppendorf tubes and 10𝜇l of Elution Buffer were added to the column and
spun through. Another 15𝜇l of Elution Buffer were added to the column, which was left to
incubate for 5 minutes at room temperature. The column was centrifuged, resulting in 25𝜇l
of flow through containing the proteins bound to the protein of interest.
2.2.10 Mass spectrometry
OPCs isolated via MACS were washed once with 1X PBS and lysed with a lysis solution
made with Lysis Buffer and 1X HALT protease inhibitor. CoIP was carried out for RXR𝛾
using rabbit anti-RXR𝛾 from Abcam (ab15518) primary antibody. The solute was then taken
to GSK for further processing and mass spectrometry analysis which was carried out by
Carla Newman. For the in-solution digest, samples were reduced, alkylated and digested
as described by Lopez- Ferrer et al., 2006. Samples were then desalted using StageTips.
Samples were run on a QExactive via EasySpray nanoelectrospray ion source, coupled to an
easy-nLC 1000 using a Acclaim PepMap 100 75μm x 2cm nanoViper pre-column and an
Easy PepMap 75μm x 15cm C18, 2μm, 100A chromatography column. For both, the mobile
phases were 0.1% formic acid in waterford the aqueous phase and acetonitrile for the organic
phase. The gradient time was 1 hour, the column temperature 40°C and data was acquired
using a Top 15 method, where HCD fragmentation was used to sequence the top 15 ions
per full scan spectrum. Additionally, the instrument was set to 2% underfill ratio and 3m/z
isolation window. Results were further processed using Scaffold Proteome 2.2 Software to
analyse the raw data and Proteome Discoverer 1.4 to search through databases.
2.2.11 Proximity ligation assay using Duolink®
Cells isolated via mixed glia were fixed with 4% PFA for 10 minutes and washed twice
with 1X PBS. The cells were then blocked in Duolink® Blocking Reagent for 30 minutes
at 37°C. The cells were consequently incubated with antibodies against nuclear receptors
or co-regulators diluted in Duolink® Antibody Diluent for 16 hours at 4°C. The cells were
washed for five minutes in Buffer A twice and incubated with anti-mouse PLA Plus and
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Antibody Dilution Supplier Cat. number
Primary antibodies for NRs
Rabbit-anti RXR𝛾 1:100 Abcam ab15518
Mouse-anti RXR𝛾 1:100 Santa Cruz sc-514134
Rabbit-anti VDR 1:100 Santa Cruz sc-1008
Rabbit-anti RAR𝛽 1:100 Santa Cruz sc-552
Rabbit-anti RAR𝛾 1:100 Santa Cruz sc-7389
Rabbit-anti THR𝛼 1:100 Abcam ab53729
Rabbit-anti THR𝛽 1:100 Abcam ab5622
Mouse-anti PPAR𝛽 1:100 Santa Cruz sc-74440
Rabbit-anti PPAR𝛾 1:100 Santa Cruz sc-7196
Rabbit-anti LXR𝛼 1:100 Abcam ab3585
Mouse-anti LXR𝛽 1:100 Abcam ab76983
Rabbit-anti Nurr1 1:100 Santa Cruz sc-990
Primary antibodies for co-regulators
Mouse-anti p300 1:100 Novus Biologicals RW105
Mouse-anti PGC1𝛼 1:100 Millipore ST1202
Mouse-anti Brg1 1:100 Santa Cruz sc-374197
Mouse-anti TRAP220 1:100 Santa Cruz sc-74475
Mouse-anti HDAC1 1:100 Cell Signaling 5356
Mouse-anti HDAC2 1:100 Cell Signaling 5113S
Mouse-anti HDAC3 1:100 Cell Signaling 3949
Mouse-anti HDAC11 1:100 Santa Cruz sc-390737
Mouse-anti NCoR 1:100 Millipore MABE570
Mouse-anti SIRT1 1:100 Cell Signaling 8469
Mouse-anti SIRT2 1:100 Santa Cruz sc-28298
Mouse-anti SRC1 1:100 Santa Cruz sc-73057
Table 2.6 Antibodies used for in vitro proximity ligation assay using Duolink®. All
antibodies are IgG subclass unless specified otherwise.
anti-rabbit PLA Minus probes diluted 1/5 in Antibody Diluent for one hour at 37°C. After
another two five minute washes of Buffer A the cells were incubated with Duolink® Ligation
solution made of Ligation Buffer diluted 1/5 in DNase-free water and ligase diluted 1/40 for
30 minutes at 37°C. The cells were washed twice with Buffer A and were incubated with
Amplification Stock diluted 1/5 in DNase-free water and polymerase diluted 1/80 for 1:40
hours at 37°C. The cells were then washed for 10 minutes with 1X Buffer B twice and once
with 0.01X Buffer B for one minute. The cells were incubated for EdU detection and with
OPC/OLG markers as described in Section 2.2.8. A list of the antibodies used for Duolink®
is shown in Table 2.6.
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Fig. 2.3 Duolink® in situ proximity ligation assay technology. (A) The blue and grey
shapes represent two hypothetical proteins of interest named A and B. These are bound with
relevant primary antibodies and with secondary probes with DNA sequences associated to
them. If the proteins are close enough to be considered interacting, the probes will ligate
in the presence of a ligase enzyme. The distance between the two epitopes can be up to
40nm for ligation to happen. The signal is amplified using a polymerase enzyme and flu-
orescent dNTPs represented here in red. The signal will be fluorescent and can be imaged
with a fluorescent microscope. (B) Panel of technical controls for Duolink® with a variety
of oligodendrocyte lineage markers.
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2.2.12 Cell cycle analysis using flow cytometry
OPCs were isolated using MACS, plated in T75 flasks and left to recover overnight. The next
morning they were treated with either 9cRA, T3 or DMSO for 48 hours in the presence of
growth factors (GF). The cells were then dissociated by removing the media and incubating
the cells with 1ml of 1X TrypLE for 6 minutes at 37°C. The cells were pipetted up and down
to fully detach them from the flask, transferred to a falcon tube and were spun at 300g for
5 minutes. The cells were then transferred to low binding microcentrifuge tubes. The cells
were stained with a live/dead stain by incubating them with ZV 1/100 in 1X PBS for 15
minutes at room temperature in the dark. They were washed once with 1X PBS and then
fixed using 70% EtOH in 1X PBS for 2 hours at 4°C. The OPCs were then washed with 1X
PBS and were incubated with a propidium iodide (PI) solution (PI 1/200 + RNase 1/100
in 1X PBS) for 30 minutes at 37°C. The cells were then transferred to flow tubes and cell
cycle stages were assessed using a BD Fortessa instrument equipped with 405nm and 561nm
lasers. Results were analysed using the ‘cell cycle analysis’ feature of FlowJo, a software for
single-cell flow cytometry analysis.
2.2.13 OPC dissociation
The media was removed and the OPCs were washed once with pre-warmed 1X PBS to re-
move any remaining media. A pre-warmed dissociation solution made of 1/100 of papain
and 40𝜇g/ml of DNase in HALF was added to the OPCs which were placed back in the incu-
bator for three minutes. The flasks were banged enough for the cells to detach. The papain
reaction was stopped by adding the the same amount of DMEM plus 10% FBS. The cells
were transferred to a falcon tube and spun at 300g for five minutes, counted and were then
used for ChIP sequencing.
2.2.14 ChIP sequencing
OPCs were isolated using MACS and were left to proliferate in T75 flasks in GF presence.
After five days the OPCs were treated for 24 hours with either 50nM 9cRA or 1/1000 DMSO,
dissociated according to Section 2.2.13 and ChIP was carried out following the method de-
scribed. For each sample five million OPCs were used. The OPCs were fixed in 1% PFA for
10 minutes and the reaction was stopped by adding glycine for 5 minutes at RT. The cells
were washed once with 1X PBS and lysed using a solution of 100𝜇l SDS Lysis Buffer and
0.5𝜇l Protease Inhibitor Cocktail II per 1 million cells. From then on all samples were kept
on wet ice to prevent dissociation of transcription factors from the chromatin. The chromatin
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was then sheared using the BiorupturPlus sonicator: OPCs were at a concentration of 1 mil-
lion OPCs in 100𝜇l and were sheared on the high power setting for six minutes composed
of 30 seconds off, 30 seconds on cycles at 4°C. This resulted in chromatin pieces between
400bp-200bp. Samples were spun at 13000g for 10 minutes at 4°C and transferred to clean
microfuge tubes to remove any insoluble material. The samples were then pre-cleared of
any unspecific stickiness by incubating them with Protein G Agarose for an hour at 4°C with
rotation. The samples were spun at 4000g for one minute to pellet the agarose and the su-
pernatant was transferred to a new microfuge tube. The samples were incubated overnight
on a rotator at 4°C with 10𝜇g of either a mouse anti-RXR𝛾 antibody or a mouse normal IgG
antibody as the negative control. Protein G Agarose was added to the samples and incubated
for an hour at 4°C with rotation after which the agarose was pelleted by spinning the samples
at 4000g for one minute and the supernatant was discarded. The agarose beads were then
washed with five minute washes using a series of buffers in the following order: one wash
of Low Salt Immune Complex Wash Buffer, one wash of High Salt Immune Complex Wash
Buffer, one wash of LiCl Immune Complex Wash Buffer and two washes of TE Buffer. The
protein-DNA complexes were eluted by incubating the agarose beads with 100𝜇l of elution
buffer (10𝜇l of 20% SDS, 20𝜇l of 1M NaHC𝑂3, 170𝜇l of sterile 𝐻2O) at RT for 15 min-
utes. The agarose was pelleted and the supernatant was transferred to a clean tube. This step
was carried out twice. The protein-DNA crosslinks were then reversed by incubating the
samples overnight at 65°C with 8𝜇l of 5M NaCl and all RNA and protein was degraded by
firstly incubating the samples with 1𝜇l RNase A for 30 minutes at 37°C and consequently
incubating with 4𝜇l EDTA, 8𝜇l 1M Tris-HCl and 1𝜇l Proteinase K for two hours at 45°C.
The remaining DNA was then purified by adding Binding Reagent A to the samples and
spinning the solution through a filter column at 13000g for 30 seconds at RT. The column
was washed with 500𝜇l of Wash Reagent B and finally the DNA was eluted by adding 50𝜇l
of Elution Buffer C and spinning the column at 13000g for 30 seconds at RT. The DNA was
further purified and concentrated for sequencing as described in Section 2.2.15.
Quantification of the material was carried out using a Quibit and the samples were paired
end sequenced with a read length of 150 on one lane of a HiSeq 4000. This was carried out
by the NGS library facility at the Cambridge Stem Cell Institute.
The subsequent peak calling was carried out by Sabine Dietmann. Paired-end read files
were quality-trimmed using TrimGalore (options: -q 30 –length 15) discarding reads
shorter than 15 nucleotides. Reads were aligned with Bowtie2 (option: --sensitive -x)
against the rat reference genome (rn6). Potential PCR duplicates were removed using Picard
tools ‘MarkDuplicates’ (https://broadinstitute.github.io/picard). UCSC genome browser pro-
files were generated using bedtools “genomeCoverageBed”.
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Peaks were called with model basis analysis of ChIP-seq 2 (options: -q 0.5). Peaks
called for three replicates were intersected and ranked by fold enrichment. Only peaks that
were called in two or more replicates were considered for further analysis.
2.2.15 Concentrating DNA
To concentrate DNA the in solution purification protocol of the ‘QUIAEX II Gel Extraction
Kit’ was followed. Three volumes of Buffer QX1 was added to on volume of sample. After
adding 15𝜇l of QIAEX II, the sample was incubated at RT for 10 minutes and mixed every
two minutes. The sample was centrifuged at maximum speed for 30 seconds and the super-
natant removed. The pellet was washed twice with 50015𝜇l of Buffer PE, the supernatant
was removed and the pellet air-dried for 15 minutes. After this, 20𝜇l of RNase and DNase-
free 𝐻2O was added, the pellet vortexed and incubated at RT for five minutes. The sample
was centrifuged and the supernatant with the purified and concentrated DNA was placed into
a new tube.
2.2.16 Western blot
Cell lysates were obtained by removing OPC media, washing the cells once with 1X PBS
and adding the lysis solution made of Lysis Buffer and 1X HALT protease inhibitor. The
cells were gently scraped using a cell scraper and the solution was collected and placed on
wet ice for 10 minutes. The protein concentration was measured using the BCA assay; for
this the protocol of the ‘BCA Assay Kit’. Standards were prepared using the Lysis Buffer
as diluent and BSA. After preparing the standards and samples, the BCA working reagent
was prepared according to the protocol and added to the samples which were placed at 37°C
for 30 minutes. The protein concentration was then measured using the Nanodrop set at an
absorbance of 562nm. The samples and mixed with LDS loading buffer and 1X Reducing
Agent and boiled for 10 minutes at 95°C after which the desired protein amount (5-15𝜇l)
was loaded on 4-12% Bis-Tris gels alongside the Precision Plus standard protein ladder. The
gels were run at 100V for one hour and 20 minutes in 1X MOPS Running Buffer made
up in d𝐻2O. When the gel finished running it was removed from the tank and transferred
onto a polyvinylidene difluoride (PVDF) membrane previously activated for one minute in
100% MeOH. The two were placed between two pieces of blotting paper previously soaked
in freezing cold Transfer Buffer (150ml of 10X Transfer Buffer, 300ml EtOH and up to 1.5L
of d𝐻2O) and all was placed in a holder. The holder was then placed in a transfer tank which
was filled with Transfer Buffer. The transfer was run at 100V for 90 minutes. The membranes
were removed from the holder and blocked in blocking solution made of Odyssey blocking
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Antibody Dilution Supplier Cat. number
Primary antibodies
Rabbit-anti RXR𝛾 1:100 Abcam ab15518
Rabbit-anti RXR𝛾 1:100 Abcam ab15519
Rabbit-anti RXR𝛾 1:100 Santa Cruz sc-365252
Rabbit-anti RXR𝛾 1:100 Santa Cruz sc-555
Mouse-anti RXR𝛾 1:100 Santa Cruz sc-514134X
Rabbit-anti VDR 1:100 Santa Cruz sc-1008
Rabbit-anti LXR𝛼 1:100 Abcam ab3585
Rabbit-anti Nurr1 1:100 Santa Cruz sc-990
Rabbit-anti THR𝛼 1:100 Abcam ab53729
Rabbit-anti THR𝛽 1:100 Abcam ab5622
Rabbit-anti NG2 1:100 Millipore AB5320
Rabbit anti-p27 1:100 Cell Signaling 3686
Rabbit anti-cyclin D1 1:500 Cell Signaling 2978
Rabbit anti-cyclin E1 1:500 Cell Signaling 20808
Mouse-nIgG 1:100 Millipore 12-371B
Rabbit-nIgG 1:100 Cell Signaling 2729
Mouse peroxidase-anti actin 1:20,000 Sigma Aldrich A3854
Secondary antibodies
IRDye 680RD donkey anti-rabbit 1:10,000 Li Cor 925-68073
IRDye 800CW donkey anti-mouse 1:10,000 Li Cor 926-32212
Table 2.7 Antibodies used for western blot experiments. All antibodies are IgG subclass
unless specified otherwise.
buffer and TBS-T (1:1) for one hour at RT on a shaker. The membranes were then incubated
with the relevant primary antibody in blocking solution for 16 hours at 4°C, after which the
membranes were washed with TBS-T and incubated in the dark with the relevant secondary
antibodies. The membranes were washed again and imaged on the Li-Cor Odyssey Blot
Imager with a two minute exposure. They were were then incubated with anti-actin primary
antibody conjugated to peroxidase for 20 minutes at RT and washed twice. The membrane
was then incubated with a solution of Detection Reagents 1 and 2 (mixed 1:1) from the ECL
Western Blotting Analysis System. The membranes were imaged on Li-Cor Odyssey Blot
Imager with a two minute exposure on the chemiluminescence setting. Intensity of the bands
was measured using the ‘measuring tool’ on the Odyssey software. A list of the antibodies
used for western blot is shown in Table 2.7.
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2.2.17 RNA extraction and purification
Cells isolated via MACS were cultured in wells of a six-well plate and treated with the
relevant small molecules for 24 hours. The cells were washed once with 1X PBS and lysed
using 300𝜇l of Trizol per well at 4°C on a shaker for 10 minutes. The solution was collected
and frozen at -80°C until RNA purification.
The samples were left to defrost on wet ice and the RNA was purified using ‘Direct-zol
RNA MicroPrep’. All centrifugations were carried out at 13500g for 30 seconds. 300𝜇l of
99% molecularly pure ethanol was added to each tube and the sample was mixed thoroughly.
The mixture was transferred to a spin column inside a collection tube and centrifuged. The
column was placed in a fresh collection tube and was washed twice with 400𝜇l of RNA Pre-
Wash solution. The flow through was discarded and 700𝜇l of RNA Wash Buffer were added
to the column and the column was centrifuged for 2 minutes, after which the column was
transferred to an RNase-free tube. To elute the RNA 15𝜇l of DNase/RNase-free 𝐻2O were
directly added to the column and centrifuged. The amount of RNA obtained was measured
using a NanoDrop instrument and was stored at -80°C or immediately converted to cDNA.
2.2.18 cDNA synthesis
To isolate cDNA from RNA the ‘QuantiTect Reverse Transcription Kit’ was used. The iso-
lated RNA template and kit components were left to defrost on wet ice. First the genomic
DNA was eliminated from the samples using a solution of 2𝜇l of 7X gDNA Wipeout Buffer
and up to 1𝜇g of RNA template. The solution was mixed on wet ice and made up to to 14𝜇l
with RNase-free 𝐻2O and incubated for 2 minutes at 42°C. The mixture was then placed on
wet ice. A second mixture was made using 1𝜇l of reverse transcriptase, 4𝜇l of 5X reverse
transcriptase buffer, 1𝜇l of reverse transcriptase primer mix and the whole 14𝜇l of the first
mix. This was also prepared on wet ice. After mixing, the solution was incubated at 42°C
for 15 minutes and for another 3 minutes at 95°C. The samples were used for qPCR.
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2.2.19 Quantitative PCR
SYBR Green qPCR protocol was used for carrying out qPCR. For each well of a 384 well-
plate the set up shown in Table 2.8 was used, and either 1𝜇g or 3𝜇g of cDNA were used.
Samples were pipetted on wet ice and triplicates were prepared for each sample. Upon com-
pletion of the sample preparation the plate was sealed, vortexed briefly and centrifuged in
order to collect the liquid at the bottom of the well. The qPCR was run on a QuantStudio 7
Flex machine, ThermoFisher, using the ΔΔCT program with the parameters shown on Table
2.9. Results were analysed using QuantStudio 6 and 7 Flex Software, ThermoFisher. If the
primer efficiency was between 90-110%, ΔΔCT approximation was used for the analysis.
Component Volume
cDNA template 2𝜇l
2X SYBR Green Mix 10𝜇l
2𝜇M forward primer 2𝜇l
2𝜇M reverse primer 2𝜇l
𝐻2O 4𝜇l
Table 2.8 Set up for qPCR run.
Step Temperature Time
Initial denaturation 94°C 2 minutes
40 cycles as follows:
Denaturation 94°C 15 seconds
Annealing, extension and read fluorescence 60°C 1 minute
Hold 4°C Infinite
Table 2.9 Parameters for the qPCR run.
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Target Primer code Primer type Sequence 5’ to 3’
CDK1 FR1 Cdk1 Forward CGCTCGTTAAGAGTTACTTG
RR1 Cdk1 Reverse CTCTTATCGGTATTCCAAACG
CDK18 FR1 Cdk18 Forward AAACATACGTGAAACTGGAC
RR1 Cdk18 Reverse CAGAGACACCTCTCGAATAG
CDKN1b FR1 Cdkn1b Forward AAAATTTGAATAATCGCCACAG
RR1 Cdkn1b Reverse GAGTTTTGCCCAGTGTTATC
MKI67 FR1 Mki67 Forward AAAAGACAAAGAAGACCCAG
RR1 Mki67 Reverse AGTCCATTTTCCAGTTTAGC
WNT7a FR1 Wnt7a Forward ATCATCGTCATAGGAGAAGG
RR1 Wnt7a Reverse ATAATTGCATAGGTGAAGGC
PDGFRL FR1 Pdgfrl Forward ACCTACATCTTCTTCACAGAG
RR1 Pdgfrl Reverse GTTCAGGTAGACAACATCAAAG
BMP4 FR1 Bmp4 Forward AAAAATTATCAGGAGATGGTGG
RR1 Bmp4 Reverse AAAGTCCAGCTATAGGGAAG
FGFR4 FR1 Fgfr4 Forward CTGTGAAGATGCTGAAAGAC
RR1 Fgfr4 Reverse GTTCTTGTGTCTTCCGATTAG
ENPP6 FR1 Enpp6 Forward AATTTGTCTCTCCTTTGACC
RR1 Enpp6 Reverse CTTTCTGGACATCAGATAGC
MOBP FR1 Mobp Forward ACAACTTCAGCTTGTTTGAG
RR1 Mobp Reverse TGTGTGTCCTTCTCTCTTTC
Table 2.10 Forward and reverse primer sequences for the qPCR targets selected. All
primers were pre-designed and purchased from Sigma Aldrich.
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2.2.20 Statistical analysis
All statistical analysis was carried out using GraphPad Prism 7 (GraphPad Software, Inc.).
The D’Agostino-Pearson omnibus test and Saphiro-Wilk test were carried out to assess how
far the distribution of the results obtained was from a Gaussian distribution. When compar-
ing two groups where the data followed a normal distribution, Unpaired Student t Test was
used assuming two-tailed distribution. When comparing more than two groups with a single
variable where the data followed a normal distribution, ordinary one-way analysis of vari-
ance (ANOVA) was carried out followed by an appropriate post-hoc test where significance
was reached for individual groups. In cases where the data did not follow a normal dis-
tribution, the Kruskal-Wallis test was used instead. If two or more variables were present,
ordinary two-way ANOVA was used to assess interaction of the variables. If these were
positive, ordinary one-way ANOVAs were carried out for each variable separately. Results
were considered significant if the p value was smaller than 0.05, with significance as follows:
*p≤0.05, **p≤0.01, ***p≤0.001, ****p<0.0001. In Chapter 3 the statistical test used, the
number of biological replicates (n) and the p value are indicated for each experiment.
Chapter 3
Results
3.1 Mass spectrometry analysis of RXRcomplexes inOPCs
RXR𝛾 heterodimers are important in OPC biology due to the influence they have on oligo-
dendrocyte lineage progression. They function via the recruitment of additional transcrip-
tion factors and co-regulators, resulting in the construction of complexes involved in aid-
ing chromatin remodelling and gene transcription. Due to both their high conservation and
ubiquitous expression, NRs elicit cell-specific effects in two principal ways: by expressing
isoforms of single receptors in a tissue-specific manner and by forming function-specific
complexes via the recruitment of the required set of co-regulators (Braissant, 1996; Glauser
and Barakat Walter, 1997; Mukherjee et al., 1997; Smith et al., 1997; Mollard et al., 2000;
Liu et al., 2002).
Thus, to validate the partner switching hypothesis and assess how RXR𝛾 heterodimers
control OPC differentiation, it is necessary to understand:
1. whether RXR𝛾 associates equally with all its partners or if its binding is temporally
skewed towards a specific subset of NRs as OPCs differentiate;
2. which components make up the overall complexes formed throughout the various
stages of differentiation.
As the partners and regulators will be associated in a cell-specific manner, I decided to an-
swer the above questions by adopting a non-biased approach involving mass spectrometry.
The experimental strategy consisted in acutely isolating primary neonatal rat OPCs via
MACS, lysing them and carrying out CoIP for RXR𝛾 , thereby obtaining a solution enriched
in RXR𝛾 and the proteins associated to it. The solution would be then taken for in-solution
mass spectrometry analysis. This method is highly sensitive and reduces sample wastage
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as it does not require the sample to be handled further, unlike with mass spectrometers that
conversely require running a gel prior to analysis. Despite the high sensitivity of the mass
spectrometer, it is necessary to obtain as many primary cells as possible in order to carry
out the CoIP with enough protein lysate, hence the use of neonatal OPCs. In the develop-
ing brain, OPC numbers increase postnatally, resulting in the isolation of approximately 2
million OPCs per neonatal brain at P7, a much higher number when compared with OPC
isolation from adult rats, typically yielding half this quantity per brain. Furthermore, neona-
tal OPCs are bona fide stem cells and are typically used as reference for the development of
remyelination therapies.
3.1.1 Purity and viability of acutely isolated OPCs
To assess the purity of my MACS isolation, flow cytometry analysis was performed on the
fraction eluted at the end of the isolation, termed “positive fraction”. The OPCs were sorted
using the marker A2B5 rather than the more commonly used OPC marker PDGFR𝛼, as the
antibodies available typically recognise the internal fraction of the receptor. Additionally, the
expression of PDGFR𝛼 decreases with ageing. Therefore, A2B5 provides a more consistent
OPC yield in ageing studies. NG2, another potential marker, is also expressed by other cell
types, including microglia, pericytes and endothelial cells (Pouly et al., 2001; Yokoyama
et al., 2006; Guimarães-Camboa et al., 2017). I then determined the viability of the isolated
cells using the live/dead stain ZV, and calculated the percentage of OPCs (A2B5+), microglia
(CD11b+), red blood cells (OX83+), oligodendrocytes (MOG+) and OPCs on their way to
becoming oligodendrocytes (A2B5+ and MOG+). The staining protocol was developed by
Natalia Murphy and was carried out by Alerie Guzmán de la Fuente, both members of the
Franklin laboratory.
In order to gate correctly, cells from an adult rat brain were used; this was to ensure the
presence of any other cell type that could contaminate the sample preparation, especially
MOG+ oligodendrocytes. Figure 3.1A illustrates the gating strategy adopted: the control
used to set the gates is shown in black, whilst the cyan sample overlaid is a neonate brain
sample. The quantification in Figure 3.1B revealed that almost all cells are viable immedi-
ately following the elution of the positive fraction, with 99.67% of single cells not presenting
ZV stain (mean=99.67%, SD=0.06, n=3).
Further analysis focused on assessing what cell types the live cell population consisted of.
The results are shown in Figure 3.1C. A2B5 was the marker used for the isolation of OPCs,
and 87.47% of the total live population resulted in being exclusively A2B5+, suggesting a
high enrichment in OPCs. With regards to other oligodendrocyte lineage cells, almost no
mature or newly forming oligodendrocytes were present in the elution of neonatal brains
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Fig. 3.1 Purity of acutely isolated OPCs. In panel (A) the gating strategy adopted for each
marker is shown. Initial gating was done on a control adult brain (shown in black) to ensure
the presence of mature oligodendrocytes. The plots are additionally overlaid with one of
the neonatal MACS positive fractions obtained (shown in cyan). The side scatter, forward
scatter and trigger pulse width were initially used to determine what was a true single cell
based on size. Once that was determined, ZV was used to distinguish between live and
dead cells. (B) This resulted in an extremely high cell viability out of the total single cell
population (mean=99.7%, SD=0.06, n=3). The live population was plotted against CD11b
and OX83, resulting in the plot of three distinct populations. The population that was double
negative was then plotted against A2B5 and MOG. Neonatal OPCs present a large A2B5 high
population and almost no MOG-expressing cells. The composition of the live population is
quantified in bar graph (C). It is made up of 8.13% ± 0.71% CD11b+, 1.41% ± 0.17% OX83+,
0.03% ± 0.004% MOG+, 0.03% ± 0.003% A2B5+MOG+, 2.39% of cells unaccounted for
and 87.47% ± 2.14% A2B5+. All data is presented as mean ± SEM, biological n=3.
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(on average 0.03% for both). Nearly no red blood cells were found, with the percentage
of OX83+ cells being on average only 1.41%. The microglial fraction made up on average
8.13% of the live cell population, which is a higher percentage than other non-specific cell
types pulled down. However, this is still a relatively low percentage compared to the number
of A2B5+ cells. This leaves 2.39% of live cells unaccounted for. These could be astrocytes,
pericytes or neurons: however, this remains a very small percentage.
Overall, sorting neonatal rat brain on A2B5 using MACS yields a population of com-
pletely viable cells which are highly enriched in OPCs. This population was then lysed
immediately without prior in vitro culturing, and CoIP for RXR𝛾 was carried out.
3.1.2 RXR CoIP and mass spectrometry analysis
RXR𝛾 has been reported to have two splice variants: RXR𝛾1 and RXR𝛾2 (Liu, 1993; Seleiro
et al., 1994). The alignment of the protein sequences of RXR𝛾1 and 2 is shown Figure 3.2A.
The overall molecular weight (Mw) of the larger isoform, RXR𝛾1, is 50.9 kilodaltons (kD),
and by subtracting the Mw of the extra amino acids, RXR𝛾2 results in a Mw of 38.6kD.
Previous characterisation of RXR𝛾 expression in the oligodendrocyte lineage was carried
out in the Franklin laboratory, and revealed that both RXR𝛾 splice variants are expressed in
OPCs and oligodendrocytes (de la Fuente, 2014).
In order to ensure that the CoIP method used was pulling down RXR𝛾 , western blots of
the eluted solution were run and stained for RXR𝛾 . Figure 3.2B shows that the RXR𝛾 CoIP
results in the pull down of RXR𝛾1, as the band obtained is approximately 50kD in size. This
result is observed in both OPC and whole brain lysate. Furthermore, previous validation
of this CoIP method by Alerie Guzmán de la Fuente demonstrated that partners reported to
heterodimerise with RXR𝛾 in the literature are also pulled down when carrying out CoIP
with RXR𝛾 , as shown in the western blots in Figure 3.2C, suggesting that this method, in
combination with an appropriate antibody, efficiently pulls down RXR𝛾 complexes (de la
Fuente, 2014).
The CoIP elution was taken to GlaxoSmithKline for mass spectrometry, which was
kindly carried out by Carla Newman. Mass spectrometry analysis revealed no presence of
RXR𝛾 , other NRs or co-regulators. The table in Figure 3.2E shows that the top 10 unique
peptide sequences detected by the mass spectrometer belong to proteins involved in organ-
ising the cytoskeletal structure of cells. Further analysis of the results was carried out using
the PANTHER database (http://www.pantherdb.org) for protein class analysis. This clus-
tered all the proteins detected into similar classes as summarised by the donut graph in Fig-
ure 3.2D. The nucleic acid binding class is composed of ribosomal proteins, histones and
mRNA-binding proteins. The transcription factor class is one of the most interesting due
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ESYGDMSVES STNDPVTNIC HAADKQLFTL VEWAKRIPHF SDLTLEDQVI
ESYGDMSVES STNDPVTNIC HAADKQLFTL VEWAKRIPHF SDLTLEDQVI 
LLRAGWNELL IASFSHRSVS VQDGILLATG LHVHRSSAHS AGVGSIFDRV
LLRAGWNELL IASFSHRSVS VQDGILLATG LHVHRSSAHS AGVGSIFDRV
LTELVSKMKD MRMDKSELGC LRAIVLFNPD AKGLSNPSEV ETLREKVYAT 
LTELVSKMKD MRMDKSELGC LRAIVLFNPD AKGLSNPSEV ETLREKVYAT
LEAYTKQKYP EQPGRFAKLL LRLPALRSIG LKCLEHLFFF KLIGDTPIDT 



























Fig. 3.2 Mass spectrometry analysis of RXR𝛾 CoIP. (A) Protein alignment of the two
RXR𝛾 splice variants: RXR𝛾1 and RXR𝛾2. RXR𝛾2 lacks the initial N terminal sequence of
RXR𝛾1, resulting in a Mw of 12.3kD less. (B) Western blot of RXR𝛾 pull down via CoIP.
The band obtained weighs approximately 50kD, matching the Mw of RXR𝛾1. (C) Further
validation of the CoIP had been previously carried out by assessing the pull down of part-
ners known to associate to RXR𝛾 . (D) Donut graph summarising the proteins in the RXR𝛾
CoIP elution identified by mass spectrometry. The proteins were clustered by protein class.
The majority of proteins identified belong to the nucleic acid binding class and cytoskeletal
class, containing 26.7% and 20.3% of the total proteins identified respectively. No RXR𝛾 ,
NR partners or co-regulators were detected. In the normal IgG control and beads-only con-
trol, less proteins were detected, however, extensive detection of nucleic acid binding and
cytoskeletal proteins still occurred, suggesting they could be pulled down due to “stickiness”
of the resin beads. (E) Table presenting the top 10 proteins detected by mass spectrometry.
The results shown are the number of times a set of unique peptide sequences were detected,
therefore this is not a fully quantitative method. Consequently the table is not a ranking of
the most abundant peptides in the sample.
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to the way in which NRs signal. However, only five proteins were clustered in this class.
Data is shown for the RXR𝛾 antibody which allowed the detection of the highest number of
peptides (Abcam, rabbit anti-RXR𝛾 , cat# ab15518). In the corresponding nIgG control and
beads-only control, significantly fewer peptides were detected, 96.5% and 93.5% less com-
pared to the RXR𝛾 sample. Thus, it shows that this antibody in particular may be pulling
down non-specific proteins. Other RXR𝛾 antibodies pulled down fewer peptides than RXR𝛾
ab15518. However, RXR𝛾 , its NR partners and co-regulators were not detected with the use
of other antibodies either.
3.1.3 Troubleshooting the mass spectrometry analysis of RXR com-
plexes
Neither NR partners nor co-regulators were detected. However, the most unexpected finding
was the absence of RXR𝛾 from the above analysis, as the CoIP is designed to enrich the
eluted solution for the protein being pulled down. To troubleshoot this issue, trials using
whole brain lysates were initially used to try and increase the yield of RXR𝛾 . Following
this, nuclear versus cytoplasmic lysis was carried out and only the nuclear lysate was used
for CoIP to enrich for NRs. However, neither attempts yielded successful results in that
RXR𝛾 was not detected by the mass spectrometer in either conditions. Three different RXR𝛾
antibodies were used for CoIP in case the specific antibody being used was not pulling down
enough RXR𝛾 . The resin beads used in the CoIP were also replaced with magnetic beads
which are less “sticky” to non-specific proteins, in order to limit contamination of proteins
known to be highly expressed in all cells, such as cytoskeletal proteins, but without success.
An attempt with no CoIP was carried out in order to avoid lysate processing and to elucidate
whether NRs could be simply picked up the the mass spectrometer: however, this also failed.
All of the above results are not presented in this thesis.
After the above attempts, there could be two main reasons as to why RXR𝛾 and its part-
ners are not picked up via mass spectrometry:
1. the antibodies used to target RXR𝛾 are not specific enough, resulting in the pull down
of contaminants;
2. the expression of NRs is too low to be detected by the mass spectrometer used.
To assess whether the antibodies used were binding to RXR𝛾 , I carried out western blot
on recombinant RXR𝛾 as shown in Figure 3.3A. This shows that all four antibodies used for
CoIP do indeed bind RXR𝛾 . Whilst this does not exclude the possibility of the non-specific
binding of these antibodies to other proteins, it gives confidence that all of them should be
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Fig. 3.3 Mass spectrometry troubleshooting. (A) Western blots run using recombinant
GST-tagged RXR𝛾 . Four different RXR𝛾 antibodies were tested and all four show binding
to RXR𝛾 . RXR𝛾 here presents a 75kD Mw as it is GST-tagged. (B) The use of the brain
RNA-seq database created by Zhang et al. (2014) shows the low expression level of RXR𝛾
in oligodendrocyte lineage cells. Interestingly, when comparing the differential expression
of genes between the three stages of the lineage, RXR𝛾 is in the top differentially expressed
genes in OPCs compared to the other two stages. (C) A heat-map generated with the Zhang
et al. (2014) database. This shows that the vast majority of NRs are expressed at extremely
low levels in oligodendrocyte lineage cells, hence the reason why mass spectrometry was
unable to detect any NRs despite the enrichment in RXR𝛾 through CoIP.
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pulling down RXR𝛾 . In order to appropriately assess non-specific binding, a protein lysate
without RXR𝛾 should be included as the most appropriate negative control. However, as
NRs are ubiquitously expressed, it is not possible to obtain this from any rat tissue.
When the lysates were spiked with recombinant RXR, this was detected by the mass
spectrometer, leading me to suspect that the expression of RXR𝛾 is below the detection limit
of the mass spectrometer. Indeed, when plotting the expression of RXR𝛾 in oligodendrocyte
lineage cells using the results obtained from the RNA-seq database created by Zhang et al.
(2014), it is clear that RXR𝛾 is expressed at extremely low levels, with 6.5 FPKM being the
highest amount observed in OPCs (Figure 3.3B). Likewise, other NRs present extremely low
expression levels, in the majority of cases close to 0 FPKM, as summarised by the heat-map
in Figure 3.3C.
3.1.4 Discussion
I have presented data indicating that the major unique signature peptides detected by mass
spectrometry upon RXR𝛾 CoIP belong to cytoskeletal and nucleic acid binding proteins.
Due to the absence of RXR𝛾 amongst the detected peptides, I believe that these results do
not provide a clear answer on the list of proteins forming RXR𝛾 complexes in OPCs. This
is due to the unspecific pull down of proteins, such as cytoskeletal ones, and/or RXR𝛾 ex-
pression levels being below the detection limit of the mass spectrometer. In order to assess
the specificity of the RXR𝛾 antibodies it is necessary to have an appropriate control not ex-
pressing any RXR𝛾 . For this purpose, western blot using cells isolated from RXR𝛾 knockout
mice could have been carried out. However, such mice would have needed to be re-derived
as none are currently available to the lab. Alternatively, RXR𝛾 could have been knocked out
in vitro using CRISPR, and for this purpose any cell type, including cell lines, could have
been used. However, OPC and whole brain western blot using the RXR𝛾 antibody reported,
results in the detection of RXR𝛾1 (Figure 3.2B), raising the question of whether it is the
antibody that is binding the array of proteins reported by mass spectrometry.
Nonetheless, it has been reported that cytoskeletal proteins are able to influence gene
transcription. This is reasonable as cells need to be able to respond to mechanical cues in
order to match and react to the physical demands of their environment (Discher et al., 2005).
Indeed, mechanobiological studies have highlighted the influence that mechanical stressors
have on an array of cellular functions, including apoptosis, migration, proliferation, differ-
entiation and lineage specification (Wang et al., 2000; Engler et al., 2006; Klein et al., 2009;
Raab et al., 2012). These processes require tight transcriptional regulation and it has been
suggested that the mechanotransduction is transferred from cytoskeletal proteins such as
actin to the nuclear lamina, whose components are able to influence transcription factors and
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can directly associate to the DNA (Stierlé et al., 2003; Malhas et al., 2009; Simon et al., 2010).
Cytoskeletal proteins such as actin have also been reported to be components of chromatin
remodelling complexes and to interact directly with NRs. Nuclear 𝛽-actin and its binding
proteins are components of the SWI/SNF family of chromatin remodelling complexes (Shen
et al., 2003; Miralles and Visa, 2006), known to be recruited by NRs. In oligodendrocyte
lineage cells, SWI/SNF promotes the expression of myelin genes via the lineage-specific
transcription factor Sox10 (Dilworth et al., 2000; Marathe et al., 2013). Furthermore, actin
binding proteins have been reported to regulate numerous class I and III NRs as reviewed by
Gettemans et al. (2005). This phenomenon has been exceptionally studied in AR signalling,
where actin binding proteins such as gelsolin, supervillin and filamin have been shown to
act as co-regulators (Loy et al., 2003; Nishimura et al., 2003; Ting, 2004). This informa-
tion points towards the possibility of a direct involvement of cytoskeletal proteins such as
actin and vimentin in the formation of NR complexes, therefore, the pull down of these pro-
teins by RXR𝛾 and their detection via mass spectrometry may not be an artefact but rather a
true result reflecting the complicated function and signalling of RXR heterodimers. Whilst
NRs have conventionally been described as transcription factors governing gene expression,
RXR and other NRs also present genomic-independent functions. These vary from phos-
phorylation control by regulating the activity of enzymes such as kinases and phosphatases,
regulation of intracellular Ca2+ levels and control of ion channel function to name a few
(Boonyaratanakornkit et al., 2001; Skildum et al., 2005; Hammes and Levin, 2007; Sarkar
et al., 2008; Ordóñez-Morán et al., 2008). RXR, and some of its partners such as PPAR,
have also been found to localise in the mitochondria, where they are believed to control tran-
scription of mitochondrial DNA (Casas et al., 2003; Lin et al., 2008; Chang and Ha, 2018).
Furthermore, in order for RXR to be translocated from the cytoplasm to the nucleus and
vice versa, its association to transporters is essential. To summarise, the array of proteins
detected by the mass spectrometer may not necessarily be due to unspecific protein binding
or contamination of the preparation via other means. It rather may reflect the complex bio-
chemical picture presented by a receptor which interacts with a plethora of different protein
classes due to both its genomic and non-genomic functions, as well as all those interactions
involved in correct receptor assembly, structure and localisation.
Despite this, the inability to detect RXR𝛾 , its partners and co-regulators raises concerns
on whether the data is a true reflection of RXR𝛾 protein complexes. The heat-map in Figure
3.3C shows the excessively low expression of NRs in oligodendrocyte lineage cells. This
could be a limiting factor that would compromise the detection of NRs despite their en-
richment via CoIP, but the proteins detected would still be trustworthy. The extremely low
expression level of NRs does not come as a surprise, as these receptors are highly specific
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to their function and, therefore, a small amount may be enough to elicit the desired effects.
Additionally, limiting the pool of RXR and other NRs, is a strategy for tightly regulating
their activation and signalling, supporting the necessity for keeping their expression at low
levels as described in Section 1.5.2.
Spiking the sample taken to mass spectrometry with recombinant RXR allowed for its
detection (results not shown). In order to troubleshoot the low expression level I decided to
overexpress RXR𝛾 in primary rat OPCs in order to see whether that would allow for RXR𝛾
detection. For this purpose I designed a FLAG-tagged RXR𝛾 vector. This would allow both
the increase of RXR𝛾 expression and the use of a highly specific antibody for the CoIP thanks
to the FLAG tag, thereby troubleshooting both issues. Unfortunately transfection of primary
OPCs with the vector resulted in excessive cell death and low levels of transfection (data not
shown). For this reason I decided to use a biased approach based on the literature, in order
to test the partner switching hypothesis. This will be further discussed in Section 3.2.4.
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3.2 Levels of control for RXR-NR signalling in oligoden-
drocyte lineage cells
3.2.1 RXR activation in serum-free conditions
In Section 3.1 I have shown that carrying out CoIP on RXR𝛾 resulted in no detection of
known NR partners by mass spectrometry. Despite the conclusion of this section, a fun-
damental question remains: if no partners are detected, does RXR𝛾 really promote OPC
differentiation via heterodimerisation, or could the effects observed by Huang et al. (2010a)
occur via homodimeric or monomeric RXR𝛾 signalling?
In order to answer this question, one must be able to observe the true effect of RXR
activation without the stimulation of other NRs. All previous experiments have been carried
out using mixed glia isolated OPCs. As explained in Section 2.2.2, this technique exposes
the culture to serum for 10 days before isolating the OPCs from other brain cells. Ligands for
NRs include hormones, vitamins and retinoids, which circulate the body via blood plasma.
Therefore, the serum used in culture is abundant in NR ligands (Chen et al., 1997; Dang
and Lowik, 2005; Rauch, 2011). Consequently, the NR data presented by studies using
mixed glia isolation may be influenced by the chronic exposure of OPCs to NR ligands, able
to activate both RXR and its partners. Thus, the effects observed would not result from the
individual treatment carried out, but rather from the overall effect of the individual treatment
combined with the cell’s prior exposure to an array of different NR ligands. The limits of
serum when assessing NR biology have been observed in past studies, where the use of mixed
glia cultures impaired the observation of the effects elicited by calcitriol on OPCs, as serum
exposure resulted in the saturation of the system (de la Fuente et al., 2015). Serum stripping
using charcoal solved the above issue; this involves incubating serum with activated carbon
which binds to and removes all steroid-like molecules such as NR ligands (de la Fuente et al.,
2015). The removal of lipophilic ligands creates a more defined serum with a lower chance
of influencing the experimental results.
However, charcoal stripping does not completely remove all forms of lipophilic molecules,
and the extent of the stripping may vary due to both the initial composition of different
batches of serum and technical inconsistencies. Due to this, I decided to carry out NR lig-
and in vitro treatments on MACS isolated OPCs. As the cells are acutely isolated from the
brain and plated directly as a pure OPC population in serum-free media, serum and NR
ligand exposure is avoided and the effect of individual receptor activation on OPCs can be
observed.
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3.2.2 Purity of cultured OPCs isolated via MACS
The purity of acutely isolated OPCs has been previously assessed in Figure 3.1. However,
OPCs are able to form type II astrocytes in vitro (Raff et al., 1984), and highly proliferative
cells such as microglia and pericytes can result in their taking over the surface area available
for culture. It is therefore important to know how the OPC culture evolves over time in order
to ensure a reliable culture system throughout the experiment.
As shown in Figure 3.4A, the density at which OPCs are plated after MACS influences
astrocyte formation over time. The panel is a qualitative representation of the amount of
astrocytes observed after eight days of in vitro culture. OPCs were plated at three different
densities immediately after MACS isolation. At lower densities less OPCs differentiate into
astrocytes: this is important as an accumulation of astrocytes prevents OPC differentiation
into oligodendrocytes, potentially due to the release of GFs that maintain OPCs in a pro-
liferative state (Raff et al., 1988; Messersmith et al., 2000; Ito et al., 2005; Lu et al., 2009;
Cabezas et al., 2016). To avoid this, all MACS isolated OPCs were plated at a density of
6250 OPCs/𝑐𝑚2.
Figure 3.4B, shows that when plated at this density, the percentage of cells expressing
Olig2 is on average 77.77% (SD=17.60, n=3) 4 hours after plating, and remains constant
as there is no significant difference in the percentage of Olig2 expressing nuclei over the
course of 72 hours in the absence of GFs (ordinary one-way ANOVA, p=0.3660, n=3). Of
this Olig2 population, no cells express the mature oligodendrocyte marker MBP and this
does not change in the first three days of culture (Kruskal-Wallis, p>0.999, n=3), whilst an
average of 62.48% (SD=7.47, n=3) of Olig2 expressing cells also express the OPC marker
NG2 (Figure 3.4C). This significantly increases over time to an average of 72.76% (SD=5.34,
n=3) (ordinary one-way ANOVA, p=0.0047**, n=3). Figure 3.4C also shows that no astro-
cytes were acutely isolated via MACS, and when plated at low densities no astrocytes form
in the first three days in culture (Kruskal-Wallis, p=0.2088, n=3). Microglia do not seem to
proliferate as there is no significant increase in the number of CD11b expressing cells after
72 hours (ordinary one-way ANOVA, p=0.9283, n=3). A percentage of cells (on average
16.48%, SD=7.47, n=3) expresses NG2 but not Olig2. These cells may be pericytes and en-
dothelial cells as they are also known to express NG2 (Pouly et al., 2001; Guimarães-Camboa
et al., 2017). However, these cell types are highly proliferative and three days after plating
there is no significant difference in the amount of NG2-only expressing cells (ordinary one-
way ANOVA, p=0.2207, n=3). If the NG2-only cells are part of the oligodendrocyte lineage
but do not express Olig2 due to excessive stress, this percentage is expected to decrease over
time. Indeed, the percentage of these cells in culture does decrease to an average of 0.44%
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(SD=0.505, n=3) 72 hours after MACS isolation; however, this does not translate to a sta-
tistically significant difference, leaving these cells unidentified.
A small percentage of DAPI cells does not express any of the assessed markers after 4
hours (on average 5.75%, SD=3.45, n=3). The number does not change significantly over
time (ordinary one-way ANOVA, p=0.3351, n=3).
According to flow cytometry, immediately after MACS isolation almost all cells iso-
lated are viable and 87.47% of the cells are OPCs (Figure 3.1). However, MACS isolation
induces shear stress on the isolated cells due to mechanical tissue dissociation and the pass-
ing through the column. Based on the above, it is probable that the majority of cells plated
are indeed OPCs: however, initial cell death and cell recovery compromise the purity in the
first hours and days following the isolation, as stressed cells may not express markers at a
level detectable by immunocytochemistry.
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Fig. 3.4 Purity of primary rat OPCs extracted by MACS and cultured in serum free
conditions. (A) Qualitative immunocytochemistry of type II astrocyte formation based on
the seeding density of OPCs. The higher the initial OPC density, the more astrocytes are
formed over the course of eight days in culture. Astrocytes are identified using the marker
GFAP. Upon determining the initial OPC seeding density of 6,250 OPCs/𝑐𝑚2, changes in the
expression of the lineage marker Olig2 were determined as shown in (B). OPCs were MACS
sorted and kept for 72 hours in the absence of GFs. The number of Olig2+ nuclei is on av-
erage 77.77% ± 17.6% 4 hours after seeding. The amount of Olig2+ nuclei does not change
significantly over the course of the first 72 hours in culture. (C) Of all the Olig2+ population,
none express the mature oligodendrocyte marker MBP and this does not change over time.
Instead, 62.48% ± 7.471% also express NG2. The amount of Olig2+NG2+ cells increases
significantly to 72.76% ± 5.34% after 72 hours (p=0.0047). The significance of multiple
comparisons for the Olig2+NG2+ is represented in the graph (*p≤0.05 **p≤0.01). Other
cell types such as astrocytes (GFAP), microglia (CD11b), NG2 only and DAPI only cells
were present in low percentages 4 hours after plating and did not change significantly over
the course of the first three days of culture (0.38% ± 0.48% for GFAP, 0.87% ± 0.88% for
CD11b, 16.48% ± 14.45% for NG2 only and 5.75% ± 3.45% for DAPI only cells). (D) Rep-
resentative pictures for each cell type reported in the purity graphs at each time point anal-
ysed. Scale bar = 50𝜇m. All data was analysed using ordinary one-way ANOVA followed
by Tukey’s multiple comparison test where significance was reached or Kruskal-Wallis test
where the data did not follow a normal distribution. All graphs are presented as mean ±
SEM, biological n=3.
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3.2.3 RXR activation alone is not sufficient to promote OPC differen-
tiation
After MACS isolation, OPCs were plated and left to recover for three days in the presence of
GFs, after which GFs were removed and OPC media with the desired treatment was added.
The media was replenished every other day and OPCs were chronically exposed to the
treatment for eight days. The cells were fixed and stained for the lineage marker Olig2 and
the differentiation marker CNPase.
Unlike what has been previously reported in the mixed glia experiments carried out by
Huang et al. (2010a), RXR activation via treatment of its agonist 9cRA resulted in no sig-
nificant difference in the percentage of differentiated cells compared to the vehicle control
DMSO after eight days of exposure as shown in Figure 3.6A (ordinary one-way ANOVA
followed by Dunnett’s multiple comparison test, p=0.8197, n=4). Figures 3.6A and B show
that this observation was true for the treatment of all NR agonists and antagonists, except
for the THR agonist T3, readily added to the the media of MACS sorted OPCs to promote
differentiation and therefore used in this experiment as a positive control (Barres et al., 1994;
Baas et al., 1997) (ordinary one-way ANOVA followed by Dunnett’s multiple comparison
test, p=0.0024, n=4). None of the treatments reported more cell death than the vehicle con-
trol as shown in Figure 3.5.
Based on the data presented it appears that the presence of a multitude of NR ligands
is important in order to promote OPC differentiation. This is immediately clear when com-
paring the spontaneous differentiation rate of MACS neonatal OPCs eight days after GF
withdrawal to the differentiation rate of mixed glia isolated OPCs after only two days of GF
removal (Figures 3.7A and B).
In this experiment the vehicle control presents an average differentiation rate of 1.55%
(SD=1.34, n=4) for MACS isolated OPCs eight days after GF withdrawal (Figure 3.7B).
When this is compared to mixed glia isolated OPCs exposed to either normal serum or
charcoal-treated serum 48 hours after the shake off (average=75%, SD=7.037 and aver-
age=61.17%, SD=0.4124 respectively), it is clear that there is a substantial difference in
the spontaneous differentiation rate of the same cells (ordinary one-way ANOVA followed
by Tukey’s multiple comparison test, p<0.0001, n=3). Additionally, there is a significant
difference in the differentiation rate of OPCs cultured with normal or charcoal-treated serum,
further suggesting the importance of steroid-like molecules in OPC differentiation (ordinary
one-way ANOVA followed by Tukey’s multiple comparison test, p=0.0130, n=3).
Therefore, activation of RXR alone via its agonist 9cRA is not sufficient to promote
OPC differentiation. The previously reported effects of 9cRA were observed in experiments
involving mixed glia isolated OPCs, whereby the cells were exposed to serum which contains
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other partner ligands. Indeed, stripping serum of such ligands using charcoal also abrogates
OPC differentiation induced by 9cRA (de la Fuente et al., 2015). The data presented suggests
that RXR does not promote OPC differentiation as a monomer or homodimer, as the presence
of other NR ligands is required for OPC differentiation to occur. This is further supported by
unpublished experiments carried out by Oihana Errea from the Franklin laboratory shown in
Figure 3.7C, where the treatment of MACS isolated OPCs with a combination of ligands such
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Fig. 3.5 Titrations assessing cell death of NR ligand treatments carried out in Figure
3.6. Rat primary OPCs were isolated using MACS and left to recover in GFs in serum-free
conditions. After two days GFs were removed and the cells were chronically exposed to the
treatments for eight days. The media was changed every other day. Cell death was assessed
by the percentage of DAPI+PI+ staining. The concentration range picked was determined
by what was reported in the literature and the experiments previously carried out in the
Franklin laboratory. Abbreviations for the treatments are explained in Figure 3.6D. All data














































































































3.2 Levels of control for RXR-NR signalling in oligodendrocyte lineage cells 89
    
D
Fig. 3.6 NR ligand treatment in serum-free conditions. Primary rat OPCs were isolated
via MACS sorting and cultured in serum-free conditions. OPCs were left to recover in the
presence of GFs. After two days the GFs were removed and the treatments were added.
OPCs were chronically exposed to the treatments for eight days with media changes carried
out every other day. Differentiation was assessed by determining the percentage of CNPase+
cells out of the Olig2+ population. Both (A) agonists and (B) antagonists for NRs show no
effect on the differentiation of MACS isolated OPCs apart from the activation of THR via
T3, here used as positive control. These treatment conditions present the same cell death as
the vehicle control as shown in Figure 3.5. (C) Panel showing the representative immuno-
cytochemistry pictures of NR ligand treatment in serum-free conditions. (D) Table showing
the full name of the ligands used in this experiment, which NR they act on and whether
they activate or prevent their action. All data was analysed using ordinary one-way ANOVA
followed by Dunnett’s multiple comparison test where significance was reached (*p≤0.05
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Fig. 3.7 Spontaneous OPC differentiation after normal serum, charcoal-treated serum
and serum-free media exposure. Primary rat OPCs were isolated via mixed glia isolation
and kept in normal or charcoal-treated serum before shake off, or via MACS and kept in
serum-free conditions. The mixed glia isolated OPCs were left to differentiate for 48 hours,
whilst the MACS isolated OPCs were left to differentiate for eight days. Differentiation
was assessed based on the percentage of MBP+ cells out of the whole Olig2+ population.
(A) Panel showing the representative immunocytochemistry pictures of spontaneous OPC
differentiation after exposure to normal serum, charcoal-treated serum and OPCs in serum-
free media. (B) Quantification of (A) showing the comparison of the spontaneous OPC
differentiation of OPCs exposed to the three different media conditions. (C) Experiments
carried out by Oihana Errea on the differentiation of OPCs sequentially exposed to T3 and
9cRA in serum-free conditions after six days of chronic exposure to the treatments. All data
was analysed using ordinary one-way ANOVA followed by Tukey’s multiple comparison
test where significance was reached (*p≤0.05 **p≤0.01 ****p<0.0001). All graphs are
presented as mean ± SEM, biological n=3. Scale bar = 50𝜇m.
92 Results
3.2.4 RXR is constantly bound to its partners during OPC differentia-
tion
To test the partner switching hypothesis, it is necessary to identify the binding of RXR𝛾
to its partners. As the mass spectrometry based unbiased approach adopted in Section 3.1
did not allow for this, I decided to adopt a biased approach. This consists of carrying out
proximity ligation assays between RXR𝛾 and partners previously reported to be involved in
OPC biology.
For these experiments I used the Duolink® technique, involving the use of antibodies and
DNA technology. If two proteins are considered close enough to be interacting, this translates
into a fluorescent signal which can be imaged via conventional fluorescent microscopy as
shown in the diagram in Figure 2.3. The advantage is that the Duolink® avoids the use
of protein engineering required for FRET, which alters protein structure and can therefore
impair the receptor’s binding ability.
I used mixed glia cultures in order to have a comparable number of differentiated oligo-
dendrocytes and OPCs for a better comparison between the various differentiation stages.
Four different lineage stages were compared as shown in Figure 3.8. OPCs were marked us-
ing NG2 and were classified as cycling or non-cycling based on EdU incorporation. Newly
formed oligodendrocytes were identified by the absence of MBP and the expression of ec-
tonucleotide pyrophosphatase/phosphodiesterase family member 6 (ENPP6) (Xiao et al.,
2016), whilst mature oligodendrocytes were identified by the expression of MBP. The asso-
ciation between RXR𝛾 and any partner was quantified based on Duolink® signal intensity
and this was normalised by the area of the nucleus at each of the four stages. Protein quan-
tification via immunofluorescence is usually avoided due to its high variability and lack of
reproducibility, and is considered semi-quantitative at best. However, the Duolink® signal
has been subject of quantitative image analysis by other studies, highlighting the possibil-
ity of its quantification provided that an automated counting method is used (Nilsson et al.,
2010).
Figure 3.9A compares the association of RXR𝛾 to each partner at each stage (ordinary
one-way ANOVA followed by Tukey’s multiple comparison test where there is significance,
n=3). In both cycling and non-cycling OPCs the Duolink® signal produced by RXR𝛾-
LXR𝛽 binding is significantly higher compared to any other RXR𝛾-NR interaction tested
(p<0.0001). This is observed only at the OPC stage of the lineage, as the later stages present
no significant difference in RXR𝛾 association with all the partners assessed. All other part-
ners show no difference in the extent of RXR𝛾 binding for all four stages.
When assessing the binding pattern for each RXR𝛾-NR individually (Figure 3.9C), it is
clear that all partners show a similar pattern of association to RXR𝛾 , where the binding is
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strongest at the early stages of the lineage and decreases significantly as OPCs differenti-
ate into mature oligodendrocytes (ordinary one-way ANOVA followed by Tukey’s multiple


































3.2 Levels of control for RXR-NR signalling in oligodendrocyte lineage cells 95
Fig. 3.8 Experimental set up for Duolink® assay. OPCs were isolated via mixed glia iso-
lation and left for 48 hours in either presence or absence of GFs. OPCs were identified using
the marker NG2 and split between cycling and non-cycling based on EdU incorporation.
Newly formed oligodendrocytes were distinguished by the expression of the marker ENPP6
and the absence of MBP. Oligodendrocytes were identified using the mature oligodendro-
cyte marker MBP. The bottom set of immunocytochemistry pictures illustrate the biological
controls used for the Duolink® assay. On the left the expression of RXR𝛾 and NG2 is shown.
The interaction between these two proteins was used as a negative control as no signal is ob-
served when carrying out Duolink®. VDR-HDAC1 was used as a positive control as this
interaction occurs throughout the whole lineage. Duolink® signal results in small, quantifi-
able, fluorescent puncta. Quantification was carried out by measuring the integrated intensity
of the Duolink® signal in either the nucleus or cytoplasm of the cells and normalising it by
the area over which the measurement was carried out. The signal was then normalised over












































































































































































































































































































































































































































































































































































































































Fig. 3.9 RXR𝛾 does not switch binding partners during OPC differentiation. Rat pri-
mary OPCs were isolated using mixed glia shake off and Duolink® was carried out for RXR𝛾
and a variety of NR partners at different stages of the lineage. The nuclear Duolink® signal
for each interaction was quantified. (A) There is no significant difference in the interac-
tion of RXR𝛾 to the array of binding partners assessed at the four different stages of the
oligodendrocyte lineage. The only heterodimer showing a significant difference is RXR𝛾-
LXR𝛽. This is true only at the initial stages of the lineage. (B) Immunocytochemistry of
the RXR𝛾-LXR𝛽 Duolink®. (C) When looking at how each RXR𝛾 heterodimer changes
over the course of OPC differentiation, all heterodimers present the same pattern. The high-
est interaction is at the two OPC stages of the lineage and as they differentiate the signal
decreases significantly. All data was analysed using ordinary one-way ANOVA followed
by Tukey’s multiple comparison test where significance was reached, (*p≤0.05, **p≤0.01,
***p≤0.001, ****p<0.0001). All graphs are presented as mean ± SEM, biological n=3.
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3.2.5 The subcellular location of RXR heterodimers during OPC dif-
ferentiation
From the Duolink® data presented, it appears that RXR𝛾 does not actively switch the partner
it is bound to as OPCs differentiate into mature oligodendrocytes.
However, the relevance of different partners at various stages of the lineage may be de-
termined at other levels of NR signalling control. One of these is subcellular location, a
salient aspect of NR control as the confinement of the receptors to the cytoplasm prevents
them from carrying out their genomic functions, whilst their transport to the nucleus allows
them to elicit transcriptional control. To assess whether subcellular location of RXR𝛾-NR
categorises heterodimers responsible for the progression of OPC differentiation, I carried out
Duolink® analysis of RXR𝛾 binding to the same set of NRs previously tested. However, this
time the cytoplasmic signal was also measured, and a ratio between nuclear and cytoplasmic
signal at the four stages of the lineage was quantified. This would aid in understanding how
the overall binding of RXR𝛾 and each partner assessed is distributed within each lineage
stage, and whether the location of the heterodimers changes over time.
Figure 3.10A shows that all RXR𝛾-NR follow a similar pattern of distribution with re-
gards to their nuclear:cytoplasmic ratio during OPC differentiation. Nuclear localisation of
the heterodimers is highest at the initial stages of the lineage compared to cytoplasmic lo-
cation. However, over the course of differentiation the ratio between nuclear:cytoplasmic
signal location decreases (ordinary one-way ANOVA followed by Tukey’s multiple compar-
ison test where there is significance or Kruskall-Wallis test, n=3).
The lower ratio is due to the significant decrease in the nuclear signal as reported in
Figure 3.9C of the previous section, but also due to an increase in cytoplasmic signal as
differentiation occurs as shown in Figure 3.10C.
This is true for all heterodimers except for RXR𝛾-LXR𝛽 which does not present a signif-
icant change in the ratio of nuclear:cytoplasmic location during OPC differentiation. This
is because, unlike what is observed for other RXR𝛾-NRs, RXR𝛾-LXR𝛽 levels also decrease
in the cytoplasm as differentiation occurs, suggesting an overall reduction in the absolute
amount of the heterodimer upon oligodendrocyte formation. The results are summarised by
the diagram in Figure 3.10B.
The data presented shows a similar pattern of subcellular distribution for the majority
of RXR𝛾-NR assessed throughout the oligodendrocyte lineage. At the initial stages of the
lineage there is a high level of both nuclear and cytoplasmic heterodimers, which could be
due to the high production of NRs necessary to be shuttled to the nucleus in order to induce
differentiation as later discussed in Section 3.2.7. However, upon mature oligodendrocyte
formation, the cytoplasmic signals increase compared to the previous newly formed oligo-
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dendrocyte stage. This could be due to the heterodimers shuttling back to the cytoplasm once
the necessary transcription regulation has occurred. Even though active shuttling of the re-
ceptors cannot be assessed with a static technique such as Duolink®, it has been reported that
continuous nucleocytoplasmic shuttling is essential to the function of transcription factors
such as Sox10, as upon inhibition of its nuclear export a reduction in the transactivation of
both transfected reporters and endogenous target genes is observed (Rehberg et al., 2002).
Similarly, prolonged localisation of GR in the nucleus of NIH3T3 cells due to reduced cyto-
plasmic shuttling resulted in increased luciferase expression compared to control when car-
rying out luciferase reporter assays (Black et al., 2001). This demonstrates that NR shuttling
is important in controlling the expression level of target genes, and even though the observa-
tions presented were obtained via the use of artificial systems, it cannot be excluded that this
could also occur at the level of endogenous gene expression in primary cells. The increase
in cytoplasmic RXR𝛾-NR may therefore be due to shuttling-mediated control of gene tran-
scription upon terminal differentiation. However, techniques such as FRET in combination
with live imaging are better suited to determine whether active nucleocytoplasmic shuttling
is indeed the reason for the cytoplasmic increase in RXR𝛾-NR in mature oligodendrocytes.
On the other hand, the increase in cytoplasmic heterodimers could result from an increase in
NR protein production and consequently RXR𝛾-NR formation, rather than shuttling itself.
The reason for an increased requirement of RXR𝛾-NR at the final stage of the lineage is
unclear, but it can be speculated that it may be for the non-genomic heterodimeric functions


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 3.10 Nucleocytoplasmic shuttling of RXR𝛾 heterodimers over the course of OPC
differentiation. Rat primary OPCs were isolated using mixed glia shake off and Duolink®
was carried out for RXR𝛾 and a variety of NR partners at different stages of the lineage. The
nuclear and cytoplasmic signals were measured to determine changes in RXR𝛾-NR subcel-
lular during differentiation. (A) The nucleus:cytoplasmic ratio of Duolink® signal changes
significantly as OPCs differentiate. (B) Summary figure for heterodimer shuttling. The ma-
jority of heterodimers increase in their cytoplasmic presence and/or decrease in the nucleus
as OPCs differentiate, except for RXR𝛾-LXR𝛽 whose ratio remains constant. (C) Duolink®
signal in the cytoplasm. All data was analysed using ordinary one-way ANOVA followed
by Tukey’s multiple comparison test where significance was reached (*p≤0.05, **p≤0.01,
***p≤0.001, ****p<0.0001). All graphs are presented as mean ± SEM, biological n=3.
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3.2.6 Co-regulator association to RXR partners during OPC differen-
tiation
The fourth level of NR signalling control consists of co-regulator association as shown in
Figure 1.7. As little differences were observed between RXR𝛾-NR behaviours when assess-
ing partner switching and changes in subcellular location throughout OPC differentiation,
co-regulator association may be the major level of signalling control. Table 3.1 summarises
an array of co-regulators that have been shown to influence both OPC and Schwann cell bi-
ology in some way. These have been broadly divided into either activators or repressors of
gene expression. However, the same co-regulator can act as either depending on the overall
machinery it associates to (Perissi and Rosenfeld, 2005).
To assess whether co-regulators switch dynamically in order to promote OPC differ-
entiation, Duolink® analysis was carried out between each RXR𝛾 partner previously as-
sessed and the set of co-regulators reported in Table 3.1. The experiment was not carried
out with RXR𝛾 in order to achieve the specific co-regulator association to each individual
heterodimer, thereby determining their activation in the different lineage stages.
As shown in Figure 3.11, throughout OPC differentiation co-regulators associate to RXR
partners following one of two main patterns.
Co-regulator Type Effect Reference
BRG1 Activator Aids the expression of myelin genes Marathe et al. (2013)
PGC1𝛼 Activator Increases myelination Yoon et al. (2016)
SRC1 Activator Affects P0 in Schwann cell lines Cavarretta et al. (2004)
TRAP220 Activator DRIP-complex components Oda et al. (2010)
p300 Activator Involved in OPC fate choice Zhang et al. (2016a)
SIRT1 Repressor Inhibits OPC differentiation Rafalski et al. (2013)
SIRT2 Repressor Inhibits OPC differentiation Li et al. (2007)
HDAC1 Repressor OPC differentiation Ye et al. (2009)
HDAC2 Repressor OPC differentiation Ye et al. (2009)
HDAC3 Repressor Involved in OPC fate choice Zhang et al. (2016a)
HDAC11 Repressor Inhibition impairs OLG maturation Liu et al. (2009)
NCoR Repressor OPC fate choice Castelo-Branco et al.
(2014)
Table 3.1 Co-regulators involved in myelin cell biology.
LXR𝛽 is shown as an example of pattern 1 of how co-regulator associate to the NRs
being assessed, and PPAR𝛾 as an example of pattern 2. Pattern 1 association is observed for
the majority of partners, where both activators and repressors increase in their association to
the partner as differentiation occurs (ordinary two-way ANOVA followed by ordinary one-
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way ANOVA where there was significant interaction between the two variables assessed,
n=3). The co-regulators reporting significant difference over the course of differentiation
vary amongst different partners. On the other hand, pattern 2 reports a lower association of
the same co-regulators to PPAR𝛾 and RAR𝛾 . Nevertheless, some report significant differ-
ence in their association over time depending on the partner they associate to.
Co-regulator association to RXR𝛾 partners changes as OPC differentiation occurs and
the specific regulators that present a significant change depend on the partner being assessed.
Even though the exact biological relevance of these results remains too complex to interpret,
it is clear that co-regulator binding to RXR𝛾 partners is more dynamic than partner bind-
ing to RXR𝛾 . Furthermore, co-regulator binding is dependent on the specific NR being
assessed, suggesting that each RXR𝛾 partner has their own inhibition and activation profile,








































































































































































































































































































































































































3.2 Levels of control for RXR-NR signalling in oligodendrocyte lineage cells 105
    
Fig. 3.11 Co-regulator association to RXR𝛾 partners is more dynamic. Rat primary
OPCs were isolated using mixed glia shake off and Duolink® was carried out for the NR
partners previously assessed and a variety of co-regulators at different stages of the lineage.
The nuclear Duolink® signal for each interaction was quantified. (A) Co-regulators associate
in one of two patterns. Pattern 1 shows the interaction of LXR𝛽 with each co-regulator
assessed, and pattern 2 shows the interactions of PPAR𝛾 with the same array of co-regulators.
Which co-regulators result in significant changes depends on the partner being assessed. (B)
The co-regulators picked and the equivalent colours used to represent them in the graphs
in (A). (C) Table showing the co-regulator pattern presented by the partners assessed. The
majority display pattern 1, whilst only PPAR𝛾 and RAR𝛾 present pattern 2. All data was
analysed using ordinary two-way ANOVA. If interactions were observed, ordinary one-way
ANOVA was carried out (*p≤0.05, **p≤0.01, ***p≤0.001, ****p<0.0001). All graphs are
presented as mean ± SEM, biological n=3.
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3.2.7 Discussion
In this section I have assessed the different levels at which NR signalling is controlled in pri-
mary neonatal OPCs. It is clear that NR ligands are salient components of the system, as the
presence of single ligands do not affect OPC differentiation except in the case of THR activa-
tion via its ligand T3. Unlike what has been previously reported, RXR activation with 9cRA
did not induce OPC differentiation in serum-free conditions, unless in combination with the
presence of another NR ligand. These observations give confidence that the presence of
multiple NR ligands is required for differentiation to occur, and that the effects observed by
Huang et al. (2010a) occur via activation of an RXR𝛾 heterodimer, rather than a monomer
or homodimer.
On the other hand, the use of Duolink® to assess the partner switching hypothesis through-
out lineage progression reported no bias in partner association to RXR𝛾 , except for the
RXR𝛾-LXR𝛽 heterodimer. The data suggests that RXR𝛾 is mainly associated with LXR𝛽
at the early stages of the lineage, and this interaction falls to the same level of associa-
tion exhibited by the other partners as OPCs differentiate. A link between LXR activation,
increased myelin gene expression, myelination and remyelination has been previously de-
scribed (Shackleford et al., 2013; Meffre et al., 2015), and these results point towards a
fundamental role for RXR𝛾-LXR𝛽 heterodimer signalling at the early stages of the lineage.
An increase in cholesterol production and metabolism is essential to OPC differentiation as
cholesterol is the major lipidic component of the oligodendrocyte plasma membrane and
consequently myelin. The importance of LXRs in fatty acid and cholesterol metabolism has
been already outlined in Section 1.6.3, and the high association between RXR𝛾 and LXR𝛽
at the OPC stage of the lineage could be essential for preparing the OPC to the necessary
increase in cholesterol production, thereby aiding progenitors in meeting the metabolic de-
mands required for successful differentiation.
A particularly interesting observation from this set of results is that all nuclear RXR𝛾-NR
interactions are highest at the progenitor stage and decrease as differentiation progresses. It
has been reported in the literature that stem cells present different chromatin structure and
organisation compared to differentiated cells.
Indeed, both ESCs and iPSCs have diffuse and less compact chromatin as well as a high
level of chromatin remodelling factors in their nucleus (Chalut et al., 2012; Mattout et al.,
2011; Delgado-Olguin and Recillas-Targa, 2011). As cells differentiate the chromatin com-
pacts and areas become transcriptionally inactive (Alcobia et al., 2000; Martou and De Boni,
2000; Alcobia et al., 2003; Santos et al., 2002). Chromatin remodelling factors such as NuRD
are essential in ESC differentiation, pointing towards a role for chromatin remodelling fac-
tors in both maintenance of stem cell identity and in priming the cell for differentiation (Kaji
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et al., 2006). These observations have lead to the hypothesis that as cells differentiate there
is a need to induce specific expression programmes, and chromatin remodellers allow this
to occur by forming chromatin domains. Epigenetic domains allow fast and easy access for
transcription and regulatory factors that can silence genes involved in stem cell maintenance
and promote a lineage-specific gene expression programme (Meshorer et al., 2006).
Being NRs key recruiters of chromatin remodelling machinery and regulatory factors
(Egea et al., 2000; Aranda and Pascual, 2001; Evans and Mangelsdorf, 2014), the high lev-
els of RXR𝛾-NR observed in OPCs reflect the need of progenitor cells to undergo chromatin
domain specification in order to induce lineage-specification and differentiation. As progen-
itors differentiate, the requirement for RXR𝛾 heterodimers decreases until differentiation is
complete. Upon terminating the differentiation programme, mature oligodendrocytes enter
a maintenance state where a low level of transcription is required and therefore a lower level
of RXR𝛾-NR are present in the nucleus.
The majority of partners show a similar extent of RXR𝛾 binding throughout the lineage
stages assessed. Despite further validation using different techniques is required to confi-
dently confirm the above, based on the Duolink® results it is tempting to conclude that the
partner switching hypothesis is incorrect. However, although the partners may not physically
switch their binding to RXR𝛾 , the possibility of specific heterodimers being responsible for
OPC lineage progression cannot be excluded. The extent of RXR𝛾 binding may not necessar-
ily imply biological function, and functionally predominant heterodimers may be determined
at other control levels despite RXR𝛾 being constantly bound to all of the partners assessed.
Functional dominance could be obtained via ligand presence, as ligands control various as-
pects of NR signalling, including subcellular shuttling and co-regulator recruitment. Both
of these were assessed. Changes in subcellular location are also similar amongst the dif-
ferent partners, however co-regulator recruitment and association is more dynamic and is
dependent on both the cell’s stage in the lineage and the partner being assessed.
This leads to an overall picture, summarised in Figure 3.12, where at each stage of the
lineage RXR𝛾 heterodimers are stable, and the biological relevance of the heterodimer is
dependent on the dynamic association of co-regulators as differentiation progresses.
The co-regulator recruitment is probably determined by the ligands that the heterodimers
are presented with, as it has been previously reported that co-regulator association is depen-
dent on the conformational changes the heterodimers undergo upon ligand binding (Heery
et al., 1997; Nolte et al., 1998; Gronemeyer et al., 2004).
Overall, the different control levels for NR signalling function in order to obtain a single
outcome: regulation in the expression of target genes. This is because the ultimate physio-
logical response is determined by the expression and repression of the desired set of genes.
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It is therefore clear that in order to understand how RXR𝛾 activation truly promotes OPC


























RXRγ is constantly bound to 
its partners throughout the
lineage. LXRβ is the
predominant one at the 
OPC stage
The presence of multiple NR
ligands is fundamental to
OPC differentiation. This
may determine which 
co-regulators and HREs
will be bound by the dimer
As OPCs differentiate there 
is a decrease in nuclear 
location and an increase in
cytoplasmic location of
the heterodimers 
Co-regulators show dynamic 
association to the different
RXRγ partners 
Fig. 3.12 Summary of the observations made on the levels of control for RXR𝛾-NR sig-
nalling in oligodendrocyte lineage cells. Multiple NR ligands need to be present in order
to observe a differentiation effect via RXR activation. This is because in serum-free con-
ditions and in charcoal-treated serum, 9cRA does not promote OPC differentiation. Based
on the Duolink® assay results, RXR𝛾 does not switch its binding partner at different stages
of the lineage, but all partners are bound to the same extent. Only RXR𝛾-LXR𝛽 show in-
teraction prevalence at the OPC stage. There are significant changes in the nuclear and
cytoplasmic locations of the heterodimers as OPC differentiation occurs, however it cannot
be stated whether this is active heterodimer shuttling with the technique used. Co-regulator
association to the RXR𝛾 partners is very dynamic, dependent on the partner being observed
and likely regulates the expression of different sets of genes that are key to different cellular
functions.
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3.3 Identifying the genes controlled by RXR in oligoden-
drocyte lineage cells: a ChIP-seq approach
In the last section I have assessed how RXR𝛾 signals and the levels at which the signalling
network are controlled. However, the ultimate goal of this study is to understand how RXR𝛾
activation translates into OPC differentiation. In Section 3.1 I have described how NRs have
non-genomic roles as well as genomic ones (Boonyaratanakornkit et al., 2001; Skildum et al.,
2005; Hammes and Levin, 2007; Sarkar et al., 2008; Ordóñez-Morán et al., 2008). Therefore,
it cannot be excluded that OPC differentiation could be elicited via a non-genomic RXR𝛾
pathway. However, NRs have been for the most part described and studied due to their role
as transcription factors. As the process of differentiation requires profound changes at the
transcriptional level, I hypothesised that RXR𝛾 activation leads to the transcriptional regu-
lation of genes specifically involved in OPC differentiation. THR, LXR and VDR have all
been shown to influence the expression levels of genes important to oligodendrocyte forma-
tion, such as MBP and PLP, and HREs for some of these receptors have been identified in
the promoter regions of these genes (Farsetti et al., 1991; Meffre et al., 2015; de la Fuente
et al., 2015; Shackleford et al., 2017). However, it is not currently known whether the tran-
scriptional control of myelin-specific genes by these receptors occurs via RXR heterodimers,
as the genes controlled by RXR𝛾 in OPCs have not been assessed to date. In order to tackle
this question, I decided to carry out ChIP-seq for RXR𝛾 in primary rat OPCs.
ChIP-seq is used to map genome-wide binding sites of transcription factors and histones
using chromatin immunoprecipitation (ChIP), in combination with DNA sequencing. The
sequenced DNA fragments are then mapped back to the genome, in order to determine the
DNA sites at which the protein of interest binds. Figure 3.13A illustrates the ChIP-seq ex-
perimental design. I used MACS sorted neonatal rat OPCs for ChIP-seq, preventing any
exposure to serum, as the presence of other NR ligands could alter RXR𝛾 binding. The
progenitors were then plated into T75 flasks and left to recover and proliferate in the pres-
ence of GFs for five days until confluent. They were then treated for 24 hours with 50nM
9cRA or 0.1% DMSO as vehicle control. The two treatments would allow the assessment of
RXR𝛾 association to the genome under both basal and activated conditions. ChIP was car-
ried out using both an anti-RXR𝛾 antibody and a nIgG control in order to assess non-specific
background binding in both conditions. A biological replicate of three was used for all the
samples and controls.
Despite the continuous evolution of the technique, ChIP-seq still presents some chal-
lenges with regards to the experimental design, especially when using primary cells. One




























































Fig. 3.13 Experimental design and controls for RXR𝛾 ChIP-seq in primary rat OPCs.
(A) Illustration of the ChIP-seq experimental design. OPCs were isolated via MACS and
plated in T75 flasks. They were kept for five days in GFs until confluent. The OPCs were
then treated for 24 hours with either 50nM 9cRA or 0.1% DMSO as vehicle control. The
OPCs were detached and ChIP using either an anti-RXR𝛾 antibody or a nIgG control was
carried out. (B) Western blot showing the CoIP binding of the chosen RXR𝛾 antibody (sc-
514134X). RXR𝛾 antibody ab15518 was used for the detection. The nIgG control shows
no RXR𝛾 pulldown. (C) Blot showing that RXR𝛾 sc-514134X antibody binds recombinant
RXR𝛾 . (D) Blot showing a further control where CoIP was carried out using anti-NG2
antibody. When RXR𝛾 is detected, no band is revealed. (E) 1% agarose DNA gel of the
chromatin shearing trial. The length of the shearing trials is shown at the top of the gel. The
majority of the fragments need to fall within 400-200bp fragment size, therefore an overall
shearing time of 6 minutes was selected.




























Fig. 3.14 Purity of OPC cultures prior to ChIP-seq. Primary rat OPCs were isolated using
MACS and kept for five days in culture in the presence of GFs in order for the progenitors to
proliferate. After five days the cells were detached, plated on coverslips and left to recover for
2 hours before fixing and assessing their purity via immunocytochemistry. (A) The number
of Olig2+NG2+ nuclei is on average 70.25% ± 2.001%. Astrocytic and microglial contam-
ination was minimal, with 4.85% ± 1.278% of GFAP+ and 1.57% ± 0.783% of CD11b+
nuclei. 10.04% ± 0.594% of nuclei expressed only Olig2; however, no mature oligoden-
drocytes are present, with (0.23% ± 0.398% of either CNPase+ and MBP+ cells). 7.66% ±
2.021% of the nuclei were positive only for the marker NG2, and almost no cell death was
observed in the cultures, as the percentage of PI+ nuclei was 1.09% ± 1.173%. Overall, this
data shows that the cultures obtained form the experimental set up for ChIP-seq result in a
relatively pure culture highly enriched for OPCs with minimal astrocyte formation and pro-
liferation of other undesired cell types. (B) Representative immunocytochemistry pictures
for graph (A). All graphs are presented as mean ± SEM, biological n=3, scale bar = 50𝜇m.
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transcription factors requires 10-20 million cells/sample (Park, 2009), which would require
the use of an excessive number of animals when using primary rat OPCs. It is for this reason
that I allowed the OPCs to proliferate for 5 days in vitro and carried out an initial sequenc-
ing trial using 5 million OPCs/sample. This yielded enough DNA for genes to be detected.
Thus, 5 million OPCs/sample were used in this set of experiments. Secondly, the exper-
imental outcome of ChIP-seq is highly dependent on the quality of the primary antibody
used (Park, 2009). For this experiment I picked the mouse monoclonal anti-RXR𝛾 antibody
from Santa Cruz Biotechnology (sc-514134X). My decision was based on the literature, as
ChIP-grade RXR antibodies from Santa Cruz have been used in previous ChIP experiments
(Daniel et al., 2014). Further CoIP validation followed by western blot of anti-RXR𝛾 sc-
514134X specifically, revealed the single 35kD band of RXR𝛾2. This same band does not
appear when using the mouse nIgG for CoIP.
A source of artefacts in the experimental outcome could arise from the chromatin shear-
ing step of the ChIP protocol (Section 2.2.14). The optimal size of the DNA fragments prior
to ChIP should be between 200-400bp and the uniformity of the chromatin shearing step
needs to be constant between the different samples. To determine the optimal shearing con-
ditions I have carried out shearing trials by changing the number of cycles whilst keeping
the sonicator power, cycle lengths and concentration of OPCs/sample constant. One of the
DNA gels ran is shown in Figure 3.13E. The shearing process should aim at obtaining the
majority of the chromatin sheared to the required fragment size with a minimal number of
cycles. This is because over-shearing can result in detachment of the cross-linked proteins
from the DNA. Based on the trials carried out I picked 6 shearing cycles. Upon completion
of the control experiments, the optimal conditions for the ChIP-seq were determined and the
experiment was carried out.
In Section 3.2.2 I have shown that OPCs differentiate into type II astrocytes in vitro when
the plating density is too high. To ensure that five days in proliferative conditions did not
cause astrocyte formation, OPCs were detached and re-plated on coverslips, left to recover
for 2 hours and stained in order to assess the purity of the culture. Figure 3.14 shows that
an average of 4.85% (SD=1.278 , n=3) of the DAPIs were positive for the astrocytic marker
GFAP. Contamination by microglia and NG2-only cells was minimal, with an average of
1.57% (SD=0.78, n=3) CD11b+ cells and 7.66% (SD=2.02, n=3) NG2+ cells. With regards
to the oligodendrocyte lineage there were almost no mature oligodendrocytes present (on
average 0.23%, SD=0.40, n=3), the percentage of Olig2-only cells was on average 10.04%
(SD=0.59, n=3), whilst the number of OPCs made up on average 70.25% (SD=2.00, n=3)
of the total cell population. The cultures presented almost no cell death as the average of PI+
cells was 1.09% (SD=1.17, n=3) and there were very few unidentified cells which stained
3.3 Identifying the genes controlled by RXR in oligodendrocyte lineage cells: a ChIP-seq
approach 113
for none of the markers assessed (on average 12.05%, SD=0.70, n=3). Overall, this suggests
that the cultures obtained for ChIP-seq are enriched in OPCs with minor contamination from
other cell types.
3.3.1 Genome-wide profiling of RXR in primary rat OPCs
I used ChIP-seq to define RXR𝛾 occupancy after 24 hours of either 0.1% DMSO (vehicle
control) or 50nM 9cRA treated OPCs. This would aid in assessing the basal occupancy of
both inactive and active RXR𝛾 . The peaks obtained from the sequencing were aligned to
the latest rat genome (rn6) and called using model basis analysis of ChIP-seq 2. The peaks
were compared to the ones obtained via ChIP of the nIgG control to remove any unspecific
background antibody binding. Once the background binding was removed, the peaks with
a q value lower than 0.5 detected in two or more biological replicates were considered to be
areas of RXR𝛾 binding. This data processing was kindly carried out by Dr. Sabine Dietmann
at the Wellcome Trust Stem Cell Institute at University of Cambridge.
It is conventionally accepted that, unlike class III NRs, RXR heterodimers do not always
shuttle to the nucleus upon activation. Instead, they can be found already associated to the
genome in the absence of their cognate ligands, and carry out the desired effect upon ligand
binding. I thus assessed the genome-wide occupancy of RXR𝛾 at both basal conditions as
well as after 9cRA exposure (Figure 3.15A). Few peaks were observed in vehicle treated
primary OPCs, revealing that the basal occupancy of RXR𝛾 is minimal in the absence of its
ligand. The Venn diagram in Figure 3.15B shows that approximately 111 peaks were called
in DMSO treated OPCs, a small number compared to the 12,372 peaks called in 9cRA treated
OPCs. The two conditions only presented 11 peaks in common. Multiple EM for Motif
Elicitation (MEME) analysis was used for the discovery of de novo sequence motifs bound
by RXR𝛾 in the ChIP-seq carried out. This analysis revealed that RXR𝛾 consistently binds
to the motif shown in Figure 3.15C, which highly resembles the previously reported core
motif for NRs AGGTCA, as over 50% of the bases are in common between the two motifs.
The low variability of the RXR𝛾 binding motif here reported gives further confidence that
the peaks derived from the ChIP-seq are not coincidental and that the data obtained can be
further analysed.
NRs act as transcription factors and it has been reported that they mainly exert their
function by binding to promoter regions in close proximity of the transcription start site
(TSS) of the gene of interest (Umesono et al., 1988; Evans and Mangelsdorf, 2014). Fig-
ure 3.15D illustrates the distribution of the peaks around their closest TSS. In contrast to
what has previously been suggested, this data shows that the majority of the peaks reside







































































































Fig. 3.15 Genome-wide RXR𝛾 binding in the absence and presence of 9cRA. (A) Heat-
maps of RXR𝛾-binding signals in rat primary OPCs after 9cRA exposure (left) and control
conditions (right). Each line on the y axis represents a genomic region ± 2kb flanking RXR𝛾
summits. This reveals that there is a higher number of peaks after 9cRA exposure compared
to control. This is further illustrated by the venn diagram (B) showing that the global RXR𝛾
occupancy under control conditions, with 111 total peaks called. 9cRA exposure resulted in
12372 RXR𝛾 peaks, suggesting that the presence of an agonist promotes genomic-binding
of RXR𝛾 . (C) MEME analysis revealed that RXR𝛾 binds to a constant motif throughout the
genome. This motif closely resembles the previously reported core motif for NRs AGGTCA.
(D) Analysis of the distribution of peaks around the closest TSS in 9cRA conditions shows
that the majority of peaks are located far away from TSS, up to 15kb upstream or downstream
of it. (E) Genomic annotations of the peaks shows that the majority of the RXR𝛾 peaks
are found in intergenic and intronic genomic areas, and almost none are found in promoter
regions where NRs have been reported to act.
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are relatively far away from promoter regions, here considered to be 5,000bp up and down-
stream of the TSS. Analysis of the genomic location of these peaks (Figure 3.15E) shows
that RXR𝛾 rarely associates to promoter regions in both control and 9cRA-treated condi-
tions, with almost no promoters bound in both cases. Instead, it is mainly bound to intronic
and intergenic genomic regions. At basal level, 29.73% and 68.47% of the RXR𝛾 peaks
fall within intronic and intergenic regions respectively, and upon 9cRA activation the peaks
redistribute to 17.82% and 81.84%. ChIP-seq experiments on other NRs reveal the same pat-
tern of association, regardless of whether they have been carried out on cell lines or primary
cells (Carroll et al., 2005; Ramagopalan et al., 2010; Boergesen et al., 2012; Singh et al.,
2015). These genomic areas make up the majority of the genome and are known to contain
numerous regulatory elements for gene transcription, including silencers and enhancers, able
to determine the likelihood of gene transcription to be promoted or prevented (Kolovos et al.,
2012). The elements contained in these areas and their exact mechanism of function are still
not completely understood, and the implication of RXR𝛾 potentially binding to regulatory
elements in OPCs will be further discussed in Section 3.3.3.
3.3.2 RXR HREs are located in proximity of genes involved in regula-
tion of proliferation and stem cell control
When OPCs are exposed to 9cRA, RXR𝛾 binds to numerous genomic areas resulting in
12,372 peaks. Despite this does not directly translate to 12,372 genes bound, it still reveals
that RXR𝛾 could bind to almost half of the rat genome, an observation which may not be
surprising considering the plethora of cellular functions that RXR and its heterodimers in-
fluence. Gene ontology (GO) analysis of all the peaks obtained (data not shown) results in a
large variety of cellular and biological processes, making it hard to identify which of these
may be specific to oligodendrocyte differentiation. To refine and simplify the search, I used
the database generated by Zhang et al. (2014) to aid in the process. Using this database I
created a unique gene signature list of the top 500 differentially expressed genes between
the three stages of the oligodendrocyte lineage that Zhang et al. (2014) analysed. This is
illustrated by the heat map in Figure 3.16A. The top 500 genes for OPCs are expressed at
extremely low levels in newly formed and mature oligodendrocytes. However, the expres-
sion levels of the unique gene signatures observed by the other two stages are less clear
cut. This is because the newly formed and mature oligodendrocyte are effectively the same
cell transitioning through different stages of the lineage, rather than two different cell types.
Therefore, it is not surprising that the difference in gene expression between the two is not
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Fig. 3.16 RXR𝛾 mainly associates to genes unique to OPCs and newly formed oligo-
dendrocytes. (A) Heat map of the top 500 differentially expressed genes for OPCs, newly
formed and myelinating oligodendrocytes according to Zhang et al. (2014). (B) I assessed
whether RXR𝛾 binds to any of these unique signatures, which it does to 380 of them. (C) GO
term analysis of the 380 genes revealed that RXR𝛾 mainly associates in proximity of genes
involved in cell cycle regulation, proliferation, oligodendrocyte development and differenti-
ation. (D) Table of the most interesting genes I have found RXR𝛾 to associate to, based on
the results of the GO term analysis and filtered based on the literature. (E) Graph showing
the validation of the ChIP-seq using qPCR. qPCR was carried out on MACS isolated OPCs
after 24 hours of DMSO or 9CRA exposure. All results were normalised to DMSO, shown
in the graph to always be at a baseline value of 1. The fold change in the expression of each
gene target assessed is shown. The expression of Cdkn1b (the transcript for p27), Enpp6 and
Mobp increase significantly after 24 hours of 9cRA exposure, whilst the expression of Fgfr4
decreases significantly compared to control conditions. Data was analysed using Unpaired
Student t Test, n=3 (*p≤0.05, **p≤0.01). Graphs are presented as fold change ± SEM,
biological n=3.
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The unique gene signatures were compared against the peaks obtained from the ChIP-
seq, resulting in a total of 380 unique genes having RXR𝛾 bound either in their proximity,
promoter or intronic regions (Figure 3.16B). Division of the 380 genes between the three
lineage stages revealed that 45.53% of the genes are unique to OPCs, 31.32% are unique to
newly formed oligodendrocytes and 23.16% are unique to mature oligodendrocytes. This
is an interesting observation as the majority of genes do not belong to the mature oligo-
dendrocyte stage, as initially hypothesised. Instead, the majority of genes belong to OPCs
and newly formed oligodendrocytes. GO term analysis of the 380 unique genes was carried
out using the online software Gene Ontology Consortium (http://geneontology.org). Figure
3.16C reveals that RXR𝛾 binding sites occur in proximity of genes involved in regulation of
TH signalling, oligodendrocyte differentiation and development, as well as cell proliferation
and stem cell biology.
To validate some of the targets of interest summarised in Figure 3.16D, I carried out
qPCR for these genes. OPCs were isolated via MACS and treated for 24 hours with either
0.1% DMSO or 50nM 9cRA as with the ChIP-seq experimental conditions. They were then
lysed and qPCR was carried out. The graph in Figure 3.16E summarises the results obtained.
The expression level of the genes assessed upon 9cRA treatment was normalised against their
basal expression level in the vehicle control sample. For this reason, the graph represents
the fold change in the mRNA levels of the genes being assessed upon RXR𝛾 activation
(Unpaired Student t Test, n=3). Four of the genes change in their expression level upon
9cRA treatment; these are Cdkn1b, Fgfr4, Enpp6 and MOBP. This suggests that RXR𝛾
affects their expression, giving further confidence in the list of genes obtained by the ChIP-
seq experiment.
3.3.3 Discussion
In this section I set out to find which genes are controlled by RXR𝛾 in primary rat OPCs. I
initially hypothesised that OPC differentiation as a consequence of RXR𝛾 activation occurs
because RXR𝛾 heterodimers control the transcription of genes involved in mature oligoden-
drocyte formation. I therefore carried out ChIP-seq for RXR𝛾 in neonatal rat primary OPCs
treated with either 0.1% DMSO or 50nM 9cRA. As suggested in the literature for other NRs,
genome-wide profiling of RXR𝛾 revealed that the receptor mainly associates to intergenic
and intronic DNA regions instead of genomic promoter regions (Carroll et al., 2005; Ram-
agopalan et al., 2010; Boergesen et al., 2012; Singh et al., 2015).
It is known that eukaryotic genomes are predominantly composed of non-protein coding
DNA found between protein coding genes, as well as protein coding exons. In the 50s and 60s
it was suggested that these genomic areas could activate and regulate transcription at certain
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developmental and cell-specific differentiation stages (McClintock, 1950; Britten and David-
son, 1969), but despite these observations, for many years the general consensus remained
that these areas were evolutionarily redundant. Instead, there is increasing evidence that non-
protein coding regions are of great evolutionary importance, as they have been described to
have functional relevance in the control of gene expression in both a condition-dependent
and tissue-specific manner. Indeed, the analysis of sequenced genomes revealed that rela-
tive amount of non-protein coding DNA increases alongside the increasing complexity of
an organism (Taft et al., 2007), with biological complexity being defined as the number of
different cell types within an organism and their organisation (Vogel and Chothia, 2006;
Taft et al., 2007). On the contrary, the amount of protein coding genes remains relatively
static across different metazoa. Furthermore, the use of RNA-seq datasets from a variety of
different animals has shown that the majority of non-protein coding DNA is transcribed in
a tissue-specific manner and these areas may be important in the development and correct
functioning of complex organisms (Liu et al., 2013).
The almost exclusive association of RXR𝛾 to non-protein coding DNA regions in OPCs
initially came as a surprise, as the role of NRs have largely been described in the promoter
regions of protein coding genes. However, after observing ChIP-seq data of other NRs, such
as VDR and GR, in a variety of cell types, it is clear that all NRs predominantly associate
to intergenic and intronic genomic regions (Carroll et al., 2005; Ramagopalan et al., 2010;
Boergesen et al., 2012; Singh et al., 2015). Non-coding DNA regions contain regulatory
elements fundamental to the control of gene transcription, including transposable elements,
alternative upstream promoters, enhancers and silencers, able to produce non-protein-coding
RNAs with the capability of influencing the transcription of protein-coding genes kilobases
away (Liu et al., 2013; Li et al., 2016). Regulatory elements have been shown to play funda-
mental roles in the correct outcome of biological processes such as development and regen-
eration. Single cell RNA-seq revealed that the expression of four ultra-conserved enhancers
on the X-chromosome correlates with the expression of the ARX gene in different cell types
in the brain (Dickel et al., 2018). ARX is a gene fundamental to neurological development.
Dickel et al. (2018) used transgenic reporter mice lacking individual or a combination of
these enhancers and followed their development. They observed that all animals were vi-
able, but presented brain defects as a consequence of altered neuronal populations and brain
structure, due to impaired ARX expression during development in the different cell types.
In this study, Dickel et al. (2018) clearly demonstrated the functional importance of highly
conserved non-coding genomic areas in driving biological processes fundamental to life.
Enhancer elements have also been involved in regenerative processes. RNA-seq revealed
an increased expression of lepb in regenerating zebrafish fins and heart compared to con-
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trol tissue (Kang et al., 2016). Two enhancer elements in proximity of lepb were identified
via the open chromatin mark Histone H3 acetyl Lys27 (H3K27ac) during tissue regenera-
tion, but not in uninjured tissue. With the use of enhancer-effector transgenes using lepb-
linked sequences upstream of factors known to influence regeneration, Kang et al. (2016)
showed that these enhancers can indeed influence regeneration efficiency, suggesting their
great potential for the development of regenerative therapies. Another interesting consider-
ation comes from the recent sequencing of the axolotl genome (Nowoshilow et al., 2018).
Among vertebrates, axolotls have no equal in their capability of adult regeneration and the
recent sequencing of their genome will open new avenues in the study of regeneration, giving
great hope to regenerative medicine. Interestingly, axolotls have one of the biggest genomes
ever to be sequenced, comprised of 32Gb, ten times that of the human genome (Nowoshilow
et al., 2018). One of the reasons for this is the huge expansion of intronic and intergenic
non-protein coding regions (Nowoshilow et al., 2018). Whilst further studies are required to
determine the reason for such an expansion, based on the papers previously mentioned it is
tempting to speculate that these areas may be packed with regulatory elements which allow
for the remarkable regenerative capacity of this animal model.
With regards to oligodendrocyte biology, the lineage-specific transcription factor Olig2
has been shown to recruit chromatin remodellers to enhancer elements involved in oligo-
dendrocyte differentiation (Yu et al., 2013). Functional studies of Olig2 patterning revealed
epigenetic marks such as H3K27ac around stage-specific enhancer elements that control the
expression of salient regulators of OPC differentiation. These include MRF, Sox10, Olig1,
Olig2 and Zfp191 (Yu et al., 2013). Regulatory elements found in intronic and intergenic
regions are therefore important in numerous cell and tissue-specific functions.
Based on the ChIP-seq data I have here reported, RXR𝛾 binds to areas abundant in reg-
ulatory elements able to influence gene transcription, raising two fundamental points:
1. RXR𝛾 does not directly influence gene transcription, but instead may determine the
likelihood and probability of a gene of interest being transcribed;
2. the proximity of an RXR𝛾 binding site to a specific gene does not necessarily mean
that that gene is the one being influenced by RXR𝛾 .
In order to address the first point, ATAC-seq (assay for transposase-accessible chromatin us-
ing sequencing) alongside either RNA-seq or ChIP-seq for RNA polymerase could be carried
out in 9cRA treated primary OPCs. The first technique would aid in understanding which
chromatin areas are made available for transcription by RXR𝛾 , while the second would give
further confidence of which genomic areas are actively being transcribed as a consequence.
In order to distinguish enhancer elements bound by RXR𝛾 , ChIP-seq for H3K27ac would
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need to be carried out and compared to the RXR𝛾 here collected. The Richard Lu labora-
tory will kindly give us access to the OPC rat enhancer database they have developed based
on H3K27ac distribution across the genome of developing OPCs. Despite the data was not
collected for OPCs exposed to 9cRA, it will be an interesting starting point to map potential
enhancer regions bound by RXR𝛾 .
In order to map which regulatory elements influence which genes, functional studies
need to be carried out. However, there is value in assuming that intergenic regions influence
the genes closest to them and intronic regulatory elements influence the expression of the
genes they are located in, as this is widely accepted in the field. The GO term analysis shown
in Figure 3.16C suggests that the majority of genes specific to the oligodendrocyte lineage
influenced by RXR𝛾 have to do with cell proliferation and aspects of cell cycle regulation,
rather than with oligodendrocyte maturation and myelination. The subsequent qPCR valida-
tions have shown that ENPP6 and myelin-associated oligodendrocyte basic protein (MOBP)
significantly increase in their expression upon 9cRA treatment, suggesting that my initial
hypothesis partly holds true. However, RXR𝛾 mainly binds in proximity of genes involved
in cell cycle regulation and control of proliferation. Interestingly, two of the genes that sig-
nificantly change in the qPCR after only 24 hours of 9cRA exposure are relevant to both the
above processes. Cdkn1b encodes for the cyclin dependent kinase inhibitor p27, a protein
important in influencing cell cycle progression through the G1 phase. It is often used as a
cell cycle exit marker as its main function is to slow down or stop cell division. Its regulation
following RXR𝛾 activation suggests that RXR𝛾 affects the expression of salient players in
cell cycle regulation and progression. FGF is a proliferative and migratory signal for OPCs,
and this is mediated by FGFRs (McKinnon et al., 1990; Barres et al., 1994; Bansal, 2002;
Lindner et al., 2015). The decrease of FGFR4 mRNA upon RXR𝛾 activation suggests that
RXR𝛾 may regulate proliferation by interfering with this signalling pathway, in this case by
limiting the amount of receptor present to detect FGF. This makes sense in an in vivo setting,
where GFs such as FGF are continually being produced by astrocytes and microglia, and one
of the potential ways to induce differentiation in the presence of proliferative signals is by
making the cell oblivious to such signals by controlling the expression of the receptors.
These observations, alongside considerations from the literature, have aided me in the
development of a new hypothesis with regards to RXR𝛾 and its influence on OPC differen-
tiation, which will be assessed and discussed in the following section.
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3.4 RXR activation regulates OPC proliferation
In Section 3.3 I have presented data showing that RXR𝛾 HREs are proximal to genes in-
volved in proliferation and cell cycle control. The potent effect NRs exert on the cell cycle
has been of particular interest in the context of cancer therapy and prevention, where the use
of retinoids and rexinoids has been studied for the development of cancer differentiation ther-
apies (Altucci et al., 2007). Unlike chemotherapy, where the aim is to destroy fast-dividing
cells, the goal of cancer differentiation therapy is to drive malignant cells into terminal dif-
ferentiation. The challenge in developing these therapies is therefore to reactivate pathways
that are usually bypassed or suppressed in tumorogenesis, restoring a normal cycle and guid-
ing the cancer cell into either differentiation or apoptosis (Altucci et al., 2007). RAR and
RXR have been the candidates of choice for such therapies, as ATRA has proven success-
ful as a differentiation therapy for the treatment of acute promyelocytic leukaemia (APL).
Using a combination of ATRA and chemotherapy, 70%-80% of patients with APL present
long-term remission, compared to only 25%-30% of patients achieving the same result prior
to the introduction of ATRA (Lengfelder et al., 2005). However, the potent side and terato-
genic effects of retinoids and pan-retinoids has pushed the field to search for less injurious
alternatives.
Rexinoids are less toxic than retinoids (Miller et al., 1997) and have been just as success-
ful in the treatment of diverse cancers, presenting an attractive alternative to retinoids. The
efficiency of 9cRA in decreasing the tumorogenic phenotype of cells has been demonstrated
in a variety of in vitro and in vivo cancer models. For example, Gottardis et al. (1996)
have shown that 9cRA decreases proliferation and increases differentiation of the human
promyelocytic leukaemia cell line HL-60 in vitro. Instead, in vivo 9cRA treatment of mice
transplanted with primary human squamous cell carcinomas resulted in complete tumour
regression (Gottardis et al., 1996). Furthermore, the RXR ligand Bexarotene has been the
first FDA approved synthetic RXR agonist to be used for the treatment of cutaneous T cell
lymphomas (Kempf et al., 2003). As a consequence, in the past years RXR agonists have
been at the centre of cancer research, in order to develop treatments for an array of diverse
tumours and different aspects of tumour biology (Altucci et al., 2007; Sabnis et al., 2013;
Huang et al., 2016; Kiss et al., 2017). However, the mechanism by which rexinoids induce
a differentiated phenotype in primary cancer cells and cell lines is still unknown.
RXR has been reported to enhance the differentiation effects of other NRs such as PPAR
(Tontonoz et al., 1997; Crowe and Chandraratna, 2004). This suggests synergism between
the activation of different NRs, which could arise from activation of the individual RXR-
PPAR heterodimer components, or from sequential activation of RXR and PPAR, with each
NR involved in different aspects of the cell cycle and progenitor differentiation. Indeed, in
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the obesity field it has been reported that RXR manipulation determines cell cycle arrest in
the G0/G1 phase in adipocytes, further suggesting its role in cell cycle regulation (Nakatsuka
et al., 2012). Taking into account the literature in both the cancer and metabolic fields, as
well as the data obtained from the ChIP-seq experiment reported in the previous section, it
is plausible to suggest that RXR may affect cell cycle regulation.
3.4.1 9cRA treatment decreases OPC proliferation in serum-free con-
ditions
To determine whether RXR activation alone affects OPC proliferation I resorted to OPC
isolation using MACS and serum-free cultures, as for the differentiation experiments in Sec-
tion 3.2.3. I assessed the percentage of proliferating progenitors using EdU, a nucleoside
analog of thymidine, which is incorporated by the dividing cell into the DNA during DNA
replication. Thus, EdU labels all cells that are in S phase of the cell cycle, as this is when
active DNA synthesis occurs. This experiment was carried out in both presence and absence
of GFs, these being strong drivers of OPC proliferation whose absence could mask the po-
tential effect elicited by the treatments being assessed (Woodruff et al., 2004; Murtie et al.,
2005). Following the same rationale of the experiments in Section 3.2.3, T3 was used as
the positive control as it has been shown to induce OPC differentiation at the expense of
proliferation in both GF presence and absence (Barres et al., 1994).
Figure 3.17A shows the effect of GF presence and absence on OPC proliferation in con-
trol conditions. The percentage of proliferating OPCs in GF presence was on average 62.9%
± 5.7% 24 hours after isolation and remains constant for the 96 hours following OPC iso-
lation (ordinary one-way ANOVA, n=3). Instead, when GFs are removed there was a con-
stant and statistically significant decrease in the number of proliferating OPCs (ordinary
one-way ANOVA followed by Tukey’s multiple comparisons test where there was signif-
icance, p<0.0001, n=3). The percent of proliferating OPCs almost halves in the first 96
hours, where the percentage of EdU+ OPCs decreased from an average of 51.56% ± 2.07%
at 24 hours, to an average of 27.07% ± 3.05% 96 hours after GF removal. This indicates that
the OPCs in culture respond as expected to GF presence and removal. The effect observed
in control conditions following GF removal was replicated in the presence of both 9cRA and
T3 treatments as illustrated in Figure 3.17B, where each treatment shows a decrease in OPC
proliferation over time (ordinary one-way ANOVA followed by Tukey’s multiple compar-
isons test where there was significance, p<0.0001 for vehicle control and 9cRA, p<0.001
for T3, n=3). However, when the treatments are compared at the same time point, no dif-
ference in the percent of proliferating OPCs was observed. This suggests that the decrease
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in proliferation in GF absence is due to the effect induced by GF removal, rather than the
treatments per se. Instead, the effect of RXR activation on OPC proliferation became imme-
diately apparent in the presence of GFs. After only 24 hours of 9cRA exposure, there was
a statistically significant decrease in the percentage of EdU+ OPCs compared to the vehicle
control, which decreased by approximately 20%, is observed (Figure 3.17B). The drop in
proliferation of 9cRA treated progenitors exceeds the one observed in T3 treated cells af-
ter 48 hours, suggesting a stronger effect of 9cRA on proliferation compared to T3 at these
early time points. However, over time both vehicle control and T3 treated cells caught up,
with the latter exceeding the decrease in OPC proliferation presented by the 9cRA treatment
(ordinary one-way ANOVA followed by Tukey’s multiple comparisons test where there was
significance, n=3).
In Section 3.2.3 the use of CNPase as a marker for differentiation did not show any sig-
nificant difference between 9cRA exposure and control conditions. ChIP-seq clearly showed
that this differentiation marker, alongside other markers such as MBP, PLP, MAG and MOG,
are not controlled by RXR𝛾 , therefore this time I used cell morphology as an indicator of
whether RXR activation affected early OPC differentiation. This method had been previ-
ously adopted by Huang et al. (2010a) to quantify OPC differentiation. After 6 days of in
vitro treatment, progenitors were classified as either bipolar or multipolar based on the mor-
phology obtained via O4 staining as shown in Figure 1.3. In both absence and presence of
GFs, the percentage of bipolar progenitors remains constant across treatments, whilst T3 re-
sults in a significant increase in the percent of multipolar cells, with p=0.0118 in GF presence
and p=0.0052 in GF absence (Figure 3.17C). Instead, there is no significant difference in the
percentage of multipolar cells in 9cRA and control conditions (ordinary one-way ANOVA
followed by Tukey’s multiple comparisons test where there was significance, n=3). The
above demonstrates that RXR activation alone affects OPC proliferation but not differenti-
ation, as shown in both Figures 3.17 and 3.6, where no changes in percentage of CNPase+
cells or multipolar morphology are observed. This reinforces the concept that proliferation
and differentiation are highly coordinated, yet independent processes.
The effect of the RXR inhibitor HX531 (HX) was also tested in these conditions. How-
ever, these experiments were carried out at a different time, and due to technical issues with
the A2B5 antibody following changes to its manufacturing process by the provider, a lack of
specificity and suboptimal purity of the MACS isolations affected the downstream results.
Consequently, OPCs in vitro were not responding as expected in control conditions. Due to
the above, this data is not presented in this thesis.
OPCs have the ability of producing endogenous 9cRA. This is carried out by the enzyme
aldehyde dehydrogenase 1A1 (ALDH1A1) whose function is the conversion of lipid alde-
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Fig. 3.17 Effect of 9cRA on the proliferation of MACS sorted rat primary OPCs cul-
tured in serum-free conditions. (A) In control conditions GF presence maintains OPCs
in constant proliferation, whilst their removal decreases their proliferation. (B) Effect of
9cRA and T3 on OPC proliferation in GF presence and absence. (C) OPC differentiation
assessed via morphology of O4 stain. Only T3 shows increased differentiation. (D) Inhibi-
tion of ALDH1A1 via TTDS shows increased OPC proliferation (biological n=2). All data
was analysed using ordinary one-way ANOVA followed by Tukey’s multiple comparison
test where significance was reached. All graphs are presented as mean ± SEM, biological
n=3 unless specified (*p≤0.05, **p≤0.01, ***p≤0.001, ****p<0.0001).















Fig. 3.18 Immunocytochemistry of 9cRA effect on OPC proliferation and morphology.
Representative pictures for the results in Figure 3.17A, B and C.The top two rows show EdU
labelled OPCs in the three conditions after 24 and 48 hours of exposure in GF presence. The
bottom row shows the morphology after six days of treatment exposure. Pink arrows show
progenitors with a bipolar morphology and white arrows show progenitors with a multipolar
morphology. Bipolar progenitors are in the early stages of the lineage, whilst multipolar
morphology suggests that the cells are beginning to differentiate. Scale bar = 50𝜇m.
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hydes to lipid carboxylic acids. It is therefore possible to use the substrate 9-cis retinal and
endogenously convert it to 9cRA (Paterson et al., 2013). ALDH1A1 appears in the top 500
unique gene signature of OPCs compared to newly formed and myelinating oligodendrocytes
shown in Figure 3.16A, suggesting an important role for 9cRA in OPC biology. To deter-
mine whether complete absence of 9cRA affected OPC proliferation, I treated MACS sorted
OPCs with the ALDH1A1 inhibitor tetraethylthiuram disulfide (TTDS) for 6 days in vitro.
The OPCs were then fixed and stained for the proliferation marker Ki67. It is possible to
observe in Figure 3.17D that TTDS treatment increases OPC proliferation in a dose depen-
dent manner. In control conditions an average of 42.66% (SD=3.271) of OPCs were Ki67+,
nearly doubling upon 5𝜇M TTDS treatment to an average of 76.36% (SD=7.903). The num-
ber of CNPase+ cells did not change significantly (DMSO: mean=12.79% ± 1.356%, 1𝜇M
TTDS: mean=19.38% ± 15.64%, 5𝜇M TTDS: mean=6.414% ± 7.592%). Statistical analy-
sis could not be carried out on these set of experiments due to the low number of biological
replicates (n=2). However, these initial observations suggest that in the absence of the RXR
agonist 9cRA, the number of proliferating OPCs increases, further supporting the hypothe-
sis that RXR modulation regulates OPC proliferation without affecting differentiation. The
ALDH1A1 experiments were kindly carried out by Alerie Guzmán de la Fuente.
3.4.2 Testing the effect of RXR on the cell cycle and the exit marker p27
Following the observation that the level of p27 mRNA increases and that OPC proliferation
in vitro decreases after 24 hours of 9cRA exposure (Cdkn1b in Figure 3.16E), I sought to
understand how RXR activation governs cell cycle dynamics. Based on the role of p27
in the literature (Fero et al., 1996, 1998; Goukassian et al., 2001; Sharma et al., 2011), I
hypothesised that there are two possibilities as to why I observe a decrease in proliferation:
1. RXR activation promotes cell cycle exit;
2. RXR activation lengthens the G1 phase of the cell cycle, thereby delaying entry into
S phase.
Either way, the ultimate effect is the decrease or the slowing down of OPC proliferation. This
would explain why less progenitors are found in S phase upon 9cRA treatment compared
to control (Figure 3.17B). Once again, the following results were carried out during the
previously mentioned technical issues with the A2B5 antibody used to isolate OPCs and so
will need to be repeated in order to properly assess the ultimate outcome. However, they are
presented in this thesis as an example of the approach that I would have used to determine
how RXR manipulation influences the cell cycle.
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In Figure 3.16E it is clear that the cell cycle exit marker p27 is significantly higher in
9cRA treated OPCs compared to the vehicle control. However, so far this has only been ob-
served at the mRNA level and in order for p27 to exert its function it needs to be translated
into protein. I therefore decided to assess the protein level of p27 in 9cRA and HX treated
OPCs using western blot. OPCs were MACS sorted and treated in vitro for 24 or 48 hours in
both presence and absence of GFs. Only the results for 24 hours are shown in Figure 3.19A
due to the previously discussed compromised purity of the isolation. From the results, it
appears that in GF presence there is no difference in the protein level of p27 between the dif-
ferent treatments, whilst in the absence of GFs it seems to decrease for 9cRA compared to
the vehicle control, and decrease even more upon RXR inhibition. Despite the unexpected
result, more technical replicates are required in order to carry out proper statistical anal-
ysis and draw appropriate conclusions. Another, yet less reliable method for determining
changes in p27 levels is by determining cells with either low or high p27 fluorescence upon
immunocytochemistry. This has been adopted and reported by groups such as the Casaccia
laboratory as a method to estimate changes in protein expression (Scaglione et al., 2018). I
therefore carried out immunocytochemistry for p27 on OPCs treated for 24 or 48 hours with
either 9cRA or HX. Figure 3.19B shows that at both time points there is no difference in the
percentage of high or low p27 expressing OPCs across treatments, suggesting no changes
in the expression level of p27 upon RXR activation or inhibition compared to control con-
ditions (ordinary two-way ANOVA, n=3). However, immunofluorescence level remains a
tenuous method for determining overall protein amount as it is not a precise quantitative
measurement. Additionally, I sought out to assess the protein levels of cyclins important to
the G1-S phase transition, such as cyclin D1 and cyclin E1. I carried out western blot for the
two cyclins on OPCs exposed for 6, 12 and 24 hours to 9cRA, for which the results are shown
in Figure 3.19C. No statistically significant differences were reported in the protein level of
either cyclins in 9cRA treated OPCs compared to vehicle control. The time of exposure to
9cRA also shows no changes in the level of these two cyclins. One of the reasons for this
result could be that the reported time points are too early in order to observe an effect at the
protein level. Furthermore, these OPCs were treated in the absence of GFs, and it may well
be that this masks any 9cRA effect as for the experiments reported in Figure 3.17. These ex-
periments should therefore be repeated in the appropriate conditions in order for the results
to be adequately interpreted.
To assess the second possibility of whether RXR activation induces G1 lengthening,
I adopted a flow cytometry approach to determine whether there is a change in the OPC
distribution between the different cell cycle stages upon 9cRA treatment. This method is




































































































































































































































3.4 RXR activation regulates OPC proliferation 129
Fig. 3.19 Changes in cell cycle markers upon RXR activation. These experiments were
unfortunately carried out following a change to the manufacturing process of the A2B5 an-
tibody used for the MACS isolation of primary OPCs. Due to this, a lack of specificity and
suboptimal purity of the isolation compromised the following results. They should there-
fore not be taken as absolute and the experiments will need to be repeated once the issue is
resolved. (A) Western blot gel and quantification of p27 expression in OPCs after 24 hours
of treatment exposure (biological n=1). (B) p27 quantification via immunocytochemistry
resulted in no significant difference in the percentage of Olig2+ cells expressing p27. Data
analysed using ordinary two-way ANOVA. All graphs presented as mean ± SEM, biological
n=3. (C) Western blot gels and quantification of cyclins D1 and E1 in OPCs. Results show
no significant difference in cyclin D1 expression between DMSO and 9cRA after 6, 12 and
24 hours of treatment exposure, nor between each time point for the same treatment. There
seems to be no difference in the level of cyclin E1 expression either. Data analysed using
unpaired student t test and ordinary one-way ANOVA. All graphs presented as mean ± SEM,
biological n=3 for cyclin D1, biological n=2 for cyclin E1. However, the purity of the OPCs
isolated for these experiments was not optimal, therefore they will need to be repeated with
the appropriate OPC purity.
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Fig. 3.20 OPC distribution across cell cycle stages upon RXR activation. These exper-
iments were unfortunately carried out following a change to the manufacturing process of
the A2B5 antibody used for the MACS isolation of primary OPCs. Due to this, a lack of
specificity and suboptimal purity of the isolation compromised the following results. They
should therefore not be taken as absolute and the experiments will need to be repeated once
the issue is resolved. Panel (A) illustrates the gating strategy adopted in order to determine
the progenitor distribution. The forward and side scatter are initially used to determine cells.
Of all the singlets only the live cells will be assessed, therefore the forward scatter and ZV
stain aid in the exclusion of the dead cell population which is high in ZV. The live singlets are
then plotted using the side scatter and PI intensity. The three populations observed are the
progenitors distributed between the G1/G0, S and G2/M. The PI intensity is plotted against
the cell count as a histogram to which the Dean-Jett-Fox model is applied, an algorithm
which allows for the correct division of the progenitors across the three stages illustrated
in three different colours (Fox, 1980). (B) The results obtained from the application of the
Dean-Jett-Fox model are used for statistical analysis. No differences are observed in the
distribution of progenitors across G1/G0 or S phases for the three treatments. However,
T3 treated OPCs present a significant decrease in the numbers found in G2/M compared to
the other two treatments (p=0.0013). Therefore, T3 could block or slow down progression
through G1/G0 and/or S, or accelerate G2/M progression. All data was analysed using or-
dinary one-way ANOVA followed by Tukey’s multiple comparisons test where there was
significance. All graphs are presented as mean ± SEM, biological n=3.
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As DNA amount and conformation are different between the G1/G0, S and G2/M phases,
PI staining allows to grossly group the cells into the above three stages, presenting a final
distribution of the overall sample tested. Based on the observation in Section 3.17, I isolated
OPCs via MACS and treated them in vitro with DMSO, 9cRA or T3 for 48 hours in GF
presence. After 48 hours the progenitors were detached, stained for cell death and PI as
explained in Section 2.2.12 and taken to the flow cytometer.
The gating strategy is shown in Figure 3.20A. To obtain cells, the progenitors are ini-
tially plotted using the forward and side scatter. Once the singlets are obtained, ZV is used
to determine which cells are dead, allowing for the exclusion of these cells from the anal-
ysis. Once the live singlets are obtained, PI is plotted against the side scatter, and based
on the complexity and PI intensity the cells are grouped into the three broad stages of the
cell cycle mentioned above. To determine the percentage of cells in each phase the Dean-
Jett-Fox model found in FlowJo is used (Fox, 1980). This is an algorithm that allows for
the precise classification of the cells into each phase. Analysis of the first set of results re-
vealed no statistically significant difference in the number of cells in each stage upon 9cRA
treatment compared to the control (3.20B). On the other hand, T3 resulted in a significant
decrease in the number of cells in the G2/M phase compared to control and 9cRA (ordinary
one-way ANOVA followed by Tukey’s multiple comparisons test where there was signifi-
cance, p=0.0013, n=3). The decrease in number of cells in G2/M phase could mean that T3
treatment slows down the progression through one or both of the other stages, or that it ac-
celerates progression through G2/M. Either way a shift in the distribution of cell numbers in
the other stages may also be expected as a consequence. However, due to the compromised
purity of the isolation, these experiments need to be repeated in order to determine the true
effect of 9cRA and T3 on the OPC cell cycle. Furthermore, the number of cells obtained
from each treatment varies substantially, meaning that there were great discrepancies in the
size of the samples analysed. In this set of results the 9cRA samples were the ones with the
least progenitors analysed, with half as many cells as the vehicle control (results not shown).
This could lead to an underrepresentation of the sample and the results could be compro-
mised. It is therefore necessary to improve the collection of the progenitors from in vitro
conditions in order to obtain samples with a high and equal number of cells to analyse.
3.4.3 Discussion
The data presented in this section shows that RXR activation in vitro results in a decrease in
proliferation. Interestingly, this occurs in serum-free conditions and GF presence, suggesting
that:
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1. the true effect of RXR activation affects OPC proliferation, which could consequently
impact on OPC differentiation in the presence of other NR ligands as observed in
Figure 3.7C;
2. RXR activation has a similar outcome to GF removal as the effect of 9cRA on prolif-
eration is masked in the absence of GFs, while it is obvious in their presence.
From the ChIP-seq results and the functional data presented above, it is clear that RXR
activation affects OPC proliferation in vitro. Further confirmation comes from the cancer
biology field where RAR and RXR have been used to develop cancer differentiation ther-
apies as previously discussed. As the main aim of the therapy is to make malignant cells
exit the cell cycle in order for differentiation to occur, it is plausible to assume that RXR
activation influences cell cycle exit. Despite the cell-specific effects of NRs, their ubiqui-
tous expression and conservation across cell-types makes it tempting to propose that they
probably control similar cellular programs in different cell types. In this case, RXR may be
involved in controlling proliferation and cell cycle exit. Furthermore, Huang et al. (2010a)
showed that 9cRA treatment in vivo accelerates remyelination in aged rats, which was ini-
tially interpreted as an induction of OPC differentiation based on in vitro experiments car-
ried out on mixed glia isolated OPCs. However, remyelination was also assessed in RXR𝛾
knockout mice, where remyelination was delayed but not completely inhibited (Huang et al.,
2010a). Moreover, the data that I have presented in Section 3.2.3 and Figure 3.17C clearly
show that RXR activation does not lead to an increase in the differentiation of MACS iso-
lated OPCs, unless other NR ligands are also present. Instead, RXR activation does lead to a
decrease in the proliferation of MACS isolated OPCs, without affecting their differentiation
(Figure 3.17B and C). Taken together, these results suggest that OPC differentiation and re-
myelination are not dependent on RXR𝛾 per se, but are still influenced by its activation and
absence. Given that RXR𝛾 associates to genes involved in OPC proliferation as reported in
the ChIP-seq in Section 3.3, and that 9cRA treatment of MACS isolated OPCs leads to an
increase in p27 mRNA as shown in the qPCR results in Figure 3.16E, the ability of RXR𝛾 to
influence the cell cycle could be a plausible explanation for this phenomenon, as cell cycle
exit or G1 lengthening would facilitate OPC differentiation and consequently remyelination,
but not necessarily depend on it.
Previous work in the laboratory did not observe this same effect on proliferation upon
9cRA treatment of mixed glia derived OPCs. This is probably because the presence of serum
saturates the system with pro-differentiation factors as discussed in Section 3.2.3 and ob-
served in Figure 3.7, resembling an environment lacking GFs or overriding the proliferative
effects of said mitogens. As the consequence of RXR activation on OPC proliferation is ob-
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vious only in the presence of GFs (Figure 3.17B), it does not come as a surprise that previous
studies involving mixed glia isolation did not discern the same observations.
In this Section, I have described the ability of RXR activation to decrease in vitro OPC
proliferation without affecting differentiation. The ChIP-seq results reported RXR𝛾 to bind
in close proximity of the cell-cycle exit marker p27. Subsequent functional validations
showed an increase in p27 mRNA after 24 hours of 9cRA exposure compared to the con-
trol. Therefore, I initially assessed whether the decrease in proliferation is dependent on cell
cycle exit. I tested whether the changes in p27 expression observed via qPCR translated
at the protein level, however due to technical issues these experiments need to be repeated.
Consequently, it would be interesting to determine whether p27 acts on OPCs by promoting
cell cycle exit, or whether it lengthens their G1 phase.
During the cell cycle, the length of the G1 phase has been shown to be important in
fate determination of pluripotent stem cells (PSC) (Sela et al., 2012; Coronado et al., 2013;
Calder et al., 2013; Pauklin and Vallier, 2014; Boward et al., 2016), the implications of which
are further discussed in the final discussion (Chapter 4). G1 lengthening, as opposed to cell
cycle exit, would result in a more subtle effect rather than a complete impairment, which
could describe the delay in remyelination observed by Huang et al. (2010a) in RXR𝛾 null
mice. To determine whether cell cycle stages were affected upon RXR activation I initially
carried out flow cytometry using PI, which allows to determine whether there are changes
in the distribution of the cell cycle stages. This initial analysis did not yield reliable results
due to the technical issues imposed by the new anti-A2B5 antibody batches used for MACS
sorted OPCs. However, this flow cytometry experiment can be improved by incorporating
the use of antibodies against cyclins specific to each stage, as this would allow for a more
precise distinction of which phase each OPC is in. Furthermore, the use of the fluorescence
ubiquitination-based cell cycle indicator (FUCCI) is an interesting avenue to study the tran-
sition from G1 to S phase both in vitro and in vivo (Sakaue-Sawano and Miyawaki, 2014).
FUCCI uses ubiquitination oscillators involved in the control of cell-cycle transition which
genetically express fluorescent probes (Sakaue-Sawano and Miyawaki, 2014). This allows
for a dynamic colour change, from red to yellow to green, displaying the progression through
the cell cycle, resulting in a more efficient technique to determine cell cycle progression.
The above would only be a starting point for the study of cell cycle dynamics, since it is
not possible to determine the length and kinetics of the cell cycle phases from flow cytom-
etry alone, which is the ultimate goal of this study. Instead, this requires prior knowledge
of the overall length of the cell cycle via pulse labelling experiments which, in combination
with PI in flow cytometry, can be used to determine the approximate length of each stage.
Ultimately, whether RXR manipulation can influence cell cycle dynamics as opposed to dif-
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ferentiation would be an interesting and relevant question with regards to stem cell ageing.
This is because young and aged progenitors have different cell cycle dynamics despite being
the same cell-type. Indeed, the OPC cell cycle has been reported to lengthen with increasing
age and this correlates with a decline in oligodendrocyte generation in homeostasis (Young
et al., 2013), as well as with an impairment in remyelination (Sim et al., 2002). Therefore, al-
tered cell cycle dynamics with ageing may be part of the reason as to why OPCs differentiate
less efficiently. Considering the observations reported above and that RXR activation accel-
erates remyelination in aged animals, it is plausible to think that it may do so by affecting
the cell cycle dynamics of the aged OPC. However, whether NR expression and their ability
to respond to ligands changes in aged OPCs, and whether these changes are detrimental to
remyelination, still needs to be understood.
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3.5 Nuclear receptors in ageing OPCs
One of the major hallmarks of chronological cellular ageing is the accumulation of epigenetic
changes. These include alterations in DNA methylation patterns, histone modifications and
chromatin remodelling. The latter is particularly interesting to NR biology as their main
role is to orchestrate chromatin remodelling in order to control gene transcription (Egea et al.,
2000; Aranda and Pascual, 2001; Evans and Mangelsdorf, 2014). It has in fact been observed
that the expression level of enzymes and proteins involved in chromatin remodelling, such as
heterochromatin protein 1𝛼 (HP1𝛼), polycomb complexes and the NuRD complex, decrease
with ageing (Pegoraro et al., 2009; Pollina and Brunet, 2011).
The loss of such proteins inevitably induces alterations in the chromatin architecture of
the cell characterised by a loss of heterochromatin. In humans it has been observed that
mutations in lamins cause the development of the premature ageing diseases Hutchinson-
Gilford Progeria Syndrome and Werner Syndrome (Shumaker et al., 2006; Zhang et al.,
2015b). Lamins are the major components of the nuclear lamina which not only structurally
supports the shape of the nucleus, but also acts as a docking site for heterochromatin. In-
deed, the cells of these patients also present altered nuclear morphology such as changes in
chromosome centromeres, a loss in the heterochromatin mark H3K9me3, as well as delocal-
isation or lack of proteins related to heterochromatin, such as HP1𝛼, pericentric satellite III
repeat and the EZH2 methyltransferase, consequently leading to altered methylation marks
(Shumaker et al., 2006). These findings point towards a disruption of the chromatin structure
in cells displaying an aged phenotype, a conclusion which has been reinforced by the obser-
vation of spontaneous chronological ageing in various animal models and humans (Haith-
cock et al., 2005; Scaffidi and Misteli, 2006; Brandt et al., 2008). For example, flies with
impaired HP1𝛼 present a reduced lifespan, whilst its overexpression extends longevity and
delays age-related muscular deterioration (Larson et al., 2012). Changes in chromatin struc-
ture inevitably lead to alterations in transcription. Indeed, quantification of mRNA levels of
cardiomyocytes from young and old mice revealed an increase in the transcriptional noise
in aged cells compared to young (Bahar et al., 2006). More recently, single cell RNA-seq
analysis of CD4+ T cells revealed an increase in transcriptional heterogeneity in the cells of
older mice compared to young (Martinez-Jimenez et al., 2017). Additionally, the produc-
tion and processing of mRNAs, both protein coding and non-coding, are impaired in aged
cells compared to young (Harries et al., 2011; Boulias and Horvitz, 2012; Lee et al., 2016;
Rodríguez et al., 2016).
Transcriptional regulation is at the basis of a cell’s ability to respond adequately to en-
vironmental signals in order to carry out its function and survive. Therefore, its impairment
in ageing can have detrimental consequences. This is particularly true for stem cells which
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need to be able to respond correctly to their environment in order to self-renew or differ-
entiate into the required cell type, making their alterations in chromatin structure arguably
more damaging than those of post mitotic cell types. NRs are key players in chromatin re-
modelling and transcriptional regulation. However, their involvement or impairment in the
context of stem cell ageing has not been researched extensively. Indeed, unpublished work
from the Franklin laboratory carried out by Björn Neumann has shown that aged OPCs in
vitro do not respond to conventional signals such as T3, ATRA and 9cRA as efficiently as
young OPCs. This suggests that ageing decreases the inherent differentiation potential of
adult OPCs. The inability of aged OPCs to respond to external signals can ultimately lead to
the impairment in remyelination that is observed in ageing scenarios (Shields et al., 1999).
A particularly important hallmark of stem cell ageing is increased cellular senescence, char-
acterised by cell cycle arrest compromising stem cell function. This has been observed in
numerous stem cell niches (Janzen et al., 2006; Nishino et al., 2008; Signer et al., 2008;
Sousa-Victor et al., 2014). As with differentiation, this could occur as a consequence of the
progenitor’s inability to respond to signals that promote cell cycle progression. Furthermore,
part of the ageing phenotype appears to be dependent on the circulatory system where NR
ligands are transported. Heterochronic parabiosis experiments have revealed that factors in
the circulation can modulate ageing organs and rejuvenate them, including the brain (Ruckh
et al., 2012). Due to the above, whether NR pathways and networks are altered with age-
ing is an interesting question, as these transcription factors bridge extracellular signals with
transcriptional regulation.
3.5.1 NR expression in ageing OPCs
In order to assess changes at the protein level, I carried western blot on MACS sorted OPCs
lysed immediately after the isolation. I isolated OPCs from 3, 10 and over 18 months old
rats, which are the equivalent of young, middle-aged and aged humans, whilst neonatal OPCs
were used as controls. The results are shown in Figure 3.21A. Statistical analysis was car-
ried out only for VDR and LXR𝛼, as only one or two biological replicates were collected
for the other NRs assessed. In both cases, the difference in expression between the various
ages was not statistically significant, suggesting no changes in the level of expression of the
receptors (ordinary one-way ANOVA, n=3). However, western blot is a semi-quantitative
technique, whereby often the variability imposed by the technique is too big to yield sig-
nificance. More precise techniques such as quantitative mass spectrometry are preferred.
However, as reported in Section 3.1, NRs are expressed at levels below the limit of detection
of the mass spectrometry technique used.
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Despite the above, it is possible to observe that the NR expression decreases after de-
velopment. Furthermore, their expression continues to be decrease in adulthood and ageing.
The levels of THR𝛼, THR𝛽 and Nurr1 decrease between 3 and 18 months of age. It would
be interesting to collect more replicates in order to determine whether this decrease is sta-
tistically significant. These observations are supported by unpublished results from the lab
yielded from the RNA-seq comparison of young and aged rat OPCs carried out by Roey
Baror. The volcano plot is shown in Figure 3.21B. Almost all the NRs detected by the se-
quencing are grouped in the right side of the plot, suggesting that their expression at the
RNA level is lower in aged OPCs compared to young. THR𝛼 and 𝛽 are present in this plot,
giving further confidence that the patterns observed in the western blot analysis may indeed
be true.
The volcano plot shows only one NR to increase at the RNA level in aged OPCs compared
to young: RXR𝛼. When looking at RXR𝛾 expression at the protein level in Figure 3.21A, it
appears that its expression at the protein level follows an increasing pattern between 3 and 18
months of age. Despite these observations require further validation, they perhaps suggest
that RXRs are the only NRs among the ones assessed so far that tend to increase in their
expression with increasing age, whilst the others decrease or remain unchanged.
3.5.2 Discussion
The preliminary data presented in this section suggests that there could be a change in the
expression level of some NRs as OPCs age. Despite this being preliminary data that requires
further validations and functional interpretation, it would be interesting to understand if these
changes are reversible. For example, it is known that the expression of NRs such as VDR
is often controlled via their ligands (Carrillo-López et al., 2008). Therefore the presence
of the cognate ligand itself induces expression of the receptor. Consequently, it would be
interesting to understand whether treating aged OPCs, where a decrease in receptor expres-
sion is observed, with the relevant ligand induces an increase in receptor expression. This
would aid in understanding whether changes in NR expression with ageing are normal due
to the necessities of the changing cell, or whether they have a detrimental nature and may
be involved in the ageing phenotype. By treating OPCs of different ages in vitro it would be
possible to correlate changes in NR expression observed via western blot with the cellular
response to ligand presence.
Additionally, a decrease in NR ligands such as vitamin D and TH has been observed in
ageing humans (Meehan and Penckofer, 2014; Hershman et al., 2015; Gesing, 2015). This
is an interesting observation as such factors are blood-borne, and heterochronic parabiosis
experiments have shown that aged animals remyelinate more efficiently when sharing the
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C
Fig. 3.21 Changes in NRprotein andRNA levels in ageingOPCs. Rat primary OPCs were
acutely isolated using MACS from rats of four different ages: neonates, three, ten and over
18 months of age. They were lysed and used for western blot to assess the protein levels of a
variety of NRs here reported. (A) To assess changes at the protein level western blot analysis
for a series of NRs was carried out on primary OPCs MACS isolated from rats of different
ages. VDR and LXR𝛼 showed no significant differences in the amount of protein expressed
at different ages. All data was analysed using ordinary one-way ANOVA, biological n=3.
Analysis for the other NRs was not possible as less than three biological replicates were
collected. Nevertheless, it is clear that the majority of cases tend to show a decrease in the
level of expression of NRs with increasing age. (B) This is supported by the unpublished
RNA-seq analysis comparing young and aged rat primary OPCs isolated via MACS. This
RNA-seq was carried out and presented with permission from Roey Baror, a former member
of the Franklin laboratory. The majority of NRs detected by RNA-seq fall to the right side
of the volcano plot, showing that they are expressed at lower levels in aged OPCs compare
to young. On the left side of the volcano plot we find RXR𝛼, which is expressed at higher
levels in aged OPCs compared to young. (C) Table illustrating the NR gene names on the
volcano plot and the corresponding NR protein names.
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vasculature with their young counterparts (Ruckh et al., 2012). Indeed, the decrease in NR
ligands with ageing can occur for a variety of reasons. However, a decrease in expression of
the enzymes involved in the production of such ligands, such as CYP enzymes, has also been
reported with increasing age (Wauthier et al., 2007). Unpublished proteomics data from the
Franklin laboratory aimed at comparing young and old OPCs has shown ALDH1A1, the
enzyme involved in endogenous 9cRA production, to significantly decrease in aged OPCs.
Lack of ligands could therefore be a salient aspect of impaired NR signalling in ageing. This
would resemble either the charcoal treated or serum-free cultures I have reported in Fig-
ure 3.7, where the deficiency of multiple ligands in the environment could lead to a lack of
signals and an inability of OPCs to respond appropriately to their environment. As a conse-
quence of this, the regulation of NR target genes would be impaired. Cell cycle regulators
such as p27 and CDKs, which are RXR targets in OPCs, have been shown to act aberrantly
in a variety of aged cell types (Tamir and Miller, 1999; Janzen et al., 2006; Hershman et al.,
2015). It would therefore not be surprising if this combination of events were to lead to an
alteration in cell cycle dynamics and potentially impair both proliferation and differentia-
tion of progenitor cells. Furthermore, the above hypothesis would support the observations
reported by Huang et al. (2010a), whereby the in vivo treatment of aged rats with 9cRA
accelerated remyelination. In a scenario where a ligand such as 9cRA may be lacking, its
restoration allowed for a gain of function that is typically observed spontaneously in young
adults.
Although so far one can only speculate on hypothetical ways in which NR pathways may
be impaired in ageing or may contribute to ageing themselves, I believe that the study of NRs
in the context of stem cell ageing to be of fundamental importance. Not only because the age-
ing field has an interest in studying chromatin alterations observed in the ageing phenotype
for which NRs may be the bridging molecules, but also because changes in the expression
of NRs and alterations in the production of NR ligands have been widely reported in the
ageing context. There is a growing interest in studying small lipophilic molecules and their
receptors as the field of molecular biology is becoming aware of their importance in the
fundamental functions of cellular life.
Chapter 4
Final discussion
4.1 RXR activation facilitates differentiation by influenc-
ing OPC proliferation: a new hypothesis
Remyelination is an endogenous regenerative process whereby entire myelin sheaths are
restored to demyelinated axons. This reinstates saltatory conduction, resolving functional
deficits that would otherwise arise due to the conduction block caused by demyelination.
This is a highly efficient process in the young adult CNS (Franklin and ffrench Constant,
2017). However, in a disease setting and with increasing age remyelination is less efficient,
resulting in axon degeneration and clinical decline. The decrease in remyelination efficiency
has been mainly attributed to a failure in the ability of OPCs to differentiate (Woodruff et al.,
2004). Consequently, the development of remyelination therapies has focused on finding
methods to enhance OPC differentiation. This involves two strategies:
1. overcoming negative regulators of OPC differentiation, such as efficient clearance of
myelin debris (Natrajan et al., 2015);
2. enhancing the differentiation potential of OPCs by targeting positive regulators of dif-
ferentiation, such as via the drug-targeted activation of RXR (Huang et al., 2010a).
The latter strategy showed great potential in the context of ageing, as in vivo administration of
the RXR agonist 9cRA accelerated remyelination in aged rats compared to the saline treated
controls (Huang et al., 2010a). Ageing adult stem cells are subject to a functional decline due
to both intrinsic and extrinsic changes in their microenvironment (López-Otín et al., 2013).
As a consequence, the efficiency of all regenerative processes declines with ageing. In vitro
assays aimed at testing agents acting on molecular targets selected for the enhancement of
remyelination usually use cells sourced from neonatal animals or iPSCs, as they are easier to
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obtain and culture than aged stem cells, as done by Mei et al. (2014) and Najm et al. (2015).
However, the use of young organisms for testing processes affected in old age can often be
misleading due to the altered biology of stem cells, as these may not respond in the same way
as their young counterparts. Therefore, the observations reported by Huang et al. (2010a)
have been crucial in taking forward RXR as a candidate for remyelination therapies. The
authors propose that the accelerated effect observed in ageing is because RXR activation,
specifically RXR𝛾 based on their microarray data, promotes OPC differentiation as shown
by their in vitro assays. However, the molecular mechanism by which RXR𝛾 activation
regulates OPC differentiation remains unknown.
In my thesis, I addressed this question by using ChIP-seq in order to find which genes
RXR𝛾 controls in primary rat OPCs. With this experiment I showed that RXR𝛾 binds in
the proximity of genes involved in stem cell regulation and proliferation, and to a lesser
extent to genes specific to oligodendrocyte maturation such as Mobp and Enpp6. These
results are further supported by the in vitro treatment of MACS isolated OPCs with 9cRA,
which resulted in a decrease in OPC proliferation but no difference in the percentage of
differentiated progenitors. This observation suggests that unlike what has been previously
hypothesised, RXR𝛾 does not directly regulate OPC differentiation. Previous interpretations
were based on the use of mixed glia isolated OPCs and, as explained in Section 3.2.3, this
exposes progenitors for 10 days to serum, a solution rich in numerous NR ligands. Mixed
glia isolation also exposes OPCs to other cell types such as astrocytes and microglia, which
could release substances able to promote OPC differentiation, as it has been shown that
monocyte conditioned media is able to promote OPC differentiation in vitro (Miron et al.,
2013). This isolation method can therefore be misleading when used to study NRs for a
number of reasons, including the promiscuous binding of RXR where its heterodimers can
be activated by a variety of ligands present in the serum, the cross-talk between the signalling
pathways of NRs belonging to different classes, and due to the non-linear ‘one ligand to one
receptor’ relationship described in the Introduction (Chapter 1). Therefore, the advantage of
MACS isolation is the absence of serum from the cultures, allowing for the observation of
the true effect of activating RXR exclusively, without the impact of other ligands.
One of the most interesting RXR𝛾 targets resulting from the ChIP-seq analysis is p27.
The canonical role of p27 is the inhibition of cyclin/CDK complexes involved in cell cycle
regulation. Consequently, p27 is a cell-cycle regulated protein, whereby in the presence of
conditions favourable to proliferation, p27 levels are low, allowing G1-S transition. Instead,
growth inhibitory signals cause p27 levels to increase and via the inhibition of various cy-
clin/CDK complexes, an accumulation of cells in the G1/G0 stage is observed (Agrawal et al.,
1996; Zhang et al., 2000). The importance of p27 in cell cycle regulation becomes apparent
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in transgenic mice lacking p27, which display an increase in overall size and organ hyper-
plasia attributed to an increase in cellular proliferation, as well as showing a predisposition
to tumour formation (Fero et al., 1996, 1998). Conversely, overexpression of p27 arrests the
cell in the G1 phase of the cell cycle (Goukassian et al., 2001; Sharma et al., 2011). The link
between cell fate and cell cycle has been extensively studied in the stem cell field. Stem cells
present a rapid cell cycle compared to somatic cells, a feature mainly attributed to the length
of G1. Indeed, a correlation between the length of G1 and the pluripotent capacity of cells
is observed; naïve cells present a shortened G1 lacking the G1 checkpoint regulation, and
primed pluripotency, whether induced or spontaneous, leads to G1 lengthening (Coronado
et al., 2013). This relationship is causal as shown by the analysis of FACS-sorted mouse
ESCs (mESC) using the FUCCI reporter. FACS-isolated mESCs in the G1 phase present a
higher percentage of differentiated colonies compared to mESCs in the S and G2/M phases,
under both untreated conditions and after exposure to pro-differentiation signals (Coronado
et al., 2013). The above has also been reported in human ESCs, suggesting that cells are
more sensitive to commit and differentiate when in the G1 phase (Sela et al., 2012; Calder
et al., 2013; Pauklin and Vallier, 2014). During G1, the cell undergoes a period of biosynthe-
sis and chromatin reorganisation necessary to undertake the following round of replication.
However, it is also the stage where decision in cell fate is made as the cell is more suscepti-
ble to regulatory signals, including pro-differentiating factors (Sela et al., 2012). Therefore
a longer G1 holds the cell in a decision-making state, raising the probability of encountering
pro-differentiation factors and giving time for lineage-specific transcription factors to bind
relevant targets, thereby enhancing the probability of cell cycle exit and differentiation.
Based on the above, I present an alternative hypothesis to what has been previously pro-
posed (illustrated in Figure 4.1). In this model RXR activation, specifically RXR𝛾 , leads to
an increase in p27 transcription which consequently influences the OPC cell cycle by length-
ening the G1 phase and increasing the likelihood of cell cycle exit. However, the presence
of other NR ligands is required to induce terminal differentiation. Potential ligands are T3
and vitamin D, activators of THR and VDR, as these have been reported to promote OPC
differentiation (Barres et al., 1994; de la Fuente et al., 2015). In this model, for example,
the simultaneous effect of 9cRA and T3 treatment should induce a higher percentage of dif-
ferentiation than T3 alone, a result which has been observed in MACS isolated OPCs as
reported in Figure 3.7C of the Results Section. Thus RXR𝛾 aids differentiation, but is not
essential to it, as supported by the work carried out by Huang et al. (2010a), where RXR
activation accelerated remyelination but RXR𝛾 absence only delayed remyelination without
impairing it. Instead, it would be interesting to assess the proliferation, p27 levels and cell




























Fig. 4.1 RXR activation facilitates differentiation by influencing OPC proliferation: a
new model. Under normal conditions OPCs present a normal cell cycle. In the presence of
an RXR ligand such as 9cRA, RXR𝛾 is activated and binds to a p27 enhancer, leading to an
increase in transcription of p27. Whether RXR𝛾 binds as a monomer or a dimer still needs
to be understood. The p27 increase consequently decreases the activity of cyclin/CDK com-
plexes involved in G1-S transition such as cyclins D and E. This influences the OPC cell cycle
by lengthening the G1 phase, thereby maintaining the OPC in the decision-making stage and
increasing the likelihood of cell cycle exit. If no other pro-differentiation signals are present,
the OPC will likely re-enter S phase for another cycle round. However, in the presence of
pro-differentiation factors, the OPC will undergo differentiation. Potential factors are T3 and
vitamin D, agonists of THR and VDR which have been shown to promote OPC differentia-
tion. They also could associate as monomers, homodimers or RXR heterodimers. Adapted
from Pauklin and Vallier (2014).
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As highlighted in Section 3.4, retinoids and rexinoids have been of great interest to the de-
velopment of cancer therapies due to the inhibitory effect they exert on proliferation. Mech-
anistically, the effect of RXR activation on increased p27, decreased proliferation and G1
arrest has been observed in cancer cell lines (Wu et al., 2006; Chen et al., 2016; Chou et al.,
2018). The use of RXR agonists such as bexarotene and 9-cis UAB30 both increase p27
levels in different cancerous cell lines, leading to their arrest in the G1 phase (Chou et al.,
2018). However, unlike the experiments reported in this thesis, the authors do not observe an
increase in p27 mRNA, therefore they propose that the increase in p27 protein is due to the
inhibition of its degradation. In other cancerous cell lines effects on decreased proliferation
and G1 arrest after rexinoid treatment have also been reported. However, no changes in p27
levels were observed despite the above (Wu et al., 2006). The opposite has also been re-
ported, whereby RXR inhibition leads to G1 arrest of primary adipocytes derived from a rat
model for obesity and type II diabetes, as well as in cell lines of preadipocytes and mesangial
cells (Nakatsuka et al., 2012). Despite the contradicting literature, all of the results reported
above have been mainly observed in cell lines or in animal models used for diseases. These
cells and animals do not present a normal physiological state as a baseline, therefore there is
the potential for the results to be dependent on the specific condition of such models. Fur-
thermore cell-specific effects of RXR could contribute to the differences observed by studies
reported above. Further research involving primary cells and the specific cell-type of interest
are necessary in order to elucidate the exact mechanism by which RXR activation influences
the G1 phase of the OPC cell cycle.
4.2 RXR activation and G1 lengthening in the ageing OPC
The experiments reported in this thesis have been carried out on primary neonatal rat OPCs.
However, as stated above, the use of ageing cells is fundamental to the development of treat-
ments aimed at targeting processes impaired with ageing. Whilst the the model described
is yet to be validated in neonatal OPCs, an interesting and valid question is how would the
model proposed work in ageing OPCs which have been reported to have a longer cell cycle in
vivo compared to their younger counterparts (Lasiene et al., 2009; Young et al., 2013). This
is believed to be due to an increase in G1 lengthening, as this feature is observed in numer-
ous, albeit not all, ageing progenitor cells (Geha et al., 2010; Daynac et al., 2014; Kowalczyk
et al., 2015). If ageing does lead to a slower progression through G1, it would be relevant to
verify which G1 sub-phase is specifically affected in both ageing and via RXR activation.
G1 is split into two sub-phases, early G1 and late G1, which are divided by the restric-
tion point (R point). At the R point, the progenitor commits to another round of cycling and
146 Final discussion
is characterised by the phosphorylation of retinoblastoma protein, which releases the tran-
scription factor E2F, responsible for the transcription of genes involved in S phase transition.
Early G1 is therefore the sub-phase where the progenitor is most susceptible to signals deter-
mining cell fate (Chen et al., 2015). RXR activation should therefore induce the lengthening
of early G1 in agreement with the model presented above. Adult human OPCs have been
proposed to have a lengthened early G1. However, only five subjects were studied in an age
range of 25–66 years of age (Geha et al., 2010). Thus, this study lacked a representative
number of subjects per age as well as subjects of older ages, and borders on what is con-
sidered to be the age milestone for acquiring permanent disability in MS (Confavreux and
Vukusic, 2006). The impairment of aged OPCs may therefore reside in a lengthened late G1,
whereby the majority of progenitors are in G1 but cannot proceed to S phase due to impaired
cell cycle, and at the same time cannot differentiate as they are past the R point. In this
scenario, lengthening early G1 would still be beneficial, as this would delay reaching the R
point and enhance the responsiveness of aged OPCs to differentiation signals. To determine
the validity of this model in aged OPCs, it is important to understand which G1 sub-phase
is affected by RXR and which is altered in the ageing OPC cell cycle.
However, an extended G1 phase as a consequence of ageing still needs to be confirmed
in OPCs. Furthermore, despite the in vivo observation that aged OPCs in both humans and
rodents present a longer cell cycle than their younger counterparts, in vitro assessment of
young and old MACS isolated OPCs does not present any statistically significant differ-
ences upon assessment of EdU incorporation. These results are not presented in this thesis
but have also been observed by other members of the lab. This hints at a similar cell cycle
length between young and old OPCs, whilst neonatal OPCs have a much shorter cell cy-
cle length. Therefore the ageing phenotype of OPCs resides in the inability to respond to
pro-differentiation signals efficiently and quickly. However, projects in the lab have shown
that aged OPCs can be manipulated to respond more efficiently to differentiation signals,
for example by altering their nutrient sensing pathways and by altering the mechanical stiff-
ness of their surrounding microenvironment. Lengthening early G1 may indeed give the
slow-responding ageing OPCs more time to not only detect differentiation signals, but also
to commit to the fate imposed by the signals detected by allowing transcription factors to
transcribe the genes required for maturation and differentiation.
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4.3 Is targeting RXR and its partners a valid strategy for
remyelination therapies in MS?
The accelerated remyelination observed by Huang et al. (2010a) after RXR activation in vivo
was initially attributed to an effect of RXR𝛾 on the differentiation capacity of OPCs. In this
thesis I propose that unlike what was previously suggested, RXR does not directly influence
differentiation. Instead, RXR activation may sensitise the cell to pro-differentiation signals
in its microenvironment, thereby aiding the differentiation process. In the light of what has
been presented and what is known, is targeting RXR and its partners a valid strategy for
remyelination therapies?
Both RXR and its partners are important players in the development and regeneration
of a variety of organs including liver, bone and skin (Scheven and Hamilton, 1990; Tog-
ari et al., 1991; Warner et al., 2008; Hellemans et al., 1999; Bruck et al., 2009). In these
organs NRs have been involved in numerous biological processes important to regenera-
tion, including inflammation and angiogenesis, as reviewed by Jin et al. (2015); Rieger et al.
(2015); Rudraiah et al. (2016). Consequently, NR activation in other cell types can be ben-
eficial to the regenerative process. Indeed, the activation of RXR in innate immune cells
resulted in an increase in their phagocytic capability despite their old age, and mice lacking
RXR𝛼 presented reduced phagocytic activity and a delay in remyelination (Natrajan et al.,
2015). The positive effect of RXR activation has also been reported in murine models for
MS. Indeed, in the EAE model, RXR𝛾 activation via agonists such as 9cRA and IRX4204
resulted in the amelioration of disease severity and prevented disease progression compared
to the control group (Diab et al., 2004; Takeuchi et al., 2013; Chandraratna et al., 2016).
This is because rexinoids exert a strong immunomodulation by decreasing the proliferative
potential of CD4+ T cells that produce pro-inflammatory cytokines and increases the ex-
pression of CTLA-4, involved in the down-regulation of the immune response (Takeuchi
et al., 2013; Chandraratna et al., 2016). Hence targeting RXR can modulate both the in-
nate and adaptive immune system, as well as OPCs, thereby attenuating the inflammatory
response, reducing the extent of damage and aiding the regenerative process. Furthermore,
RXR𝛾 has been shown to mediate the action of mTORC1 in Schwann cells, by transcribing
sterol regulatory element-binding protein 1c (SREBP1c) through which mTORC1 regulates
lipid biosynthesis which, if compromised, leads to Schwann cell hypomyelination (Norrmén
et al., 2014). This could also be relevant to OPCs, as studies in the lab have shown that
calorie restriction, a paradigm that affects mTORC1, restores regenerative function in aged
animals by increasing the differentiation efficiency of aged OPCs. This could be one of the
ways in which RXR𝛾 sensitises the cell to pro-differentiation signals.
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All the above observations suggest that targeting RXR would have clear benefits in the
context of a chronic demyelinating disorder such as MS, as it could hypothetically decrease
the severity of the immune attacks and aid the efficiency of remyelination, thereby limiting
the damage and delaying accumulation of disability. In humans, studies have pointed towards
a link between low amounts of NR ligands and the risk of developing MS. For example,
both vitamin D and RA serum levels have been used as predictors of MS, as their levels
are lower in MS patients compared to controls (Royal et al., 2002; Ascherio et al., 2014).
Based on these epidemiological observations MS patients were administered vitamin D and
retinyl palmitate with the hope of ameliorating the disease. However, no improvements
were observed on clinical scores and relapse rates (Bitarafan et al., 2013; Jafarirad et al.,
2013). Lower levels of PPAR𝛾 in the cerebral spinal fluid and higher levels of anti-thyroid
autoantibodies have also been found in MS patients compared to healthy controls. However,
attempts at using these features as biomarkers for the risk of developing MS and as predictors
of relapses failed due to the lack of a clear relationship (Szalardy et al., 2013; Fallahi et al.,
2017). At the same time, larger clinical studies with a longer administration course of vitamin
A presented significant improvements in the performance of the MS functional composite
test, which measures the progression of disability in both cognitive and upper limb function
(Bitarafan et al., 2015). Furthermore, a phase II trial assessing the use of agonists targeting
class III NRs, such as using a combination of estriol and glatiramer acetate, reduced the rate
of relapses (Voskuhl et al., 2016).
Based on the above, I believe that RXR and other NRs have great potential in the devel-
opment of remyelination therapies. The most interesting aspect of RXR and NR biology is
their ability to influence both proliferation and differentiation. This is especially interesting
in the context of MS, as this disorder presents heterogeneous lesions, where approximately
30% of the lesions lack OPCs whilst the remaining are abundant in OPCs but remyelination
fails due to a failure in their differentiation (Lucchinetti et al., 1999; Boyd et al., 2013). This
suggests that the development of a therapy aimed at targeting either OPC proliferation or
OPC differentiation would be inefficient in a large proportion of the lesions presented. The
use of NR ligands opens new avenues for the development of patient tailored therapies which
could target either or both processes, according to the need of the individual. However, a
careful characterisation of their signalling pathway and an appropriate clinical trial design
are necessary in order to properly predict and assess the true outcome of their manipulation
in the disease context.
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4.4 The complexity of NR signalling and clinical trial de-
sign
In recent years there has been a considerable interest in the use of NRs as therapeutic targets
for both MS and remyelination, as shown by the current efforts of testing agonists for GCR,
THR, VDR and RXR (de la Fuente et al., 2015; Najm et al., 2015; Zhang et al., 2016b; Plemel
et al., 2017). This is due the numerous appealing principles of NR biology, including:
• their evolutionary conservation across organisms which should make the use of animal
models representative and translatable to humans;
• they are ligand-induced and therefore easily targetable with small molecules;
• they present a direct bridge for the manipulation of gene transcription;
• they signal through a common network at which we can intervene at various points;
• drugs targeting NRs are already FDA approved for cancer treatments, which should
facilitate their approval and production process.
Despite their biology pointing towards success in remyelination in animal models as well as
in their translation to the clinic, clinical trials still fail. The reason lies in their biological and
molecular complexity, the current animal models used to study remyelination in MS as well
as our lack of knowledge on how NRs function, all of which hinder the design of proficient
clinical trials. Due to the pleiotropic effects exhibited by NRs, the use of rexinoids presents
potent side effects. This leads to a high drop out rate and not enough patients to conclude
clinical trials. Furthermore, if the drugs were to be approved despite the strong side effects,
the therapy could lead to the requirement of a complex drug regime to counteract these issues.
Complex drug regimes are problematic to both patients and medics, as they are expensive
and cause issues of non-adherence and adverse drug reactions (Golchin et al., 2015).
Clinical trials are also ineffective due to the lack of a single appropriate animal model
for studying MS, a topic reviewed by Franklin and ffrench Constant (2017). In particular, we
lack a model for the progressive phase of the disease, which is currently untreatable by the
currently available disease modifying drugs. In order to assess remyelination, toxin mod-
els of demyelination are used. However, these lack the important interaction between the
detrimental inflammation observed in MS and the regenerative process. Furthermore, most
of the NR studies carried out use the cuprizone model for which an attentive experimen-
tal design is required, as explained in the Introduction (Chapter 1). NR ligands have been
studied much more in the context of EAE. However, EAE does not recapitulate the chronic
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aspect of MS and makes it complicated to distinguish the true effect a molecule may have
on remyelination due to the strong inflammatory reaction. Therefore these studies concen-
trate on the effect NRs have on the immune system rather than on remyelination itself. As a
consequence, the use of either model comes with the risk of identifying a promising target
which may ultimately fail in clinical trials.
The ultimate reason for weak clinical trial outcomes lies in the lack of knowledge of
how the NR system functions and signals. This can prompt researchers to ask the wrong
questions and draw the wrong conclusions from studies. The NR field of research is relatively
young, as it has been approximately 16 years since the discovery of multiple NR isoforms
and the realisation that they function via association to co-regulators that allow for chromatin
remodelling (Tata, 2002). The above two discoveries are central to the modern understanding
of how NRs signal, but have been extremely recent. The above begs the question of how
much more is still to be understood and discovered. Therefore, a better in vitro and in vivo
characterisation of both NR structure and function is required before venturing into human
clinical trials.
In this thesis I characterised the different levels of RXR signalling in primary OPCs. Al-
though the results require further validation, I believe this characterisation to be fundamental
in contributing to the overall picture of NR signalling, as this knowledge will aid the reduc-
tion of undesired side effects that would arise from using NRs as a therapy for remyelination.
By understanding which RXR heterodimer complex is involved in the transcriptional regu-
lation of the gene necessary for the desired outcome, one can try to target the complex via
the NR partner or the co-regulators instead of RXR itself. This would limit the side effects
that arise from activating all RXR heterodimers in the cell of interest, as well as in other cell
types. For example, I have shown that the RXR𝛾 principally binds to LXR𝛽 at the OPC stage
of the lineage. Despite not knowing the true biological significance of this, it hints at an im-
portant role for RXR𝛾-LXR𝛽 in OPCs. Whether RXR𝛾-LXR𝛽 is important in regulating the
OPC cell cycle is still unknown, but its involvement in the regulation of cholesterol and fatty
acid metabolism has been extensively described (Courtney and Landreth, 2016b). If activat-
ing this heterodimer aids oligodendrocyte formation by influencing cholesterol metabolism
to meet differentiation demands, then this could be a valid target for remyelination therapies.
At this point, with the use of ligands specific to LXR𝛽, one should achieve the transcription
of genes specific to cholesterol metabolism, thereby sparing the effect that RXR𝛾 activation
would have on the cell cycle or other biological processes that need to remain unaffected.
This is an oversimplified example, but the raw ChIP-seq data reveals that RXR𝛾 binds prox-
imal to about half of the total protein coding genes of the genome, suggesting its importance
in influencing almost all housekeeping cellular processes (Figure 3.15B). Due to this, tar-
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geting RXR𝛾 exclusively may not be the optimal strategy going forward in the development
of a therapy. It is therefore important to select the biological process that needs to be tar-
geted, whether this is cell cycle regulation, migration, lipid metabolism, differentiation and
so on, in order to fully understand which partner and co-regulators are responsible, and to
consequently produce patient specific therapies. Taken together, I believe that a better char-
acterisation of the complex and interconnected signalling of RXR𝛾 heterodimers is required,
as this knowledge is essential in choosing the most appropriate target and suitable ligands,
allowing optimal clinical trial design.
4.5 Directions for future research
Throughout this thesis I have demonstrated that much more work is required in order to vali-
date the observations and new hypotheses presented, as well as to take forward the knowledge
of how RXR𝛾 regulates oligodendrocyte lineage cell function.
Despite the ChIP-seq results being extremely interesting and informative on RXR𝛾 bind-
ing dynamics and genomic preferences, additional experiments are required to determine
whether RXR𝛾 regulates genes involved in OPC differentiation and oligodendrocyte mat-
uration. As well as ChIP-seq, it would be interesting to carry out RNA-seq of 9cRA and
vehicle control treated OPCs. Unlike ChIP-seq, which shows the binding location of tran-
scription factors, RNA-seq is much more informative with regards to the actual change in
gene expression as a consequence of a treatment or the regulation of a transcription factor of
interest. The outcome of the experiment would be the generation of a transcriptional profile
governed upon RXR𝛾 activation in OPCs, leading to a more complete picture of the func-
tional consequences of RXR𝛾 activation. This is especially important following the results
generated via ChIP-seq, which show that upon 9cRA treatment RXR𝛾 associates to regula-
tory regions of the genome and consequently could be regulating any protein coding gene
in the genome. As well as answering the original hypothesis, this experiment would lead to
the generation of candidates presenting transcriptional changes that could be used as a direct
functional read out for any future experiment assessing RXR𝛾 activity in the oligodendrocyte
lineage.
In Section 3.2.4 I have shown that RXR𝛾 does not physically switch binding partners
as OPCs progress throughout the lineage. The aim was to determine whether OPC dif-
ferentiation and oligodendrocyte maturation are regulated by specific RXR𝛾 heterodimers,
and whether certain binding partners are more relevant than others at different stages of the
lineage. The use of Duolink® to determine the above has given insight on the association
dynamics between RXR𝛾 and its partners. However, physical association may not directly
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translate to functional relevance. Therefore, determining the functional relevance of these
RXR𝛾 heterodimers when it comes to OPC proliferation, differentiation and oligodendro-
cyte maturation is fundamental when assessing predominant binding partners at different
stages of the lineage. To answer the above question, simple in vitro studies can be car-
ried out whereby OPCs are treated with 9cRA together with a partner antagonist, and if the
9cRA effect is abrogated compared to the 9cRA treatment alone, then it can be proposed
that the specific effect being observed is elicited by that specific heterodimer. If this were
to be carried out for proliferation, differentiation and maturation, or using changes in tran-
scripts obtained via the previously mentioned RNA-seq, then we would have new insights
into which RXR heterodimers are important in eliciting a specific effect or result in a certain
outcome.
An interesting observation resulting from the ChIP-seq experiment is that RXR𝛾 largely
associates to intergenic and intronic genomic areas known to contain numerous regulatory
elements. RXR𝛾 rarely binds to promoter regions or in proximity of transcription start sites
of protein coding genes. This observation has led me to hypothesise that RXR𝛾 does not
directly regulate transcription of target genes. Instead, it purely determines the likelihood
or probability of a gene being transcribed or an effect occurring upon its activation. In
this scenario, RXR𝛾 would act as a factor priming the OPC for a response by regulating
the state of the chromatin, but other signals and factors would ultimately be required to
execute the change in gene transcription. Therefore, chromatin modifications due to RXR𝛾
activation or repression would tip the balance in favour of certain transcriptional profiles,
thereby facilitating certain cellular and physiological outcomes. It would be interesting to
test this hypothesis using a paradigm where cells are no longer responsive to conventional
OPC differentiation signals, such as the MACS isolated aged OPC. By using aged OPCs,
one can carry out treatment combinations such as 9cRA and T3, calcitriol or ATRA, and
determine whether priming cells via RXR activation can restore the response to the original
NR ligands. This can be carried out with a variety of compounds as well as conditioned
media from other cell types, known to promote OPC differentiation. Although it has been
shown that aged OPCs do not respond to 9cRA treatment in vitro as mixed glia cells do, it is
important to consider that these cells were MACS isolated and cultured in serum-free media.
This could result in the same outcome observed when treating MACS sorted neonatal OPCs
with 9cRA in serum-free conditions, a result that could partly be due to the paradigm being
used. Overall, it would be interesting to understand if RXR activation can indeed aid in
priming OPCs to differentiate when used in a paradigm known to not respond efficiently to
differentiation signals.
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All of the above experiments have the additional advantage of avoiding the use of RXR𝛾
antibodies. Following from the mass spectrometry experiments it is clear that NR antibody
validations are fundamental in order to fully trust experimental outcomes. Such antibodies
can be validated by carrying out a simple western blot on cells derived from an RXR𝛾 knock-
out mouse, or on cell lines in which in vitro RXR𝛾 knockout using CRISPR was carried out.
Furthermore, if the effect of RXR𝛾 is observed in vivo, in the presence of other cell types
or conditioned media, then the MACS paradigm may be too simplistic and result in the ab-
rogation of the RXR𝛾 effect. Due to the ubiquitous expression of RXR, its ligands are able
to affect numerous different cell types including neurones, astrocytes and microglia. There-
fore, it is important to use paradigms that also include other cell types, such as co-cultures,
ex vivo cerebellar slices and in vivo assessments in order to validate what is carried out in




In this thesis I have shown that RXR𝛾 signalling does not influence OPC differentiation
directly, as 9cRA treatment in serum-free cultures did not induce oligodendrocyte forma-
tion. Instead, using a ChIP-seq approach, I have demonstrated that RXR𝛾 influences genes
involved in proliferation and cell cycle control. They probably do so via the activation of
non-protein coding regulatory regions, a hypothesis which will need to be verified with the
use of reporter assays. Further functional assessments aided me in the development of a new
hypothesis where RXR𝛾 activation sensitises the OPC to pro-differentiation signals. Based
on the targets obtained, such as the cell cycle exit marker p27, I developed a yet to be val-
idated hypothesis where RXR𝛾 activation lengthens the G1 phase of the OPC cell cycle,
thereby increasing the likelihood of the cell to detect pro-differentiation signals and fully
commit to terminal differentiation. It will be interesting to understand which NR partner(s)
form the RXR𝛾 heterodimer, if any, involved in regulating the OPC cell cycle. However,
many more genes involved in processes important to the oligodendrocyte lineage resulted
from the ChIP-seq experiment. One of these is cholesterol and lipid metabolism, a funda-
mental aspect of oligodendrocyte formation, which presents an alternative and interesting
avenue worth exploring further. The above demonstrates that NRs signal in complex ways
with unexpected outcomes, and whilst the use of rexinoids has the potential for the devel-
opment of remyelination therapies, their use may not suffice in human clinical trials prior to
acquiring further knowledge on how these receptors signal.
Discoveries in the NR field have gone hand in hand with the development of new tech-
nologies, from ChIP to X-ray crystallography and NMR. Consequently, as new experimental
techniques are developed, it will be inevitable for our understanding of NRs to change fur-
ther, creating an increasingly complicated picture. With this in mind, there is an urgent need
for collaboration and data integration of the broader scientific community if we want the use
of NRs in remyelination therapies to become a reality.

‘Cominciate col fare ciò che è necessario, poi ciò che è possibile.
E all’improvviso vi sorprenderete a fare l’impossibile.’
- San Francesco d’Assisi
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Appendix A
Product Provider Catalogue number
1-850 Calciochem 609315
1a25-Dihydroxyvitamin D3 Sigma Aldrich D1530
22(S)-Hydroxycholesterol Sigma Aldrich H5884
9 cis retinoic acid Sigma Aldrich R4643
Activated charcoal Sigma Aldrich C9157-500g
All-trans retinoic acid Sigma Aldrich R2625
Apo-transferrin Sigma Aldrich T1147-100MG
B27 Gibco Life Tech 17-504-044
BCA assay kit ThermoFisher 23227
BSA Gibco Life Tech 15260-037
Bolt 4-12% bis/tris plus Gel Invitrogen NW04120BOX
CD2314 Tocris 3824
D-(+)-glucose Sigma Aldrich G8644-100ML
DMEM Gibco Life Tech 41966-029
DMEM-F12 Gibco Life Tech 11039-021
DMSO Sigma Aldrich D8418
DNAse I Type IV Sigma Aldrich D5025-150KU
Direct-zol RNA MicroPrep Kit Zymo Research R2060
Duolink® Click-iT Plus EdU AlexaFluor 488 Kit ThermoFisher C10637
Duolink® Detection reagent orange SigmaAldrich DUO9007
Duolink® PLA probe anti-mouse PLUS Sigma Aldrich DUO9001
Duolink® PLA probe anti-rabbit MINUS Sigma Aldrich DUO9005
Duolink® Wash Buffers Sigma Aldrich DUO82049
EDTA Invitrogen 15575-038
EZ-chIP coimmunoprecipitation kit Millipore 17-371
204
Ethanol Sigma Aldrich 32221
Fetal bovine serum Biosera 8670,9910,3040
Fluoromount G Southern Biotech 0100-01
Gel purification QIAEX II Kit Qiagen 20021
𝐻2𝑂 RNase/DNase free Invitrogen 10977-035
HALT protease & phosphatase inhibitor ThermoFisher PN78441
HBSS-/- Gibco Life Tech 14170-088
HX531 Tocris 3912
Höechst Sigmal Aldrich 33258
Immobilon FL PVDA transfer membrane Merck Millipore IPFL00010
Insulin Gibco Life Tech 12585-014
LDS Sample Buffer (4X) Invitrogen NP0007
LE135 Tocris 2012
MOPS SDS Running Buffer 20X Invitrogen NP0001
MS columns Myltenyi Biotech 130-042-201
Magnet Myltenyi Biotech
Methanol Honeywell 32213
Mouse anti-A2B5 IgM antibody Millipore MAB312
Mycozap Plus-PR Lonza VZA-2011
N-Acetyl-L-cysteine Sigma Aldrich A7250
Normal donkey serum Sigma Aldrich D9663
Odyssey Blocking Buffer Li-Cor 927-50000
PBS 10X (-/-) Gibco Life Tech 70013-016
Papain Worthington 3126
Paraformaldehyde Fisher Scientific P/0840/53
Penicillin streptomycin Sigma Aldrich P4333
Pentoject Animalcare XVD 135
Percoll GE Healthcare 17-0891-01
Phosphate buffered saline 10X Fisher Bioreagents BP-39920
Pierce Crosslink IP Kit ThermoFisher 26147
Pierce IP Lysis buffer ThermoScientific 87787
Pluronic acid Gibco Life Tech 24040-032
Poly D-lysine Sigma Aldrich P6407
Precision plus protein standard BioRad 161-0374
Progesterone Sigma Aldrich P-8783
Propidium Iodide Flow Cytometry Kit Abcam ab139418
205
Propidium iodide Invitrogen P3566
Putrescine Sigma Aldrich P5780
Quantitect Reverse Trancription Kit Qiagen 205310
RXR𝛾 recombinant protein Novus NBC1-18416
Rat anti-mouse IgM MicroBeads Myltenyi Biotech 130-047-301
Recombinant human FGF-basic Peprotech 100-18B
Recombinant human PDGF-AA Peprotech 100-13A
Rosiglitazone Sigma Aldrich R2408
SYBR Green PCR Master Mix ThermoFisher 4309155
Sample Reducing Agent (10X) Invitrogen NP0004
Sodium pyruvate Invitrogen 11360-039
Sodium selenite Sigma Aldrich S5261
T 0901317 Tocris 2373
T00709 Sigma Aldrich T8703
Tetraethylthiuram disulfide Sigma Aldrich 86720
TGS Tris/Glycine/SDS Transfer Buffer 10X BioRad 161-0772
Triiodothyronine Sigma Aldrich T6397
Tris buffered saline 10X Fisher Bioreagents BP2471-1
Triton-X 100 Sigma Aldrich T9284
Trizol ThermoFisher 15596026
TrypLE Express Enzyme (1X) ThermoFisher 12604013
Tween Sigma Aldrich 93773-250G
Western Blot Filter Paper ThermoFisher 88600
Zombie violet BioLegend 423113
Table A.1 Table of all the materials used.

